Mitochondria-targeted anti-tumor agents

ABSTRACT

Described are mitochondria-targeted anti-tumor agents, and methods of making and using the same for the treatment of disorders associated with unwanted cell proliferation.

CLAIM OF PRIORITY

This application claims the benefit of U.S. Provisional PatentApplication Ser. No. 60/993,195, filed on Sep. 10, 2007, the entirecontents of which are hereby incorporated by reference.

FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with Government support under Grant Nos.HL54131, CA78810, and CA90917, awarded by the National Institutes ofHealth. The Government has certain rights in the invention.

TECHNICAL FIELD

This invention relates to mitochondria-targeted inhibitors of molecularchaperones, e.g., Heat Shock Protein 90 (Hsp90), Hsp60, Heat Shock 70kDa Protein 9 (HSPA9/mortalin), or TNF Receptor-Associated Protein 1(TRAP-1), used as anti-tumor agents, and methods of making and using thesame for the treatment of disorders associated with unwanted cellproliferation.

BACKGROUND

Tumor cells exhibit an enhanced ability to survive and proliferate inhighly unfavorable environments. They have been shown to down-regulatemany of the cellular pathways that prevent normal (i.e., non-cancerous)cells from dividing in a hostile environment, and they also inactivateapoptotic pathways that bring about cell death in many normal tissuesunder adverse conditions. Tumor cells are also believed to up-regulatepathways required to maintain active proliferation. For example, manytumor cells activate the cellular stress-response pathway that allowstumor cells to synthesize and maintain the protein machinery they needto continue proliferating. The activated stress response in tumorsincludes up-regulation of heat-shock proteins (Hsps), which areATPase-directed molecular chaperones. In particular, Hsp90 isupregulated in many cancerous tissues. Hsp90 controls the balancebetween folding/maturation and proteasomal destruction of a restrictednumber of client proteins, some of which are involved in signaltransduction and cell proliferation.

SUMMARY

The present invention is based, at least in part, on the discovery thatthe molecular chaperones Hsp90, Hsp60, and TRAP-1 are found at increasedlevels in mitochondria of tumor cells as compared to normal cells, andthat inhibition of molecular chaperones in tumor cell mitochondria usingmitochondrial-targeted chaperone inhibitors results in tumor cell death.

In one aspect, the invention provides compositions having the formula:A-B,wherein A is a molecular chaperone inhibitor and B is amitochondria-penetrating moiety and A and B are linked, optionally by alinking moiety; or a pharmaceutically acceptable salt thereof. However,if A is Shepherdin or a fragment thereof, then B is not Antennapediahelix III homeodomain cell-penetrating peptide (ANT) or a fragmentthereof.

In some embodiments, A is or includes a small molecule, e.g., anAnsamycin class Hsp90 inhibitor; a geldanamycin analogue; apurine-scaffold class Hsp90 inhibitor, a resorcinol; or amacrolactone-Hsp90 inhibitor; a peptide inhibitor of Hsp90, e.g., aShepherdin peptide including SEQ ID NO:2 (His-Ser-Ser-Gly-Cys); or apeptide including a sequence that is at least 95% identical to SEQ IDNO:1, that binds to and inhibits Hsp90. In some preferred embodiments, Ais or includes radicicol or an analog thereof; a purine inhibitor ofHsp90; 17-allylamino-demethoxygeldamycin (17-AAG);17-dimethylaminogeldanamycin; 17-GMB-APA-GA (a maleimido derivative ofgeldanamycin that enables the conjugation of GA to a polypeptide);17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG);17-[2-(Pyrrolidin-1-yl)ethyl]amino-17-demethoxygeldanamycin (17-AEP-GA);or 17-(Dimethylaminopropylamino)-17-demethoxygeldanamycin (17-DMAP-GA).

In some embodiments, the cationic mitochondrial-penetrating moiety, B,includes:

where R¹ is H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, orR^(a)R^(b)R^(c)Si; R^(a), R^(b), and R^(c) are independently selectedfrom alkyl or aryl; and n can be 0, 1, 2, 3, 4, 5, or 6.

In some embodiments, the cationic mitochondrial-penetrating moiety, B,includes

where, R^(a), R^(b), and R^(c) are independently selected from alkyl oraryl; and n can be 1, 2, or 3.

In some embodiments, B is a mitochondria penetrating peptide, e.g., amitofusin peptide, a mitochondrial targeting signal peptide,Antennapedia helix III homeodomain cell-penetrating peptide (ANT) (e.g.,comprising SEQ ID NO:18), HIV-1 Tat basic domain (e.g., comprising SEQID NO:19 or 20); VP22 peptide, or Pep-1 peptide; an RNA mitochondrialpenetrating signal (e.g., comprising SEQ ID NO:21, 22, 23, or 24); orselected from the group consisting of guanidine-rich peptoids,guanidine-rich polycarbamates, β-oligoarginines, and proline-richdendrimers. In some embodiments, B is a tetraguanidinium,triguanidinium, diguanidinium, or monoguanidinium compound, or atriphenylphosphonium compound.

In some embodiments, the cationic mitochondrial-penetrating moiety, B,includes (aryl)₃P—.

In some embodiments, the cationic mitochondrial-penetrating moiety, B,includes Rhodamine 123:

In some embodiments of the composition, the molecular chaperoneinhibitor, A, includes geldanamycin analogues:

where, R² is H, alkyl, aryl, or arylalkyl; R³ is H, alkyl; and R⁴ is H,alkyl, alkenyl, aryl, arylalkyl, OR^(d), wherein R^(d) is H, alkyl, orarylalkyl.

In some embodiments of the composition, R² is H or alkyl; R³ is H,alkyl; and R⁴ is H, or OR^(d), wherein R^(d) is H, alkyl.

In some embodiments of the composition, R² is H; R³ is methyl; and R⁴ isH.

In some embodiments of the composition, B is a mitochondria penetratingpeptide, e.g., a mitofusin peptide, a mitochondrial targeting signalpeptide, Antennapedia helix III homeodomain cell-penetrating peptide(ANT) (e.g., comprising SEQ ID NO:18), HIV-1 Tat basic domain (e.g.,comprising SEQ ID NO:19 or 20); VP22 peptide, or Pep-1 peptide; an RNAmitochondrial penetrating signal (e.g., comprising SEQ ID NO:21, 22, 23,or 24); or selected from the group consisting of guanidine-richpeptoids, guanidine-rich polycarbamates, β-oligoarginines, andproline-rich dendrimers. a phosphonium salt, e.g.,methyltriphenylphosphonium and tetraphenylphosphonium. In someembodiments of the composition, B is or includes ANT or amitochondrial-penetrating fragment thereof. In some embodiments of thecomposition, B is a tetraguanidinium, triiguanidinium, diguanidinium, ormonoguanidinium compound, or a triphenylphosphonium compound.

In some embodiments, the compositions include a linking moiety between Aand B, e.g., a peptide linker or a chemical linker.

In some embodiments, the linker moiety is divalent and can be selectedfrom the group consisting of alkylene, alkenylene, alkynylene,cycloalkylene, arylene, heteroarylene, and peptide linker, wherein anytwo adjacent carbon-carbon bonds of said alkylene, alkenylene, oralkynylene, can be optionally replaced with one or more of O, NH, S,PR^(e), C(O)NR^(f), arylene, heterocycloalkylene, or heteroarylene;wherein R^(e) and R^(f) are independently selected from alkyl or aryl.

In some embodiments, the linker moiety is:

In some embodiments, the linker moiety is alkylene

In some embodiments, the linker moiety is alkylene with six carbonatoms.

In some embodiments, the compositions include compounds of the formula:

wherein, R¹ is H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl,or R^(a)R^(b)R^(c)Si; R² is H, alkyl, aryl, or arylalkyl; R³ is H,alkyl; R⁴ is H, alkyl, alkenyl, aryl, arylalkyl, OR^(d), wherein R^(d)is H, alkyl, or arylalkyl; R^(a), R^(b), and R^(c) are independentlyselected from alkyl or aryl; and n is an integer between 1 and 10,inclusive; or a pharmaceutically acceptable salt thereof.

In some embodiments, the salt is a hexafluorophosphate salt

In some embodiments, R¹ is R^(a)R^(b)R^(c)Si, R^(a), R^(b), and R^(c)are independently selected from alkyl or aryl; R² is H; R³ is H, alkyl;R⁴ is H; and n is 1, 2, 3, or 4.

In some embodiments, the compounds can be of the formula:

wherein, q is 1, 2, 3, 4, 5, or 6.

In some embodiments, q is 3.

In some embodiments, aryl is phenyl.

In some embodiments, aryl is phenyl and q is 3.

In some embodiments, X can be hexafluorophosphate.

In some embodiments, the compound can be:

In a further aspect, the invention includes methods for inducing cancercell death or tumor cell death, e.g., in a subject, e.g., a mammal,e.g., a human or non-human mammal, the method comprising administeringto the subject a mitochondrial-targeted chaperone inhibitor describedherein an amount sufficient to induce cancer cell death.

In another aspect, the invention provides methods for inducing cancercell death or tumor cell death, e.g., in a subject, e.g., a mammal,e.g., a human or non-human mammal. The methods include identifying asubject having cancer or a tumor, e.g., cancer or a tumor comprisingcancer cells or tumor cells; and determining whether cells of saidcancer or tumor have increased mitochondrial concentrations of achaperone, e.g., Hsp90 or Trap-1, e.g., as compared to a control, e.g.,a normal, non-tumor, non-cancer cell. If the subject has increasedmitochondrial levels of said chaperone, then the methods includeadministering to the mammal a mitochondrial-targeted chaperone inhibitorcomprising the formula:A-B,wherein A is a chaperone inhibitor and B is a mitochondria-penetratingmoiety and A and B are linked, optionally by a linking moiety, e.g., asdescribed herein.

In yet a further aspect, the invention provides methods for identifyinga candidate agent for inhibiting chaperone activity. The methods includeproviding a sample comprising at least one chaperone and Cyclophilin D;contacting the sample with a test agent; and detecting binding of theChaperone and Cyclophilin D in the sample in the presence and absence ofthe test agent. A test agent that inhibits binding is a candidate agentfor inhibiting Chaperone activity. In some embodiments, the chaperone isHsp60, HspA9, Hsp90, or TRAP-1.

“Cancer,” as the term is used herein, refers to a disease characterizedby uncontrolled, abnormal growth of cells. A “cancer cell” is cell thatdivides and reproduces abnormally with uncontrolled growth. This cellcan break away from the site of its origin (e.g., a tumor) and travel toother parts of the body and set up another site (e.g., another tumor),in a process referred to as metastasis. A “tumor” is an abnormal mass oftissue that results from excessive cell division that is uncontrolledand progressive, and is also referred to as a neoplasm. Tumors can beeither benign (not cancerous) or malignant. The methods described hereinare useful for the treatment of cancer and tumor cells, i.e., bothmalignant and benign tumors as well as cancers with no solid tumors(such as hematopoietic cancers), so long as the cells to be treated havemitochondrial localization of the chaperones as described herein.

Molecular chaperones are any of a group of proteins that are involved inthe correct intracellular folding and assembly of polypeptides withoutbeing components of the final structure. Molecular chaperones are foundin bacteria, mitochondria, and the eukaryotic cytosol. Herein,“molecular chaperones” and “chaperones” are used interchangeably.

Herein, the term “mitochondriotropic” is used interchangeably with“mitochondrial targeting” and “mitochondrial-penetrating”.

Herein, the term “mitochondriotropic agent” refers to compositionshaving the formula A-B as described herein, wherein the agent inhibitschaperone activity and localizes to mitochondria.

As used herein, “Gamitrinib” refers to a geldanamycin analogue, e.g.,17-AAG, conjugated via an amino group at the C17 position via a linkerto a mitochondrial penetrating moiety, for example, a tetraguanidinium(G4), triguanidinium (G3), diguanidinium (G2), monoguanidinium (G1), ora triphenylphosphonium (TPP) moiety. Throughout this application, themitochondrial penetrating moiety that is part of a particular Gamitrinibis sometimes indicated. For example, Gamitrinib-G4 refers to aGamitrinib in which a tetraguanidinium moiety is present. For example,Gamitrinib-TPP refers to a Gamitrinib in which a triphenylphosphoniummoiety is present. Also throughout this application, the use of theplural form “Gamitrinibs” indicates one or more of the following:Gamitrinib-G4, Gamitrinib-G3, Gamitrinib-G2, Gamitrinib-G1, andGamitrinib-TPP.

Although the following description is, at times, directed to themolecular chaperone Hsp90, it should be understood that the descriptioncan be generalized to structurally related molecular chaperones that areoverexpressed in the mitochondria of cancer cells, e.g., TRAP-1 (Song etal., J. Biol. Chem., 270:3574-3581 (1995); Cechetto and Gupta,Experimental Cell Research, 260:30-39 (2000)); Heat Shock 60 kDa Protein1 (Hsp60/HspD1) (Singh et al., Biochem. Biophys. Res. Commun. 169 (2),391-396 (1990)); Bross et al., J. Hum. Genet. 52 (1), 56-65 (2007)); andHeat shock 70 kDa protein 9 (HSPA9/mortalin) (Domanico et al., Mol.Cell. Biol. 13 (6), 3598-3610 (1993); Bhattacharyya et al., J. Biol.Chem. 270 (4), 1705-1710 (1995); Kaul et al., FEBS Lett. 361 (2-3),269-272 (1995)).

In one aspect, the present invention provides molecular chaperoneinhibitors that are targeted to the mitochondria, i.e., that penetratethe mitochondrial membrane and accumulate there. Chaperone inhibitorscan be targeted to the mitochondria via association with a mitochondrialpenetrating moiety. The molecular chaperone inhibitor may be, forexample, a protein, or chaperone binding fragment thereof, that binds toa chaperone protein. For example, certain Inhibitors of ApoptosisProteins (IAPs) can be used. IAPs are a family of antiapoptotic proteins(Schimmer, Can. Res. 64:7183-7190 (2004)); useful IAPs include thosethat bind to the molecular chaperone Hsp90. Fragments of these and otherproteins that naturally bind to molecular chaperones are part of thisinvention. Peptidomimetics of these and other peptides or proteins thatnaturally bind to and inhibit molecular chaperones can also be used.

The chaperone inhibitor can also be a small molecule, the mitochondriatargeted chaperone inhibitor described herein, e.g., a small moleculeidentified through screening methods described herein.

The molecular chaperone inhibitors are linked to a mitochondrialpenetrating moiety. The mitochondrial penetrating moiety can be, forexample, a basic or positively charged peptide sequence, e.g., from thethird helix of the Antennapedia-homeodomain (ANT). In some embodiments,the mitochondrial penetrating moiety can be a tetraguanidium compound asdescribed in Fernandez-Carneado et al. (J. Am. Chem. Soc., 127:869-874(2005)).

The link between the molecular chaperone inhibitor and the mitochondrialpenetrating moiety can be a covalent bond, e.g., a peptide bond or athioether bond. In some embodiments, e.g., one or both of the chaperoneinhibitor or the mitochondrial penetrating moiety is non-peptidic, e.g.,a small molecule, the molecular chaperone inhibitor and mitochondrialpenetrating moiety are joined through a chemical linker. In someembodiments, the link between a molecular chaperone inhibitor and amitochondrial penetrating moiety can be a non-covalent interaction,e.g., an ionic interaction. In another aspect, the present inventionalso features methods for identifying chaperone inhibitors. Inparticular, this invention features methods for identifying candidatecompounds that disrupt the interaction between Hsp90 and Cyclophilin D(CypD), between Hsp60 and CypD, or between TRAP-1 and CypD.

The invention provides several advantages. For example, the increasedexpression of the chaperones in mitochondria, as compared to normalcells as described herein, provide a targeted approach that can be usedto kill tumor cells without harming normal cells, thus minimizing sideeffects and increasing efficacy. In addition, a wide variety of tumorand cancer cell types show mitochondrial accumulation of chaperones,thus, numerous types of tumors and cancers that can be treated by themethods described herein.

This invention provides mitochondriotropic agents (e.g., mitochondriallytargeted chaperone inhibitors) that are advantageous over the art. Theseagents are localized to mitochondria with increased efficiency andselectively induce mitochondrial collapse and cell death in cells thatshow mitochondrial accumulation of chaperones (e.g., cancer cells).These agents have maximal effect on the function ofmitochondrially-localized chaperones present in transformed cells (e.g.,cancer cells) while having minimal effect on normal chaperone function(e.g., Hsp90 function in normal or non-transformed cells). Thus, theseagents are ideal candidates for cancer therapy as they are expected tohave lower toxicity than presently known chaperone inhibitors, which donot specifically inhibit mitochondrially-localized chaperones.

For example, Gamitrinibs as described herein are novel, small moleculeanticancer agents suitable for testing in humans. Although applicants donot wish to be bound by theory, the combinatorial design of Gamitrinibsefficiently targets them to mitochondria, thereby maximizing theircytotoxic effects on tumor cells while minimizing their effects onnon-tumor or normal cells. This is because of the presence of amitochondrial pool of chaperones (e.g., Hsp90 and TRAP1) in tumor cellsthat is vital to tumor cell survival but that is not present in normalcells or has negligible effect on normal cell survival. In addition, thecombinatorial design of Gamitrinibs minimizes their effects on non-tumoror normal cells which express chaperones predominantly in the cytosol.Compared to current Hsp90 inhibitors (see, e.g., Drysdale et al.,“Targeting Hsp90 for the treatment of cancer,” Curr Opin Drug DiscovDevel, 9:483-495 (2006)), Gamitrinibs have improved cytotoxic activityon tumor cells, supported by in vitro and in vivo results. Another keyadvantage is that these agents do not affect the general homeostaticfunctions of Hsp90 in the cytosol, and therefore do not elicitpotentially compensatory survival signals seen with general Hsp90antagonists, e.g. Hsp70 induction ((see, e.g., Drysdale et al., (2006)supra). Because mitochondrial Hsp90 chaperones are absent in most normaltissues (as demonstrated herein), Gamitrinibs are selective for tumorcells and have reduced toxicity for normal cells, making Gamitrinibsfavored candidates for anti-cancer therapy. In addition,tumor-associated Hsp90 binds ATPase pocket antagonists with higheraffinity compared to normal cells (see, e.g., Kamal et al., Nature,425:407-410 (2003)), and this may further protect normal organs with lowlevels of mitochondrial Hsp90, i.e. brain, from Gamitrinib-basedtherapy. Following the paradigm of Gamitrinibs, other chaperoneinhibitors, e.g., the purine inhibitors or resorcinol inhibitors (e.g.,piperazinyl, morpholino and piperidyl derivatives of the pyrazole-basedresorcinol Hsp90 inhibitor CCT018159), may be used to target cancercells (see, e.g., Sharp et al., Cancer Res. 67 (5):2206-16 (2007); Sharpet al., Mol Cancer Ther. 6 (4):1198-1211 (2007); Eccles et al., CancerRes. 68 (8):2850-60 (2008); Strausberg et al., Nature, 429:469-474(2004); Butcher, Nat Rev Drug Discov 4, 461-467 (2005); Philips, BiochemSoc Trans, 33:657-661 (2005)).

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Methods and materials aredescribed herein for use in the present invention; other, suitablemethods and materials known in the art can also be used. The materials,methods, and examples are illustrative only and not intended to belimiting. All publications, patent applications, patents, sequences,database entries, and other references mentioned herein are incorporatedby reference in their entirety. In case of conflict, the presentspecification, including definitions, will control.

Other features and advantages of the invention will be apparent from thefollowing detailed description and figures, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1A is a pair of immunoblots showing that the Hsp90-like chaperoneTRAP-1 localizes to mitochondria at increased levels in tumor cellsrelative to normal cells. Immunoblots of TRAP-1 and the mitochondrialmarker Cox-IV in cytosolic or mitochondrial extracts purified from theindicated tumor cell types (top panel), or mitochondria from normalmouse organs (bottom panel) are shown. β-Actin expression is shown as acontrol in the top panel.

FIGS. 1B-I are images of immunohistochemically stained primary tissuesamples showing in vivo expression of TRAP-1 in specimens of normalpancreas (B), breast (D), colon (F) or lung (H), or cases ofadenocarcinoma of pancreas (C), breast (E), colon (G), or lung (I).

FIG. 1J is a series of three related immunoblots of mitochondrial orcytosolic extracts showing that Hsp90 localizes to mitochondria in tumorcells. Cox-IV expression levels and β-actin expression levels are shownas controls.

FIGS. 1K-L are electron micrographs showing that an antibody to Hsp90localizes to isolated HeLa cell mitochondria (FIG. 1K) but that anon-specific antibody does not localize to isolated HeLa cellmitochondria (FIG. 1L).

FIG. 1M is a series of six related immunoblots of total cytosol extracts(TCE) or isolated mitochondria (PK-treated) or cytosolic extracts fromHeLa cells showing expression levels of Calnexin, Lamp-1, GAPDH, Cox-IV,TRAP-1, and Hsp90.

FIG. 2A is a set of two autoradiographs of extracts from purified mousebrain mitochondria incubated with ³⁵S-labeled, in vitro transcribed andtranslated Hsp90 or control PiC with or without valinomycin and treatedwith proteinase K (PK) showing levels of radiolabeled Hsp90 or controlPiC following treatment.

FIG. 2B is a pair of immunoblots of pellets (P) or supernatants (S) fromPK treated HeLa cell mitochondria incubated with varying concentrationsof digitonin showing protein levels of Hsp90 and mt-Hsp70 as control.

FIG. 2C is a set of four immunoblots of the protein content of HeLa cellmitochondria suspended in buffer with (SHE) or without (HE) sucrose inthe presence or absence of PK and having outer mitochondrial membranemechanically disrupted by repeated pipetting showing protein levels ofHsp90, Smac, and CypD.

FIG. 2D is a set of five immunoblots of total mitochondrial extracts(MTE) from HeLa cells, further fractionated outer membrane extracts(OM), intermembrane space extracts (IMS), inner membrane extracts (IM)and mitochondrial matrix extracts (Matrix) showing protein levels ofHsp90, VDAC, Cyt c, Cox-IV, and CypD.

FIG. 2E is a set of seven immunoblots of mouse organs fractionated intomitochondria (left) or cytosol (right), showing protein levels of Hsp90,Cox-IV, and Cyt c. β-actin is a cytosolic control.

FIG. 2F is a pair of immunoblots of total cell extracts from tumor(HeLa, MCF-7, Raji) or normal (HFF, HGF, WS-1) cells showing Hsp90 andTRAP-1 levels. β-actin is a control.

FIG. 2G is a set of seven immunoblots of indicated normal cell types orcontrol HeLa cells fractionated in mitochondria (left three blots) orcytosolic extracts (right four blots), showing levels of Hsp90, TRAP-1,and Cox-IV. β-actin is a control.

FIGS. 3A-D are fluorescence microscopy images of mitochondrialaccumulation of FITC-conjugated Shepherdin with (A, C) or without (B)Antennapedia cell-penetrating sequence (ANT) or scrambled peptidomimeticwith ANT (D) incubated in the presence (A, B, D) or absence (C) of HeLacell mitochondria showing that both Shepherdin with ANT (Sheph-ANT) andcell permeable scrambled peptidomimetic with ANT (Scram-ANT) accumulatein mitochondria.

FIG. 3E is a bar graph of the fluorescence intensity quantified inisolated mitochondrial fractions following treatment of cells withFITC-conjugated Sheph-ANT or FITC-conjugated Scram-ANT, showing thatSheph-ANT and Scram-ANT accumulate to similar levels in mitochondria.

FIG. 3F is a bar graph of fluorescence intensity quantified in extractsof mitochondria and mitochondrial fractions isolated from HeLa cellmitochondria incubated with FITC-conjugated Shepherdin (Sheph), orFITC-conjugated Shepherdin with ANT (Sheph-ANT), showing that Sheph-ANTaccumulates in the mitochondria, outer membrane/inner membrane space(OM+IMS), and inner membrane/matrix (IM+Matrix). Untreated sample (None)is a control.

FIG. 3G is a pair of immunoblots of eluted fractions from Rajimitochondrial extracts (MTE) fractionated over Shepherdin-Sepharose(top) or scrambled peptidomimetic-Sepharose (bottom) beads, showing thatHsp90 and TRAP-1 are bound by Shepherdin-Sepharose and not scrambledpeptidomimetic-Sepharose.

FIG. 3H is a line graph of mitochondrial membrane potential over timegiven increasing concentrations (μg) of TMRM-loaded mitochondriapurified from HeLa cells incubated with Sheph-ANT and analyzed forchanges in fluorescence emission, showing that Sheph-ANT induces achange in mitochondrial membrane potential and that the effect decreaseswith increasing concentrations of mitochondria. A scrambledpeptidomimetic (Scram-ANT) was incubated with 60 μg of TMRM-loadedmitochondria as control.

FIG. 3I is a pair of immunoblots of extracts from purified mitochondriaof Raji cells treated with Sheph-ANT or Scram-ANT, showing thatSheph-ANT treatment reduces mitochondrial Cyt c in a dose-dependentmanner.

FIG. 3J is a set of three immunoblots of extracts from a primary humansarcoma sample obtained by treating sample with Sheph-ANT or Scram-ANTand fractionating mitochondria (Mito) from supernatant (Sup), showingthat Sheph-ANT treatment increases Cyt c release into the supernatant ina dose-dependent manner.

FIG. 3K is an immunoblot of HeLa cell mitochondria incubated with DMSOor 17-AAG, showing protein levels of inner mitochondrial membraneproteins Smac and Cyt c.

FIG. 3L is an immunoblot of supernatants from 17-AAG-treated HeLa cellmitochondria, showing Smac and Cyt c levels in the supernatant.Mitochondrial extract (MTE) is used as a control.

FIG. 4A are two line graphs showing mitochondrial membrane potentialover time following the addition of Sheph-ANT or Scram-ANT in primaryWS-1 fibroblasts (left) or Raji lymphoblastoid cells (right).

FIG. 4B shows three sets of immunoblots of total cell extracts (TCE, twoblots on the left) or extracts from isolated mitochondrial (middle setof three blots) and cytosolic (right hand set of four blots) fractionsobtained after incubating normal WS-1 fibroblasts or HeLa cells in thepresence (+) or absence (−) of glucose, showing protein levels of Hsp90,TRAP-1, or Grp94. CoxIV and β-actin are controls.

FIG. 4C is a graph of mitochondrial membrane potential over timefollowing the addition of Sheph-ANT or Scram-ANT to TMRM-loadedmitochondria isolated from glucose-starved WS-1 fibroblasts.

FIG. 4D is a pair of immunoblots of extracts from isolated mitochondriafrom normal mouse liver incubated with Sheph-ANT or Scram-ANT.

FIG. 4E is two line graphs of mitochondrial membrane potential over timefollowing the addition of Sheph-ANT or Scram-ANT to TMRM-loadedmitochondria isolated from normal mouse liver (left) or normal mousebrain (right).

FIG. 4F is a set of four immunoblots of mitochondrial (MTE) or cytosolicextracts from wildtype NIH3T3 (normal) or Ras-transformed NIH3T3fibroblasts, showing Hsp90, TRAP-1 protein levels. Cox-IV and β-actinare controls.

FIG. 4G consists of two line graphs of mitochondrial membrane potentialover time following addition (at arrow) of Sheph-ANT or Scram-ANT toTMRM-loaded mitochondria isolated from NIH3T3 (left) or Ras-transformedNIH3T3 (right) fibroblasts, showing that Sheph induces loss ofmitochondrial membrane potential in transformed cells.

FIG. 5A and FIG. 5B are confocal microscopy images of HeLa cellsdoubled-labeled with a mitochondrial stain (MitoTracker) andFITC-conjugated Sheph-ANT (FIG. 5A) or FITC-conjugated Scram-ANT (FIG.5B) and analyzed by image merging.

FIG. 5C is a bar graph showing fluorescence intensity in total cellextracts (TCE), cytosolic extracts, or mitochondrial extracts of HeLacells treated with FITC-conjugated Sheph-ANT or FITC-conjugatedScram-ANT.

FIG. 5D is a line graph showing mitochondrial membrane potential overtime following the addition of Sheph-ANT (solid line), 17-AAG (dottedline), or Scram-ANT (broken line) in JC-1-loaded Raji cells.

FIG. 5E panels are immunoblots of cytosolic extracts from HeLa cellsincubated with different concentration of 17-AAG, showing cytochrome cand β-actin as a control.

FIG. 5F panels are time-lapse video microscopy still images of HeLacells treated with Sheph-ANT or Scram-ANT showing cellular morphology ofapoptosis (top, right panel) or mitochondria fusion/fission (bottom,right panel).

FIG. 5G consists of two line graphs showing percent viabilities, asdetermined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) viability analysis, of tumor cells (left) and normal cells(right) incubated with increasing concentrations of Sheph-ANT (solidline) or increasing concentrations of Scram-ANT (broken line).

FIG. 5H consists of two line graphs showing percent viabilities, asdetermined by MTT, of tumor cells (left) and normal cells (right)incubated with increasing concentrations of 17-AAG for 4 hours (left) or24 hours (right).

FIG. 6A is a set of two immunoblots of mitochondrial TRAP-1 and CypDimmunoprecipitated using antibody to TRAP-1 or IgG (as control), frompurified Raji mitochondrial extracts treated with cyclosporine A (CsA)or geldanamycin (GA). Mitochondrial extracts not treated with any drug(None) is a control.

FIG. 6B is a set of two immunoblots of Hsp90 and CypD immunoprecipitatedfrom Raji mitochondrial extracts treated with (+) or without (−) CsAusing antibody to Hsp90 or IgG (as control).

FIG. 6C is a set of three immunoblots; the upper and middle panels areimmunoblots of Hsp90 and TRAP-1 captured from Raji mitochondrialextracts treated with CsA or GA or no drug (None) using GST (as control)or GST-CypD. The lower panel is the Coomassie stained gel correspondingto immunoblots in upper and middle panels.

FIG. 6D is a line graph showing mitochondrial membrane potential overtime following addition (at arrow) of Sheph-ANT or Scram-ANT in thepresence (broken line) or absence (solid line) of CsA to TMRM-loadedmitochondria isolated from HeLa cells.

FIG. 6E is a line graph showing percent viability, as determined by MTT,of HeLa cells treated with increasing concentrations of Sheph-ANT (solidsymbols) or Scram-ANT (open symbols) in the presence (circles) orabsence (squares) of CsA.

FIG. 6F is a line graph showing percent viability, as determined by MTT,of HeLa cells transfected with control siRNA (open symbols) orCypD-directed siRNA (solid symbols), treated with increasingconcentrations of Sheph-ANT (squares) or Scram-ANT (circles).

FIG. 6G is a bar graph showing percent viability, as determined by MTT,of HeLa cells transfected with control siRNA or TRAP-1-directed siRNA inthe presence or absence of CsA.

FIG. 6H is a set of two pairs of immunoblots of extracts of HeLa cellstransfected with control siRNA, or CypD-directed siRNA (top set of twopanels) or TRAP-1-directed siRNA (bottom set of two panels).Non-transfected cultures (None) are controls. β-actin immunoblots arecontrols.

FIG. 6I is a bar graph of percent viability, as determined by MTT, ofnormal WS-1 fibroblasts transfected with pcDNA3 (as a control) or TRAP-1cDNA, treated with increasing concentrations of staurosporine.

FIG. 7A is a line graph showing mitochondrial membrane potential overtime following addition (at arrow) of ANT-GA or the uncoupled mixtureGA/ANT, for varying concentrations (μg) of TMRM-loaded mitochondriaisolated from HeLa cells. The uncoupled mixture GA/ANT, incubated with60 μg of isolated mitochondria, is a control.

FIG. 7B consists of two line graphs showing mitochondrial membranepotential over time following addition (at arrow) of ANT-GA or theuncoupled mixture GA/ANT with or without CsA of TMRM-loaded mitochondriaisolated from HeLa cells (left) or mouse brain (right).

FIG. 7C is a pair of sets of two immunoblots of cytochrome c releasedfrom isolated HeLa cell mitochondria (top set of two panels) or isolatedmouse-liver mitochondria (bottom set of two panels) treated with ANT-GAor the uncoupled mixture of GA/ANT.

FIG. 7D is a line graph showing percent viability, as determined by MTT,of HeLa cells incubated with GA, ANT-GA, or GA/ANT at varyingconcentrations.

FIG. 7E is a line graph showing percent viability, as determined by MTT,of primary human fibroblasts WS-1 (black), HGF (purple), or HFF (green),treated with ANT-GA (solid squares) or GA/ANT (open circles). Prostatecancer PC3 cells (blue) are a control.

FIG. 7F is four scatter plots, with propidium iodide staining intensityon the y-axis and DEVDase activity on the x-axis, of flow cytometryanalysis of p53^(+/+) (two plots at top) and p53^(−/−) (two plots atbottom) HCT116 cells treated with ANT-GA (two plots at left) or theGA/ANT (two plots at right). The percentage of cells in each quadrant isindicated.

FIG. 8 is a set of four immunoblots. The top panel is an Hsp90immunoblot of proteinase K (PK) treated mitochondria isolated fromtestis, lung, spleen, kidney, brain, and liver, showing minimalexpression in testis and brain, only. Bcl-2 (middle panels) and Cox-IV(bottom panel) immunoblots were used as negative and positive controls,respectively. A Bcl-2 immunoblot in brain mitochondria without PKtreatment was also used as a positive control (panel to left).

FIG. 9 is a pair of immunoblots. The upper panel is a Cyt c immunoblotof extracts prepared from mitochondria isolated from primary p53−/−mouse lymphoma specimen and incubated with Sheph-ANT or Scram-ANT. ACox-IV immunoblot was used as a positive control (lower panel).

FIG. 10A is a set of two immunoblots. The top panel is a CypD immunoblotin which GST or GST-TRAP-1 was incubated with recombinant CypD withaddition of CsA, GA, or no drug, showing that GST-TRAP1 CypD is pulleddown by GST-TRAP-1 but not GST. The bottom panel of FIG. 10A is aCoomassie stain of the immunoblotted gel.

FIG. 10B is a set of two immunoblots. The top panel is an autoradiographof a protein gel from electrophoresis of GST or GST-CypD pull-down of invitro transcribed and translated ³⁵S-labeled Hsp90. FIG. 10B, bottompanel, is a Coomassie stain of the gel used in the experiment.

FIG. 10C is a set of two immunoblots. The top panel is an autoradiographof a protein gel from electrophoresis of GST or GST-Hsp90 pull-down ofin vitro transcribed and translated ³⁵S-labeled CypD. FIG. 10C, bottompanel, is a Coomassie stain of the gel used in the experiment.

FIG. 11 is a bar graph showing percent viability, as determined by MTT,of normal HFF human fibroblasts transfected with pcDNA3 (as a control)or TRAP-1 cDNA and treated with various concentrations of staurosporine.

FIG. 12A is a set of six panels of images; the top and middle rows arefluorescent microscopy images of FITC-GA (top, left panel), FITC-ANT(top, right panel), or FITC-ANT-GA (middle, left panel) incubated withpurified Raji cell mitochondria or FITC-ANT-GA (middle, right panel)incubated without purified Raji cell mitochondria. The panels in thebottom row are FITC-ANT-GA incubated with purified Raji cellmitochondria before (bottom, left panel) and after (bottom, right panel)PK treatment.

FIG. 12B is a diagram showing one scheme for the coupling of 17-AAG or17-GMB-APA-GA to ANT by a thioether linkage to produce ANT-GA.

FIG. 12C is a pair of mass spectrographs. The upper panel is a massspectrum of the coupling reaction performed to produce ANT-GA showingthe peak for 17-GMP-APA-GA at arrow. The lower panel is a mass spectrumof the coupling reaction of performed to produce ANT-GA showing thepeaks for ANT and ANT-GA at arrows.

FIG. 12D is an immunoblot showing Akt expression (upper panel) in HeLacells treated with ANT-GA (middle lane) or the uncoupled mixture GA/ANT(right lane). Untreated HeLa cells were used as a control (left lane).β-actin was used as a control (bottom panel, lanes as in the top panel).

FIG. 13A is a pair of Western blots showing Hsp60 and COX-IV expressionin isolated cytosolic (C) or mitochondrial (M) fractions from MCF-7 orHCT116 cells (top panel), or primary WS-1 or HFF human fibroblasts(bottom panel).

FIG. 13B is a set of six photomicrographs showing primary human tissuespecimens of adenocarcinoma of breast, colon, or lung (tumor), ormatched normal tissues (normal) stained with an antibody to Hsp60, andanalyzed by immunohistochemistry. Magnification, ×200.

FIG. 13C is a set of six plots showing the results of experiments inwhich 74INT normal epithelial cells or primary WS-1 normal fibroblastswere transfected with non-targeted or Hsp60-directed siRNA, and analyzedby DEVDase activity and propidium iodide staining by multiparametricflow cytometry. The percentage of cells in each quadrant is indicated.None, non transfected cells.

FIG. 14 is an informal sequence listing of the sequences set forthherein.

FIG. 15A is a diagram showing the combinatorial modular structure ofGamitrinibs in which TBDPS indicates tert-butyldiphenylsilyl.

FIG. 15B left panel at top is an autoradiogram showing chaperoneactivity as Chk1-dependent phosphorylation of Cdc25 in cells treatedwith 17-AAG or Gamitrinib-G4 (indicated as “G4”) (1-10 μM) with loadingcontrols shown at middle (Cdc25) and bottom (GST-Chk1). The right panelis a bar graph showing densitometric quantification of the bands shownin the left panel and is representative of two experiments.

FIG. 15C is a bar graph quantifying mitochondrial accumulation of 17-AAGor Gamitrinib-G4 (indicated as “G4”) in which “None” indicates vehiclecontrol. Mean±SEM (n=3).

FIG. 16A is a line graph showing mitochondrial inner membrane potentialover time in TMRM-loaded mitochondria treated with Gamitrinib-G1 (“G1”),Gamitrinib-G2 (“G2”), Gamitrinib-G3 (“G3”), Gamitrinib-G4 (“G4”),Gamitrinib-TPP (“TPP”), GA, or 17-AAG (at a concentration of 1 μM) andanalyzed for fluorescence emission.

FIG. 16B, left panel is a line graph showing mitochondrial innermembrane potential over time in TMRM-loaded mitochondria incubated with17-AAG mixed with tetraguanidinium (17-AAG+TG-OH), 17-AAG and 1 μMCyclosporin A (“17-AAG+CsA”), 1.5 μM Gamitrinib-G4 (“G4”), 1.5 μMGamitrinib-G4 and 1 μM Cyclosporin A (“G4+CsA”). The right panel is aline graph showing mitochondrial inner membrane potential over time inTMRM-loaded mitochondria incubated with GA mixed withtriphenylphosphonium (“GA+TPP-OH”), GA mixed with triphenylphosphoniumand 1 μM Cyclosporin A (“GA+TPP-OH+CsA”), triphenylphosphonium by itself(“TPP”) and triphenylphosphonium and 1 μM Cyclosporin A (“TPP+CsA”).Arrows indicate point of addition.

FIG. 16C is a panel of immunoblots showing cytochrome c release insupernatants (S) or pellets (P) showing Cox-IV as a mitochondrial markerin tumor mitochondria treated with Gamitrinib-G1 (“G1”), Gamitrinib-G2(“G2”), Gamitrinib-G4 (“G4”), or 17-AAG (20 minutes).

FIG. 16D is a line graph showing percent cytochrome c release over timefrom mitochondria incubated with IPI-504, BIIB021, NVP-AUY922, 17-AAG,or Gamitrinib-G4 (“G4”) for 3 hours. Data are representative of twoindependent experiments.

FIG. 17A consists of two line graphs showing percent viability of H460cells, as analyzed by MTT, treated with Gamitrinib-G1 (“G1”),Gamitrinib-G2 (“G2”), Gamitrinib-G3 (“G3”), Gamitrinib-G4 (“G4”),Gamitrinib-TPP (“TPP”), or 17-AAG at different concentrations after 3hours of treatment in the line graph to the left and after 24 hours oftreatment in the line graph to the right. Mean±SD (n=2).

FIG. 17B is a line graph showing percent viability over time of SKBr3cells treated with Gamitrinib-G4 (“G4”), Gamitrinib-TPP (“TPP”), or17-AAG (at a concentration of 10 μM) and analyzed by MTT.

FIG. 17C is a bar graph showing the percentage of dead cells as analyzedby Trypam blue staining in SKBr3 cells treated with 10 μM ofGamitrinib-G4 (“G4”), Gamitrinib-TPP (“TPP”), or 17-AAG at the indicatedtime intervals. Mean±SEM (n=3).

FIG. 17D consists of four scatter plots. H460 cells were treated withGamitrinib-G4 (“G4”) or vehicle for four hours and were labeled withJC-1, and analyzed (by multiparametric flow cytometry) for loss ofmitochondrial membrane potential by changes in FL2/FL1 fluorescenceratio as shown in the scatter plots at top, or DEVDase (caspase)activity as shown in the scatter plots at bottom. The percentage ofcells in each quadrant is indicated and PI is used to indicate propidiumiodide.

FIG. 17E are two pictures of colony formation in soft agar showingcolony formation after two weeks using H460 cells treated with vehicle(None) for 4 hours in the top picture and colony formation after twoweeks using H460 cells treated with Gamitrinib-G4 (“G4”) at 50 μM for 4hours in the bottom picture. Magnification, ×200.

FIG. 17F is a line graph showing percent viability as a function ofconcentration Gamitrinib-G4 (solid lines) or 17-AAG mixed with TG-OH(dashed lines) in tumor cell lines (K562, black; MDA-MB-231, lightorange; U87MG, red; MCF-7, pink; H1975, light brown; DU145, orange;H460, blue; HCT116, purple; HL-60, violet; Raji, dark pink; THP-1,green) as analyzed by MTT. Data are representative of two experiments.

FIG. 17G is a line graph showing percent viability as a function ofconcentration 17-AAG (circles) or Gamitrinib-G4 (squares) in H460 cellstransfected with control (closed symbols) or CypD (open symbols) siRNAas analyzed by MTT. Mean±SEM (n=3).

FIG. 17H is a series of immunoblots showing Akt, Hsp70, Chk1, and GAPDHprotein levels in HeLa cells treated with Gamitrinib-G1 (“G1”),Gamitrinib-G2 (“G2”), Gamitrinib-G3 (“G3”), Gamitrinib-G4 (“G4”),Gamitrinib-TPP (“TPP”), or 17-AAG (at a concentration of 5 μM for 24hours).

FIG. 18A consists of two line graphs at top and bottom. The line graphat top shows tumor volume as a function of time in SCID/beige micecarrying H460 lung adenocarcinoma xenograft tumors (100-150 mm³) andtreated with Gamitrinib-G4 (“G4”) or 17-AAG. The line graph at bottomshows tumor volume as a function of time in mice treated with a doseescalation regimen as described in Example 11 with vehicle,Gamitrinib-G1 (“G1”) or Gamitrinib-TPP (“TPP”). Tumor volume wasmeasured with a caliper.

FIG. 18B shows two images labeled “Vehicle” and “G4” of internucleosomalDNA fragmentation in tumor specimens from vehicle (“Vehicle”) orGamitrinib-G4 (“G4”) treated tumors as visualized in situ by TUNEL. Thebar graph at bottom shows quantification of positive cells.Magnification, ×400. ***, p<0.0001.

FIG. 18C shows a series of immunoblots for cytochrome c (Cyto c),Cox-IV, and GAPDH in cytosolic fractions of H460 xenograft tumorsharvested from vehicle- or Gamitrinib-G4 (“G4”) treated animals. Twomice/group (animal #) were analyzed.

FIG. 18D is a bar graph showing percentage weight loss in mice treatedwith vehicle, 17-AAG, Gamatrinib-G1 (“G1”), Gamatrinib-G4 (“G4”), orGamatrinib-TPP (“TPP”) as measured at the end of the experiment.Mean±SEM.

FIG. 18E is a line graph showing percentage membrane potential over timein TMRM-loaded mitochondria isolated from normal WS-1 fibroblasts andincubated with uncoupled 17-AAG/TG-OH or Gamitrinib-G4 (“G4”), with orwithout CsA. Arrow, point of addition.

FIG. 18F shows two immunoblots for Cyto c and Cox-IV in mitochondriaisolated from normal HFF fibroblasts or HeLa cells and treated withGamitrinib-G1 (“G1”), Gamitrinib-G2 (“G2”), Gamitrinib-G3 (“G3”),Gamitrinib-G4 (“G4”), Gamitrinib-TPP (“TPP”), or 17-AAG. Cox-IV was usedas a mitochondrial marker.

FIG. 18G is a line graph showing percent viability as a function ofconcentration of Gamitrinib-G4 (solid lines) or 17-AAG (dashed lines) inhuman fibroblasts (HFF, black line), bovine aortic endothelial cells(medium grey), intestinal epithelial cells (dark grey), or humanumbilical vein endothelial cells (light grey) as analyzed by MTT after24 hours of incubation. Data are representative of two experiments.

FIG. 19 is a schematic diagram of chemical structures of GA (17-AAG),IPI-504, and non-GA based (BIIB021 and NVP-AUY922) Hsp90 inhibitors usedin these studies.

FIG. 20A is a line graph showing human acute leukemia HL-60 tumor volumeover time (2/mouse, 6 tumors/group) treated with vehicle orGamitrinib-G4 (“G4”) at 2 mg/kg twice daily i.p. (HL-60) for theduration of treatment. Arrow, start of treatment.

FIG. 20B is a line graph showing human breast adenocarcinoma MDA-MB-231tumor volume over time (2/mouse, 6 tumors/group) treated with vehicle orGamitrinib-G4 (“G4”) with a dose escalation regimen (MDA-MB-231)starting at 2 mg/kg twice daily (day 0-2), 2.5 mg/kg twice daily (day3-5), and 3 mg/kg twice daily for the duration of treatment. Arrow,start of treatment.

DETAILED DESCRIPTION

Mitochondria play a critical role in cell survival and cell death(Pandey et al., EMBO J., 19:4310-4322 (2000); Green and Kroemer,Science, 305:626-629, (2004)). Dysfunction and loss of integrity ofthese organelles are molecular prerequisites of multiple cell deathpathways, characterized by increased permeability of the innermitochondrial membrane, loss of membrane potential, swelling of thematrix, and ultimately rupture of the outer membrane with release ofapoptogenic proteins, i.e., cytochrome c, in the cytosol (Green andKroemer, Science, 305:626-629, (2004)). How this process, known as“mitochondrial permeability transition,” is regulated is not completelyunderstood (Green and Kroemer, Science, 305:626-629, (2004)); componentsof the permeability transition pore, including the voltage-dependentanion channel (VDAC-1), the adenine nucleotide translocator (ANT), orthe immunophilin Cyclophilin D (CypD), were found to be eitherdispensable (Kokoszka et al., Nature, 427:461-1465, (2004); Krauskopf etal., Biochim. Biophys. Acta, 1757:590-595, (2006)), or implicated insome, but not all forms of mitochondrial cell death (Baines et al.,Nature, 434:658-662, (2005); Nakagawa et al., Nature, 434:652-658,(2005)).

The present invention is based, at least in part, on the discovery thatthe molecular chaperones Hsp60, Hsp90 and TRAP-1 are found at increasedlevels in mitochondria of tumor cells, and that inhibition of molecularchaperones in tumor cell mitochondria using mitochondrial-targetedchaperone inhibitors results in cancer cell death. Without wishing to bebound by theory, the inhibition of these mitochondrial chaperones mayresult in the activation of mitochondrial permeability transition withcollapse of mitochondrial function, including loss of mitochondrialmembrane potential and release of cytochrome c, which leads to celldeath.

Thus, described herein are mitochondriotropic agents that include achaperone inhibitor, e.g., an HSPA9, Hsp60, Hsp90 or TRAP-1 inhibitor,and a mitochondrial penetrating moiety, optionally with an interveninglinker, and methods of making and using these compositions to treatdisorders associated with aberrant cellular proliferation, e.g., cancerand tumors, e.g., to kill cancer and tumor cells, e.g., in vivo and invitro. Also described herein are compositions containing thesemitochondriotropic agents.

I. Molecular Chaperones

Molecular chaperones, especially members of the Heat Shock Protein (Hsp)gene family (Lindquist and Craig, Annu. Rev. Genet. 1988; 22:631-77),assist in protein folding quality control, protein degradation, andprotein trafficking among subcellular compartments (Hartl andHayer-Hartl, Science 2002; 295:1852-8). This involves periodic cycles ofATPase activity, recruitment of additional chaperones, andcompartmentalization in subcellular microdomains, including mitochondria(Young et al., Cell 2003; 112:41-50). Molecular chaperones have oftenbeen associated with enhanced cell survival (Beere, J Cell Sci 2004;117:2641-51), via suppression of apoptosome-initiated mitochondrial celldeath (Paul et al., Mol Cell Biol 2002; 22:816-34), increased stabilityof survival effectors (Sato et al., Proc Natl Acad Sci USA 2000;97:10832-7), and inactivation of p53 (Wadhwa et al., J Biol Chem 1998;273:29586-91). As described herein, the chaperone anti-apoptoticfunction play a central role in tumor cell maintenance and can beselectively targeted to kill cancer cells. See also: Whitesell et al.,Nat Rev Cancer 2005; 5:761-72; and Isaacs et al., Cancer Cell 2003;3:213-7.

The following is a brief description of some of the molecular chaperonesthat can be targeted using the present methods. In some embodiments, amolecular chaperone polypeptide useful in the present methods (e.g., inscreening methods) is at least about 90%, 95%, 99%, or 100% identical toan amino acid sequence described herein (e.g., to a human sequence). Insome embodiments, a nucleic acid encoding a molecular chaperone usefulin the present methods (e.g., in screening methods) is at least about90%, 95%, 99%, or 100% identical to a nucleic acid sequence describedherein (e.g., to a human sequence).

The comparison of sequences and determination of percent identitybetween two sequences can be accomplished using a mathematicalalgorithm. For example, the percent identity between two amino acidsequences can determined using the Needleman and Wunsch ((1970) J. Mol.Biol. 48:444-453) algorithm which has been incorporated into the GAPprogram in the GCG software package (available on the world wide web atgcg.com), using the default parameters, e.g., a Blossum 62 scoringmatrix with a gap penalty of 12, a gap extend penalty of 4, and aframeshift gap penalty of 5.

Hsp90 (Heat-Shock 90-kD Protein 1)

HSP90 is a molecular chaperone that plays a key role in theconformational maturation of a number of proteins, including oncogenicsignaling proteins. As described herein, Hsp90 accumulates in themitochondria of cancer cells, but not normal cells, and can be targetedusing the compositions described herein including amitochondrial-penetrating sequence.

GenBank Acc. Nos. for human Hsp90 include NM_(—)001017963.2 (nucleicacid) and NP_(—)001017963.2 (protein), for heat shock protein 90 kDaalpha (cytosolic), class A member 1 isoform 1, and NM_(—)005348.3(nucleic acid) NP_(—)005339.3 (protein), for heat shock protein 90 kDaalpha (cytosolic), class A member 1 isoform 2. Variant 2 differs in the5′ UTR and coding sequence compared to variant 1. The resulting isoform2 is shorter at the N-terminus compared to isoform 1.

Hsp90 is also known as HSPCA; HSPC1; HSP90A; HSP89-ALPHA (HSP89A);Lipopolysaccharide-Associated Protein 2 (LAP2); and LPS-associatedprotein 2.

TRAP-1 (TNF Receptor-Associated Protein 1)

TRAP-1 has high homology to hsp90, and binds the type 1 tumor necrosisfactor receptor (see Song et al., J. Biol. Chem., 270:3574-3581 (1995)).The deduced 661-amino acid protein is 60% similar to HSP90 familymembers, although it lacks the highly charged domain found in HSP90proteins. See, e.g., Felts et al., J Biol. Chem. 2000; 275(5):3305-12.As described herein, TRAP-1 accumulates in the mitochondria of cancercells, but not normal cells, and can be targeted using the compositionsdescribed herein including a mitochondrial-penetrating sequence.

GenBank Acc. Nos. for human TRAP-1 include NM_(—)016292.2 (nucleic acid)and NP_(—)057376.2 (amino acid). TRAP-1 is also referred to asHeat-Shock Protein, 75-KD (HSP75); Tumor Necrosis FactorReceptor-Associated Protein 1; TRAP1; and TNFR-Associated Protein 1.

Hsp60 (Heat-Shock 60-kD Protein 1)

Hsp60, together with its associated chaperonin, Hsp10, has beenrecognized as an evolutionary conserved stress response chaperone (Zhaoet al., Embo J 2002; 21:4411-9), largely, but not exclusivelycompartmentalized in mitochondria (Soltys and Gupta, Int Rev Cytol 2000;194:133-96), and with critical roles in organelle biogenesis andfolding/refolding of imported preproteins (Deocaris et al., Cell StressChaperones 2006; 11:116-28). However, whether Hsp60 also contributes tocell survival is controversial, with data suggesting a pro-apoptoticfunction via enhanced caspase activation (Samali et al., Embo J 1999;18:2040-8; Xanthoudakis et al., Embo J 1999; 18:2049-56), or,conversely, an anti-apoptotic mechanism involving sequestration ofBax-containing complexes (Shan et al., J Mol Cell Cardiol 2003;35:1135-43). A role of Hsp60 in cancer was equally uncertain, as up-(Thomas et al., Leuk Res 2005; 29:1049-58; Cappello et al., BMC Cancer2005; 5:139), or down-regulation (Tang et al., Cell Stress Chaperones2005; 10:46-58; Cappello et al., Cancer 2006; 107:2417-24) of thischaperone has been reported in various tumor series correlating withdisease outcome. As described herein, Hsp60 is highly expressed in tumorcells, as compared to normal cells, and targeting of Hsp60 causesmitochondrial dysfunction and apoptosis, whereas loss of Hsp60 in normalcells is well tolerated, and does not result in cell death.

Hsp60 is also known as CPN60; GROEL; HSP60; HSP65; SPG13; and HuCHA60.Exemplary GenBank Acc. Nos. for human Hsp60 include NM_(—)002156.4(nucleic acid) and NP_(—)002147.2 (protein) for transcript variant 1(the longer variant), and NM_(—)199440.1 (nucleic acid) andNP_(—)955472.1 (protein) for transcript variant 2. Variant 2 differs inthe 5′ UTR compared to variant 1. Both variants 1 and 2 encode the sameisoform.

HspA9 (Heat Shock 70 kDa Protein 9

HspA9 belongs to the heat shock protein 70 family, which contains bothheat-inducible and constitutively expressed members. The latter arecalled heat-shock cognate proteins, of which HspA9 is one. HspA9 plays arole in the control of cell proliferation, and may also act as achaperone. See, e.g., Wadhwa et al., Int J Cancer. 2006;118(12):2973-80; Wadhwa et al., J Gene Med. 2004; 6(4):439-44.

HspA9 is also known as mortalin, mthsp70, and GRP75. Exemplary GenBankAcc. Nos. for human HspA9 include NM_(—)004134.5 (nucleic acid) andNP_(—)004125.3 (protein), the heat shock 70 kDa protein 9 precursor.

II. Inhibitors of Molecular Chaperones

The compositions and methods described herein include the use ofinhibitors of molecular chaperones, e.g., inhibitors or Hsp60, HspA9,Hsp90 and/or TRAP-1. The inhibitors useful in the methods andcompositions described herein act directly on the chaperone proteinitself, i.e., they do not act upstream or downstream. A number of suchinhibitors are known in the art, e.g., peptide inhibitors and smallmolecule inhibitors. In some embodiments, the molecular chaperoneinhibitors useful in this invention inhibit the ATPase activity of thechaperone, e.g., of Hsp60, HspA9, Hsp90, and/or TRAP-1. In someembodiments, the molecular chaperone inhibitors useful in this inventioninhibit the binding of Hsp60, HspA9, Hsp90, or TRAP-1 to Cyclophilin D.In some embodiments, the molecular chaperone inhibitors useful in thisinvention inhibit the binding of Hsp60, HspA9, Hsp90, or TRAP-1 tosurvivin. In some embodiments, molecular chaperone inhibitors bind to achaperone, and induce the proteasomal degradation of the chaperone'sclient proteins.

In addition, there are numerous methods useful for identifying,designing, and assaying candidate chaperone inhibitors. For example,rational screening methods have been used to identify additionalmolecules that target Hsp90, using a computational approach using ashepherdin peptide (LFACGSSHK, all D-amino acids, as a scaffold toscreen a database of nonpeptidic structures. See, e.g., Meli et al., J.Med. Chem., 49:7721-7730 (2006).

Peptide Inhibitors of Molecular Chaperones

A number of peptide inhibitors of molecular chaperones, e.g., of Hsp90and/or TRAP-1, are known in the art. The inhibitors useful in thecompositions and methods described herein can include the entire peptideor polypeptide (e.g., all of an apoptosis-inducing protein (AIP such assurvivin), or an active (i.e., inhibitory) fragment thereof that retainsthe Hsp90 inhibitory activity of the parent, i.e., at least 40% of theactivity of the parent; an active fragment preferably has at least 50%,60%, 70%, 80%, 90%, 100% or more of the Hsp90-inhibitory activity of theparent polypeptide.

Survivin Peptides and Derivatives

Survivin peptides and peptide derivatives are disclosed in U.S. patentapplication Ser. No. 11/187,230 (herein incorporated by reference in itsentirety). Active survivin peptides share a core Hsp90 binding sequencemotif of SEQ ID NO:2 (His Ser Ser Gly Cys), which is located in thesingle Baculovirus Inhibitor of Apoptosis (IAP) Repeat (BIR) domain ofthe Survivin protein. This motif corresponds to amino acid residues atposition 80-84 of full-length Survivin (SEQ ID NO:1). Peptides includingthis motif, and peptide derivatives thereof, can (a) bind to theN-terminal ATPase domain of Hsp90 (the “ATP pocket”) and (b) inhibitHsp90-Survivin protein-protein interactions in vitro and in vivo.

The terms Survivin peptide and Survivin peptide derivative, as usedherein, refer to peptides that include less than the complete amino acidsequence of a functional Survivin protein that prevents cell death.Survivin peptides and peptide derivatives useful to this inventioninhibit molecular chaperones and in particular, inhibit interactionbetween a molecular chaperone, e.g., Hsp90 or TRAP-1, and Cyclophilin D.

The full-length human, wild type Survivin polypeptide has the followingamino acid sequence:

(SEQ ID NO: 1) MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQLAAMD

The following table (Table 1) lists some exemplary Survivin peptidesthat can bind to Hsp90:

TABLE 1 Exemplary Survivin peptides SEQ ID NO: 2 His Ser Ser Gly CysSEQ ID NO: 3 Lys His Ser Ser Gly Cys Ala Phe Leu Ser Val LysSEQ ID NO: 4 Ile Asp Asp His Lys Lys His Ser Ser Gly Cys Ala Phe LeuSEQ ID NO: 5 Lys Lys His Ser Ser Gly Cys Ala Phe Leu SEQ ID NO: 6Lys His Ser Ser Gly Cys SEQ ID NO: 7 His Ser Ser Gly Cys AlaSEQ ID NO: 8 Lys His Ser Ser Gly Cys Ala SEQ ID NO: 9Lys Lys His Ser Ser Gly Cys SEQ ID NO: 10 His Ser Ser Gly Cys Ala PheSEQ ID NO: 11 His Lys Lys His Ser Ser Gly Cys AlaPhe Leu Ser Val Lys Lys SEQ ID NO: 12Lys His Ser Ser Gly Cys Ala Phe Leu

Variants of Survivin peptides can also be used in the methods andcompositions described herein. Conservative and non-conservative aminoacid substitutions may be made. In particular, conservative amino acidsubstitutions can be made for one or more, e.g., up to five, ten,twenty, or thirty, amino acids outside of the core pentamer sequencecorresponding to His 80 to Cys 84 in SEQ ID NO:1 (i.e., SEQ ID NO:2 setforth above). Peptidomimetics of Survivin peptides are described byPlescia et al. (Rational design of Shepherdin, a novel anticancer agent.Cancer Cell. 7(5):457-68 (2005)) herein incorporated by reference in itsentirety.

Other IAP Peptides and Derivatives

Other Inhibitors of Apoptosis Proteins (IAPs) interact with Hsp90,including cIAP1 (Entrez Accession No.: NP_(—)001156), cIAP2 (EntrezAccession No.: NP_(—)001157), and XIAP (Entrez Accession No.:NP_(—)001158). See, e.g., Deveraux and Reed, Genes and Dev., 13:239-252(1999). These IAP proteins contain at least one Baculovirus IAP repeatdomain that mediates Hsp90 interactions, as disclosed herein. Forexample, the first BIR domain of XIAP (BIR1) mediates Hsp90-XIAP bindinginteractions.

IAP proteins, or Hsp90-binding and -inhibiting fragments thereof, cantherefore be used in the present compositions and methods. For example,peptides corresponding to one or more BIR domains in these IAP proteins,or Hsp90-binding fragments thereof, can be used in the compositions andmethods disclosed herein to induce cancer or tumor cell death. IAPproteins, or Hsp90-binding fragments thereof, can also be screened astest compounds, e.g., to identify candidate compounds that inhibitbinding between molecular chaperones and Cyclophilin D. In someembodiments, IAP proteins, or Hsp90-binding fragments thereof, can bescreened as test compounds to identify candidate compounds that inducecancer cell death.

An exemplary first BIR domain of XIAP includes the sequence:

(SEQ ID NO: 14) RLKTFANFPSGSPVSASTLARAGFLYTGEGDTVRCFSCHAAVDRWQYGDSAVGRHRKVSPNCRFIN

An exemplary first BIR domain of cIAP1 includes the sequence:

(SEQ ID NO: 15) RMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKRGDSPTEKHKKLYPSCRFVQ

An exemplary first BIR domain of cIAP2 includes the sequence:

(SEQ ID NO: 16) RMSTYSTFPAGVPVSERSLARAGFYYTGVNDKVKCFCCGLMLDNWKLGDSPIQKHKQLYPSCSFIQ

Variants of Peptide Inhibitors

Variants of peptide inhibitors of molecular chaperones are also part ofthis invention. These include sequence variants. Where a conservativeamino acid substitution is made, the substitution can be of one aminoacid residue for another in any of the following groups: arginine,histidine, and lysine; aspartic acid and glutamic acid; alanine,leucine, isoleucine and valine; and phenylalanine, tryptophan andtyrosine. The amino acid residues listed here are naturally occurring.Non-naturally occurring amino acid residues of like kind may also besubstituted. For example, a negatively charged non-naturally occurringamino acid residue may be substituted for a negatively charged naturallyoccurring amino acid residue; a hydrophobic aromatic non-naturallyoccurring amino acid residue may be substituted for a hydrophobicaromatic naturally occurring amino acid residue; and so forth.

The degree of identity can vary and can be determined by methods wellestablished in the art. “Homology” and “identity” each refer to sequencesimilarity between two polypeptide sequences, with identity being a morestrict comparison. Homology and identity can each be determined bycomparing a position in each sequence which may be aligned for purposesof comparison. When a position in the compared sequence is occupied bythe same amino acid residue, then the polypeptides can be referred to asidentical at that position; when the equivalent site is occupied by thesame amino acid (e.g., identical) or a similar amino acid (e.g., similarin steric and/or electronic nature), then the molecules can be referredto as homologous at that position. A percentage of homology or identitybetween sequences is a function of the number of matching or homologouspositions shared by the sequences. A biologically active variant of apolypeptide described herein can have at least or about 80%, 85%, 90%,95%, 96%, 97%, 98%, or 99% identity or homology to a correspondingnaturally occurring polypeptide (e.g., a survivin fragment or a IAPfragment, e.g., as described herein). The nucleic acids encoding thebiologically active variant polypeptides can be similarly described ashaving at least or about 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%identity to a corresponding naturally occurring nucleic acid sequence.Those of ordinary skill in the art will readily recognize degeneratevariants of nucleic acid sequences, and such variants can be used forthe purposes described herein.

When using a peptide inhibitor and/or mitochondrial penetrating moietyin a human subject, it will generally be desirable to use a human orhumanized sequence. Thus, the methods described herein can include usingstandard molecular biology techniques to humanize a non-human sequence.Alternatively, human sequences can be used to make the construct.

Modifications of Peptide Inhibitors

Modified versions of the peptides described herein can also be used inthe compositions and methods described herein. The peptides andbiologically active variants thereof can be modified in numerous ways.For example, agents, including additional amino acid residues, othersubstituents, and protecting groups can be added to either the aminoterminus, the carboxy terminus, or both. The modification can be madefor the purpose of altering the peptides' form or altering the way thepeptides bind to or interact with one another, with non-identicalpeptides, or with other polypeptides. For example, the peptides can bemodified to include cysteine residues or other sulphur-containingresidues or agents that can participate in disulphide bond formation.For example, one can add at least two cysteine residues, one or both ofwhich are, optionally, at the C-terminal or N-terminal of the peptide.

The peptides can be cyclized by formation of a disulfide bond betweencysteine residues (or, more generally, between two of the at least twocysteine residues present in the polypeptide (e.g., at the terminalregions)). While the peptides of the present invention may be linear orcyclic, cyclic peptides generally have an advantage over linear peptidesin that their cyclic structure is more rigid and hence their biologicalactivity may be higher than that of the corresponding linear peptide(see, generally, Camarero and Muir, J. Am. Chem. Soc., 121:5597-5598,(1999).

Strategies for the preparation of circular polypeptides from linearprecursors have been described and can be employed with the presentpeptides. For example, a chemical cross-linking approach can be used toprepare a backbone cyclized version of the peptide (Goldenburg andCreighton, J. Mol. Biol., 165:407-413, (1983)). Other approaches includechemical intramolecular ligation methods (see, e.g., Camarero et al.,Angew Chem. Int. Ed., 37:347-349, (1998); Tam and Lu, Prot. Sci.,7:1583-1592, (1998); Camarero and Muir, Chem. Commun., 1369-1370,(1997); and Zhang and Tam, J. Am. Chem. Soc., 119:2363-2370, (1997) andenzymatic intramolecular ligation methods (Jackson et al., J. Am. Chem.Soc., 117:819-820, (1995), which allow linear synthetic peptides to beefficiently cyclized under aqueous conditions. See also U.S. Pat. No.7,105,341.

Alternatively, or in addition, the peptide can further include asubstituent at the amino-terminus or carboxy-terminus. The substituentcan be an acyl group or a substituted or unsubstituted amine group(e.g., the substituent at the N-terminus can be an acyl group and theC-terminus can be amidated with a substituted or unsubstituted aminegroup (e.g., an amino group having one, two, or three substituents,which may be the same or different)). The amine group can include alower alkyl (e.g., an alkyl having 1-4 carbons), alkenyl, alkynyl, orhaloalkyl group. The acyl group can be a lower acyl group (e.g., an acylgroup having up to four carbon atoms), especially an acetyl group.

As used herein, the term “alkyl” is meant to refer to a saturatedhydrocarbon group which is straight-chained or branched. Example alkylgroups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl andisopropyl), butyl (e.g., n-butyl, isobutyl, t-butyl), pentyl (e.g.,n-pentyl, isopentyl, neopentyl), and the like. An alkyl group cancontain from 1 to about 20, from 2 to about 20, from 1 to about 10, from1 to about 8, from 1 to about 6, from 1 to about 4, or from 1 to about 3carbon atoms.

As used herein, “alkenyl” refers to an alkyl group having one or moredouble carbon-carbon bonds. Example alkenyl groups include ethenyl,propenyl, and the like.

As used herein, “alkynyl” refers to an alkyl group having one or moretriple carbon-carbon bonds. Example alkynyl groups include ethynyl,propynyl, and the like.

As used herein, “haloalkyl” refers to an alkyl group having one or morehalogen substituents. Example haloalkyl groups include CF₃, C₂F₅, CHF₂,CCl₃, CHCl₂, C₂Cl₅, and the like.

As used herein, “aryl” refers to aromatic monocyclic or multicyclicgroups containing from 6 to 19 carbon atoms. Examples of aryl groupsinclude, but are not limited to unsubstituted or substituted phenyl,unsubstituted or substituted fluorenyl, and unsubstituted or substitutednaphthyl.

As used herein, “heterocycloalkyl” refers to a monocyclic ormulticyclic, saturated or unsaturated ring system, in one embodiment of3 to 10 members, in another embodiment of 4 to 7 members, in a furtherembodiment of 5 to 6 members, where one or more, in certain embodiments,1 to 3, of the atoms in the ring system is a heteroatom, that is, anelement other than carbon, including but not limited to, nitrogen,oxygen or sulfur. In certain embodiments, one of the atoms of the ringcan be replaced with a carbonyl or sulfonyl group.

As used herein, “alkylene,” “alkenylene,” “alkynylene,” “cycloalkylene,”“arylene,” “heteroarylene,” and “heterocycloalkylene” refer to divalentlinking “alkyl,” “alkenyl,” “alkynyl,” “cycloalkyl,” “aryl,”“heteroaryl,” and “heterocycloalkyl” groups. The divalent linkers, insome embodiments, can be present in both directions, e.g., a C(O)NH caneither be —C(O)NH— or —NHC(O)—.

As noted, the peptides can vary in length and can be or can includecontiguous amino acid residues that naturally occur in chaperone bindingproteins (CBP), e.g., Survivin or IAPs, or that vary to a certain degreefrom naturally occurring CBP sequences (but retain sufficient activityto be useful). Where the peptides include, at their N-terminus orC-terminus (or both), amino acid residues that are not naturally foundin CBPs, the additional sequence(s) can be about 200 amino acid residueslong, and these residues can be divided evenly or unevenly between theN- and C-termini. For example, both the N- and C-termini can includeabout 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 amino acid residues.Alternatively, one terminus can include about 10, 20, 30, 40, 50, 60,70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200residues, and one terminus can include none (e.g., it can terminate inan amino acid sequence identical to a naturally occurring Survivinsequence).

More specifically, the N- or C-termini can include 1 to about 100 (e.g.,1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90,or 100) amino acid residues that are positively charged (e.g., basicamino acid residues such as arginine, histidine, and/or lysineresidues); 1 to about 100 amino acid residues that are negativelycharged (e.g., acidic amino acid residues such as aspartic acid orglutamic acid residues); 1 to about 100 glycine residues; 1 to about 100hydrophobic amino acid residues (e.g., hydrophobic aliphatic residuessuch as alanine, leucine, isoleucine or valine or hydrophobic aromaticresidues such as phenylalanine, tryptophan or tyrosine); or 1 to about100 (e.g., 1-4) cysteine residues.

The peptides, including the modified peptides described above, can beprotease resistant and can include one or more types of protectinggroups such as an acyl group, an amide group, a benzyl or benzoyl group,or a polyethylene glycol. More specifically, a peptide, including themodified peptides described above, can be N-terminally acetylated and/orC-terminally amidated.

Where non-naturally occurring or modified amino acid residues areincluded they can be selected from the following or many othersavailable in the art: 4-hydroxyproline, gamma-carboxyglutamic acid,o-phosphoserine, o-phosphotyrosine, or delta-hydroxylysine. Otherexamples include naphthylalanine, which can be substituted fortryptophan to facilitate synthesis, L-hydroxypropyl,L-3,4-dihydrooxyphenylalanyl, alpha-amino acids such asL-alpha-hydroxylysyl and D-alpha-methylalanyl, L-alpha-methylalanyl,beta-amino acids, and isoquinolyl. Peptides having non-naturallyoccurring amino acid residues may be referred to as synthetic peptidesand constitute one type of variant as described herein. Other variantsinclude peptides in which a naturally occurring side chain of an aminoacid residue (in either the L- or D-form) is replaced with anon-naturally occurring side chain.

In one embodiment, the peptides can have three extra amino acids(Met-Gly-Ser) at either terminus (or both) (e.g., at the N-terminus) andseven to eight extra amino acids (Thr-Ser-His-His-His-His-His-His-Cys(SEQ ID NO:13)) at either terminus (or both) (e.g., at the C-terminus).

In another embodiment, the peptides can be PEGylated by methods known inthe art.

For guidance on peptide modification by reduction/alkylation and/oracylation, one can consult Tarr, Methods of ProteinMicrocharacterization, J. E. Silver ed., Humana Press, Clifton N.J.(1986) 155-194; for guidance on chemical coupling to an appropriatecarrier, one can consult Mishell and Shiigi, eds, Selected Methods inCellular Immunology, WH Freeman, San Francisco, Calif. (1980) and U.S.Pat. No. 4,939,239; and for guidance on mild formalin treatment, one canconsult Marsh, Int. Arch. Allergy Appl. Immunol., (1971) 41:199-215.

Peptidomimetics of the inhibitory peptides can also be used. Peptideinhibitors disclosed herein and known in the art can be modifiedaccording to methods known in the art for producing peptidomimetics.See, e.g., Kazmierski, W. M., ed., Peptidomimetics Protocols, HumanPress (Totowa N.J. 1998); Goodman et al., eds., Houben-Weyl Methods ofOrganic Chemistry: Synthesis of Peptides and Peptidomimetics, ThieleVerlag (New York 2003); and Mayo et al., J. Biol. Chem., 278:45746,(2003). In some cases, these modified peptidomimetic versions of thepeptides and fragments disclosed herein exhibit enhanced stability invivo, relative to the non-peptidomimetic peptides.

Methods for creating a peptidomimetic include substituting one or more,e.g., all, of the amino acids in a peptide sequence with D-amino acidenantiomers. Such sequences are referred to herein as “retro” sequences.In another method, the N-terminal to C-terminal order of the amino acidresidues is reversed, such that the order of amino acid residues fromthe N-terminus to the C-terminus of the original peptide becomes theorder of amino acid residues from the C-terminus to the N-terminus inthe modified peptidomimetic. Such sequences can be referred to as“inverso” sequences.

Peptidomimetics can be both the retro and inverso versions, i.e., the“retro-inverso” version of a peptide disclosed herein. The newpeptidomimetics can be composed of D-amino acids arranged so that theorder of amino acid residues from the N-terminus to the C-terminus inthe peptidomimetic corresponds to the order of amino acid residues fromthe C-terminus to the N-terminus in the original peptide.

Other methods for making a peptidomimetics include replacing one or moreamino acid residues in a peptide with a chemically distinct butrecognized functional analog of the amino acid, i.e., an artificialamino acid analog. Artificial amino acid analogs include β-amino acids,β-substituted β-amino acids (“β³-amino acids”), phosphorous analogs ofamino acids, such as α-amino phosphonic acids and α-amino phosphinicacids, and amino acids having non-peptide linkages. Artificial aminoacids can be used to create peptidomimetics, such as peptoid oligomers(e.g., peptoid amide or ester analogues), β-peptides, cyclic peptides,oligourea or oligocarbamate peptides; or heterocyclic ring molecules.Exemplary Survivin retro-inverso peptidomimetics include LFACGSSHK (SEQID NO:25), CGSSH (SEQ ID NO:26), GSSHK (SEQ ID NO:27),KKWKMRRNQFWVKVQRLFACGSSHK (SEQ ID NO:28), KKWKMRRNQFWVKVQRCGSSH (SEQ IDNO:29), and KKWKMRRNQFWVKVQRGSSHK (SEQ ID NO:30), wherein the sequencesinclude all D-amino acids. These sequences can be modified, e.g., bybiotinylation of the amino terminus and amidation of the carboxyterminus.

Any of the peptides described herein, including the variant formsdescribed herein, can further include a heterologous polypeptide (e.g.,a polypeptide having a sequence that does not appear in a CBP). Theheterologous polypeptide can be a polypeptide that increases thecirculating half-life of the peptide to which it is attached (e.g.,fused, as in a fusion protein). The heterologous polypeptide can be analbumin (e.g., a human serum albumin or a portion thereof) or a portionof an immunoglobulin (e.g., the Fc region of an IgG). The heterologouspolypeptide can be a mitochondrial-penetrating moiety.

Compounds mimicking the necessary conformation of the peptides describedherein are contemplated as within the scope of this invention. A varietyof designs for such mimetics are possible. U.S. Pat. Nos. 5,192,746;5,169,862; 5,539,085; 5,576,423; 5,051,448; and 5,559,103, all herebyincorporated by reference, describe multiple methods for creating suchcompounds.

Non-peptidic compounds that mimic peptide sequences are known in the art(Meli et al. J. Med. Chem., 49:7721-7730 (2006), describing methods ofidentifying nonpeptide small molecule mimics of shepherdin). Synthesisof non-peptide compounds that mimic peptide sequences is also known inthe art (see, e.g., Eldred et al. J. Med. Chem., 37:3882, (1994); Ku etal. J. Med. Chem., 38:9, (1995); Meli et al. J. Med. Chem., 49:7721-7730(2006)). Such nonpeptide compounds that mimic CBP peptides that bindchaperones are specifically contemplated by the present invention.

The present invention also contemplates synthetic mimicking compounds.As is known in the art, peptides can be synthesized by linking an aminogroup to a carboxyl group that has been activated by reaction with acoupling agent, such as dicyclohexylcarbodiimide (DCC). The attack of afree amino group on the activated carboxyl leads to the formation of apeptide bond and the release of dicyclohexylurea. It can be necessary toprotect potentially reactive groups other than the amino and carboxylgroups intended to react. For example, the (α-amino group of thecomponent containing the activated carboxyl group can be blocked with atertbutyloxycarbonyl group. This protecting group can be subsequentlyremoved by exposing the peptide to dilute acid, which leaves peptidebonds intact.

With this method, peptides can be readily synthesized by a solid phasemethod by adding amino acids stepwise to a growing peptide chain that islinked to an insoluble matrix, such as polystyrene beads. Thecarboxyl-terminal amino acid (with an amino protecting group) of thedesired peptide sequence is first anchored to the polystyrene beads. Theprotecting group of the amino acid is then removed. The next amino acid(with the protecting group) is added with the coupling agent. This isfollowed by a washing cycle. The cycle is repeated as necessary.

In one embodiment, the mimetics of the present invention are peptideshaving sequence homology to the herein-described chaperone inhibitorpeptides. These mimetics include, but are not limited to, peptides inwhich L-amino acids are replaced by their D-isomers. One commonmethodology for evaluating sequence homology, and more importantlystatistically significant similarities, is to use a Monte Carlo analysisusing an algorithm written by Lipman and Pearson to obtain a Z value.According to this analysis, a Z value greater than 6 indicates probablesignificance, and a Z value greater than 10 is considered to bestatistically significant (Pearson and Lipman, Proc. Natl. Acad. Sci.(USA), 85:2444-2448, (1988); Lipman and Pearson, Science, 227:1435-1441,(1985). More generally, the CBP peptides described herein and themimetics described above can be synthesized using any known methods,including tea-bag methodology or solid phase peptide synthesisprocedures described by Merrifield et al., Biochemistry, 21:5020-5031,(1982); Houghten Wellings, Proc. Natl. Acad. Sci. (USA), 82:5131-5135,(1985); Atherton, Methods in Enzymology, 289:44-66, (1997), or Guy andFields, Methods in Enzymology, 289:67-83, (1997), or using acommercially available automated synthesizer.

Small Molecule Inhibitors of Molecular Chaperones

A number of small molecule chaperone inhibitors useful in the methodsand compositions described herein are known in the art. For example,small molecule chaperone inhibitors that are useful in the compositionsand methods described herein include, but are not limited to, moleculesthat bind to a Hsp90 ATP binding pocket. Small molecule Hsp90 inhibitorsknown in the art are described, for example, in Rodina et al., (NatureChemical Biology, published online Jul. 1, 2007).

In some embodiments, the chaperone inhibitor is an Hsp90 inhibitorselected from one of several chemotypes. Two of these chemotypes areansamycin and macrolactone inhibitors. These are represented byradicicol and cycloproparadicicol, members of the macrolactone Hsp90inhibitor class, and 17-dimethylaminoethylamino-17-demethoxygeldanamycin(17DMAG) and 17AAG, members of the ansamycin class of Hsp90 inhibitors.The structural basis for inhibition of Hsp90 by radicicol andgeldanamycin is known, so one of skill in the art could readily generateand test analogs thereof that would retain Hsp90 inhibitory activity,see, e.g., Roe et al., J. Med. Chem. 42(2):260-6 (1999). Purineinhibitors form a third class of compounds useful in the compositionsand methods described herein.

Ansamycin Inhibitors of Hsp90

Further examples of molecular chaperone inhibitors that are useful inthis invention include, but are not limited to, quinine ansamycinantibiotics, such as the macbecins, geldanamycin, geldanamycinanalogues, and herbimycin A.

Geldanamycin is an inhibitor of heat shock protein-90 (Hsp90), which isinvolved in the folding, activation and assembly of a wide range ofproteins (“client proteins”), including key proteins involved in signaltransduction, cell cycle control and transcriptional regulation. Thebinding of geldanamycin to Hsp90 disrupts Hsp90-client proteininteractions, preventing the client proteins from folding correctly.Geldanamycin and geldanamycin analogues are part of this.

As used herein, “geldanamycin analogues” refers to compounds that sharea common core structure with geldanamycin but have minor chemicalmodifications.

Geldanamycin analogues that are variant at position 17 of geldanamycinare known in the art and many are commercially available. Examples ofcommercially available geldanamycin analogues include, but are notlimited to, 17-allylamino-demethoxygeldamycin (17-AAG),17-dimethylaminogeldanamycin, 17-GMB-APA-GA (a maleimido derivative ofgeldanamycin that enables the conjugation of GA to a polypeptide),17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG),17-[2-(Pyrrolidin-1-yl)ethyl]amino-17-demethoxygeldanamycin (17-AEP-GA),and 17-(Dimethylaminopropylamino)-17-demethoxygeldanamycin (17-DMAP-GA).See also Sasaki et al., U.S. Pat. No. 4,261,989 (1981); Schnur et al.,U.S. Pat. No. 5,932,566 (1999); Schnur et al., J. Med. Chem.,38:3806-3812, (1995); Schnur et al., J. Med. Chem., 38:3813-3820,(1995); and Santi et al., US 2003/0114450 A1 (2003).

Geldanamycin analogues that are variant at position 11 are known in theart. Examples include, but are not limited to, Muroi et al., U.S. Pat.No. 4,421,688 (1983); Schnur, U.S. Pat. No. 5,387,584 (1995); Schnur etal., U.S. Pat. No. 5,932,566 (1999); Welch et al., U.S. Pat. No.6,015,659 (2000); Whitesell et al., WO 94/08578 A2 (1994); Ho et al., WO00/03737 A2 (2000); Snader et al., WO 02/36574 A1 (2002); Snader et al.,WO 02/079167 A1 (2002); Santi et al., WO 03/013430 A2 (2003); Zhang etal., WO 03/066005 A2 (2003); Omura et al., JP 63-218620 (1988); Schnuret al., J. Med. Chem., 38:3806-3812, (1995); and Schnur et al., J. Med.Chem., 38:3813-3820, (1995); which are herein incorporated by reference.11-O-methylgeldanamycin compounds known in the art are described in U.S.Pat. Nos. 6,855,705, 6,887,993, and 6,870,049.

In some embodiments of the composition, the molecular chaperoneinhibitor includes geldanamycin analogues:

where, R² is H, alkyl, aryl, or arylalkyl; R³ is H, alkyl; and R⁴ is H,alkyl, alkenyl, aryl, arylalkyl, OR^(d), wherein R^(d) is H, alkyl, orarylalkyl.

In some embodiments of the composition, R² is H or alkyl; R³ is H,alkyl; and R⁴ is H, or OR^(d), wherein R^(d) is H, alkyl.

In some embodiments of the composition, R² is H; R³ is methyl; and R⁴ isH.

Resorcinol-Derived Inhibitors of Hsp90

Compounds derived from Resorcinol are potent inhibitors of Hsp90. Theseinclude compounds based on the 4,5-diarylisoxazole scaffold (see, forexample, Brough et al., J. Med. Chem., 2007), compounds based on the3,4-diarylpyrazole scaffold (see, for example, U.S. Pat. No. 7,247,734and Sharp et al., Cancer Res. 67 (5):2206-16 (2007)), and 3,4-diarylpyrazole resorcinol HSP90 inhibitor (CCT018159), amide resorcinolcompounds (as described, for example, in International Publication No.WO/2006/117669), and isoxazole resorcinol compounds. See also Sharp etal., Mol Cancer Ther. 6 (4):1198-1211 (2007) (synthetic, potentresorcinylic pyrazole/isoxazole amide analogues, e.g., VER-49009 and thecorresponding isoxazole VER-50589); Eccles et al., Cancer Res. 68(8):2850-60 (2008) (NVP-AUY922, a novel resorcinylic isoxazole amideheat shock protein 90 (HSP90) inhibitor); Barril et al., Bioorg. Med.Chem. Let. 16(9):2543-2548 (2006) (piperazinyl, morpholino and piperidylderivatives of the pyrazole-based Hsp90 inhibitor CCT018159).

Macrolactone-Hsp90 Inhibitors

The macrocyclics radicicol and monocillin, and analogs thereof such ascycloproparadicicol, are inhibitors that bind the ATP-binding site ofHsp90. See, e.g., Turbyville et al., J. Nat. Prod., 69(2):178-184(2006), Soga et al., Curr. Cancer Drug Targets. 3(5):359-69 (2003),Shiotsu et al., Blood. 96(6):2284-91 (2000), and U.S. Pat. No.7,115,651. KF25706, a novel oxime derivative of radicicol, has in vivoantitumor activity via selective depletion of Hsp90 binding signalingmolecules (Soga et al., Cancer Res. 59(12):2931-8 (1999)).

Chimeric inhibitors that include structural components of radicicol andgeldanamycin are also known, see, e.g., Hadden et al., Curr. Top. Med.Chem. 6(11):1173-82; Shen et al., J. Org. Chem. 71(20):7618-31 (2006).

Purine Inhibitors of Hsp90

Hsp90 inhibitors of the purine-scaffold class have been reported to bepotent and selective against Hsp90 both in vitro and in vivo models ofcancer, and the structural basis of this activity has been determined.See Wright et al., Chem. Biol. 11(6):775-85 (2004). Several8-Aryl-Sulfanyl Adenine compounds have been synthesized and shown tohave Hsp90 inhibitory activity, e.g., PU-H71 and PU-H64, the structuresof which have been solved with Hsp90. See Immormino et al., J. Med.Chem. 49(16):4953-60 (2006). Other purine class Hsp90 inhibitors areknown in the art and include, for example, 3,4-diaryl pyrazoles andrelated analogs (McDonald et al., Curr. Top. Med. Chem. 6(11):1193-203(2006)); pyrazolopyrimidines and related analogs (U.S. Pat. No.7,148,228), pyrrolopyrimidines and related analogs (U.S. Pat. No.7,138,402), and 2-aminopurine analogs (U.S. Pat. No. 7,138,401).

Hsp60 Inhibitors

Several Hsp60 inhibitors are known in the art, including epolactaene(Nagumo et al., Biochem. J. 387:835-840 (2005); Tan and Negishi, Org.Lett. 8(13):2783-2785 (2006); and Nagumo et al., Bioorganic & MedicinalChemistry Letters 14:4425-4429 (2004)), and mizoribine (bredinin) (Itohet al., J. Biol. Chem. 274:35147-35151 (1999)).

HspA9 (Mortalin) Inhibitors

MKT-077, a cationic rhodacyanine dye analogue with selective toxicity tocancer cells, binds to HspA9/mortalin, and abrogates its interactionswith the tumor suppressor protein, p53. See, e.g., Wadhwa et al., CancerRes. 2000; 60(24):6818-21.

Other Inhibitors

Molecular chaperone inhibitors that are useful in this invention alsoinclude molecules that inhibit interaction between Hsp60 and CyclophilinD, Hsp90 and Cyclophilin D, or TRAP-1 and Cyclophilin D. Theseinhibitors may be identified from molecules known in the art, or presentin chemical libraries by the methods described herein; see, e.g., Meliet al., J. Med. Chem. 49:7721-7730 (2006), and Howes et al., Anal.Biochem., 350(2):202-213 (2006). For example, the non-peptidic smallmolecule 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR)was identified as a structurally novel inhibitor of Hsp90 (see Meli etal., 2006, supra), and can be used in the methods described herein. Seealso Blagg et al., Med. Res. Rev. 26(3):310-338 (2005).

III. Mitochondrial-Penetrating Moieties

Described herein are mitochondrial penetrating molecular chaperoneinhibitors. Any of the molecular chaperone inhibitors described hereincan be modified by association with mitochondrial-penetrating moietiesusing methods known in the art, with the proviso that if the chaperoneinhibitor is Shepherdin or an active fragment thereof, themitochondrial-penetrating moiety is not Antennapedia or a fragmentthereof. Examples are given below.

As used herein, a mitochondrial-penetrating moiety is a chemical group,e.g., a peptide, peptidomimetic, or other compound, that increasesmitochondrial localization of an associated, e.g., chemicallyconjugated, molecular chaperone inhibitor, as compared to the molecularchaperone inhibitor alone.

Peptide Mitochondrial-Penetrating Moieties

In the compositions described herein, a chaperone inhibitor (asdescribed herein) can be attached to a peptide mitochondrial-penetratingmoiety. For example, an Antennapedia carrier sequence, corresponding toa sequence found on the third α-helix of the Antennapedia (Gratton etal., Cancer Cell, 4:31, (2003)), can be used. An exemplary sequence ofsuch a peptide is RQIKIWFQNRRMKWKK (SEQ ID NO:18), herein ANT. Otherexamples of targeting peptides to which the chaperone inhibitorsdisclosed herein can be attached include, but are not limited to, e.g.,the TAT protein sequence from HIV-1 (Chen et al., Proc. Natl. Acad. Sci.USA, 96:4325, (1999); Kelemen et al., J. Biol. Chem., 277:8741-8748,(2002)), e.g., RKKRRQRRR (SEQ ID NO:19) (Brooks et al., Adv. Drug Del.Rev., 57(4):559-577 (2005)), or a modified TAT having the sequenceRKKRRORRRGC (SEQ ID NO:20) (Barnett et al., Inv. Ophth. Vis. Sci.,47:2589-2595 (2006)). Yet other examples include VP22 protein fromHerpes Simplex virus (Lundberg and Johansson, Biochem. Biophys. Res.Comm., 291:367-371, (2002)), and the Pep-1 peptide carrier (Morris etal., Nature Biotech., 19:1173-1176, (2001)). In some embodiments, thepeptides comprise D-isomer amino acids or other modifications, e.g., toimprove uptake or reduce cellular degradation.

Polypeptides that include peptide mitochondrial-penetrating moieties canbe produced by standard techniques, such as chemical synthesis, orexpressed from a nucleic acid that encodes the polypeptide.

Other fragments that may be useful as mitochondrial-penetrating moietiesinclude, but are not limited to, mitochondrial-targeting sequences thatare found in proteins that localize to mitochondria. Non-limitingexamples of mitochondrial-targeting sequences include the N-terminalregion of human cytochrome c oxidase subunit VIII, the N-terminal regionof the P1 isoform of subunit c of human ATP synthase, or the N-terminalregion of the aldehyde dehydrogenase targeting sequence as described inU.S. Pat. App. 20040072774, herein incorporated by reference. Forexample, fragments of mitofusins (human mitofusin 1 sequence is atGenBank Acc. No. NP_(—)284941.2; human mitofusin 2 sequence is atGenBank Acc. No. NP_(—)055689.1), e.g., amino acids 97-757 of humanmitofusin 2 (see U.S. Pat. No. 6,953,680, herein incorporated byreference), are useful as mitochondrial-targeting moieties in thisinvention.

Peptidomimetic Mitochondrial-Penetrating Moieties

Peptidomimetic mitochondrial penetrating moieties can also be used inthe compositions and methods disclosed herein. A general description ofpeptidomimetics, and methods for making them, can be found above.

For example, non-hydrolyzable tetraguanidinium compounds as described inFernández-Carneado et al. J. Am. Chem. Soc. 127(3):869-74, (2005),incorporated herein, can be used in the present compositions andmethods.

Mitochondrial Targeting Signal Peptides

Fragments of that direct proteins to the mitochondria can also be used.Examples include RRIVVLHGYGAVKEVLLNHK (SEQ ID NO:41), amino acids 74-95of Rat Cytochrome P450 2E1 (CYP2E1) (Neve and Ingelman-Sundberg, J.Biol. Chem., 276(14):11317-11322 (2001); the cleavable prepiece from theyeast cytochrome c oxidase IV precursor (MLSLRQDIRFFKPATRTLCSSR (SEQ IDNO:42), see Maarse et al., EMBO J. 3(12):2831-2837 (1984) and Hurt etal., FEBS 178(2) 306-310 (1984)); mitochondrial-targeting signal fromthe PB2 protein of influenza viruses (Carr et al., Virology,344(2):492-508, (2006); import signal contained within heme lyases(Diekert et al., Proc. Natl. Acad. Sci. U.S.A. 96(21):11752-11757,(1999); the leader peptide of the mitochondrial matrix enzyme ornithinetranscarbamylase (OTC) (Horwich et al., EMBO J. 4(5):1129-1135, (1985).Hay et al., Biochim. Biophys. Acta. 779(1):65-87, (1984); Fujiwara etal., Genome Inform. Ser. Workshop, Genome Inform. 8:53-60, (1997).

Nucleic Acid Mitochondrial-Penetrating Moieties

Nucleic acids that act as mitochondrial penetrating moieties (such asthose described in U.S. Pat. No. 5,569,754, herein incorporated byreference, e.g., CCGCCAAGAAGCG (SEQ ID NO:21); GCGTGCACACGCGCGTAGACTTCCCCCGCAAGTCACTCGTTAGCCCGCCAAGAAGCGACCCCTCCGGGGCGAGCTGAGCGGCGTGGCGCGGGGGCGTCAT (SEQ ID NO:22);ACGTGCATACGCACGTAGACATTCCCCGCTTCCCACTCCAAAGTCCGCCAAGAAGCGTATCCCGCTGAGCGGCGTGGCGCGGGGGCGTCATCCGTCAGCTC (SEQ ID NO:23); orACTTCCCCCGCAAGTCACTCGTTAGCCCGCCAAGAAG CGACCCCTCCGGGGCGAGCTG (SEQ IDNO:24) can also be used in the compositions and methods describedherein. Methods for linking nucleic acids to peptides are known in theart.

Lipophilic Cation Mitochondrial-Penetrating Moieties

Lipophilic cations that act as mitochondrial penetrating moieties aredescribed in Smith et al., Proc. Natl. Acad. Sci. U.S.A., 100(9):5407-12(2003), which is herein incorporated by reference in its entirety.Lipophilic cations that are useful to this invention include, forexample, Rhodamine 123 and phosphonium salts, e.g.,methyltriphenylphosphonium and tetraphenylphosphonium.

In some embodiments, the cationic mitochondrial-penetrating moietyincludes:

where R¹ is H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl, orR^(a)R^(b)R^(c)Si; R^(a), R^(b), and R^(c) are independently selectedfrom alkyl or aryl; and n can be 0, 1, 2, 3, 4, 5, or 6.

In some embodiments, the cationic mitochondrial-penetrating moietyincludes

where, R^(a), R^(b), and R^(c) are independently selected from alkyl oraryl; and n can be 1, 2, or 3. In some embodiments, the cationicmitochondrial-penetrating moiety includes (aryl)₃P—. In someembodiments, the cationic mitochondrial-penetrating moiety includesRhodamine 123:

IV. Linking Moiety

In some embodiments, the mitochondrial penetrating moiety is linked to amolecular chaperone inhibitor as described herein via a linker. As usedherein, to “link” means to associate a mitochondrial-penetrating moietyand a chaperone inhibitor via a covalent or non-covalent bond orassociation.

A number of linkers can be used to link the chaperone inhibitor, to themitochondrial-penetrating moiety. For example, a peptide linker can beused, e.g., a peptide linker including one, two, three, four, five, six,seven, eight, or more amino acids. In some embodiments, the peptidelinker is flexible, i.e., contains amino acids that adopt flexibleconformations, e.g., comprising glycine, alanine, and/or glutamineresidues.

In embodiments where the mitochondrial-penetrating moiety and thechaperone inhibitor are both peptides, it will generally be desirable toproduce the mitochondrial-targeted chaperone inhibitor as a fusionprotein, with or without an intervening linker, e.g., using a nucleicacid that encodes the entire fusion protein.

In some embodiments, the linker moiety is divalent and can be selectedfrom the group consisting of alkylene, alkenylene, alkynylene,cycloalkylene, arylene, heteroarylene, and peptide linker, wherein anytwo adjacent carbon-carbon bonds of said alkylene, alkenylene, oralkynylene, can be optionally replaced with one or more of O, NH, S,PR^(e), C(O)NR^(f), arylene, heterocycloalkylene, or heteroarylene;wherein R^(e) and R^(f) are independently selected from alkyl or aryl.

In some embodiments, the linker moiety is:

In some embodiments, the linker moiety is alkylene

In some embodiments, the linker moiety is alkylene with six carbonatoms.

One type of mitochondrial-targeted chaperone inhibitor is produced bycrosslinking a chaperone inhibitor to a mitochondrial-penetratingmoiety. Suitable crosslinkers include those that are heterobifunctional,having two distinctly reactive groups separated by an appropriate spacer(e.g., m-maleimidobenzoyl-N-hydroxysuccinimide ester) orhomobifunctional (e.g., disuccinimidyl suberate). Such linkers areavailable from Pierce Chemical Company, Rockford, Ill.

General methodology useful for making the compositions described hereinare known in the art. In some embodiments, the methods can includecontacting a mitochondrial-penetrating moiety, e.g., ANT as describedherein, with a linker, e.g., a disulfide linker such as SSP, to form areaction mixture, contacting the reaction mixture with a chaperoneinhibitor, e.g., a geldanamycin analog, and obtaining a composition thatincludes a mitochondrial-penetrating moiety conjugated to the chaperoneinhibitor. In some embodiments, the methods include contacting themitochondrial-penetrating moiety with an amount of linker such that theratio of linker to mitochondrial-penetrating moiety in the reactionmixture is about 1:1. Accordingly, the invention features methods ofpreparing a mitochondrial-penetrating moiety, e.g., ANT as describedherein, conjugated to a chaperone inhibitor, e.g., a geldanamycin analogsuch as 17-AAG.

The mitochondrial-penetrating moiety and chaperone inhibitor can bejoined, using recombinant methods known in the art, by a syntheticlinker that enables them to be made as a single protein chain; see e.g.,Bird et al., Science, 242:423-426 (1988); and Huston et al. Proc. Natl.Acad. Sci. USA, 85:5879-5883 (1988)).

For example, chaperone inhibitor of the invention can be functionallylinked (by chemical coupling, genetic fusion, noncovalent association orotherwise) to one or more mitochondrial-penetrating moieties.

The compositions described herein include compounds of the formula:

wherein, R¹ is H, alkyl, alkenyl, alkynyl, haloalkyl, aryl, arylalkyl,or R^(a)R^(b)R^(c)Si; R² is H, alkyl, aryl, or arylalkyl; R³ is H,alkyl; R⁴ is H, alkyl, alkenyl, aryl, arylalkyl, OR^(d), wherein R^(d)is H, alkyl, or arylalkyl; R^(a), R^(b), and R^(c) are independentlyselected from alkyl or aryl; and n is an integer between 1 and 10,inclusive or a pharmaceutically acceptable salt thereof.

In some embodiments, the salt is a hexafluorophosphate salt

In some embodiments, R¹ is R^(a)R^(b)R^(c)Si, R^(a), R^(b), and R^(c)are independently selected from alkyl or aryl; R² is H; R³ is H, alkyl;R⁴ is H; and n is 1, 2, 3, or 4.

In some embodiments, the compounds can be selected from:

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compounds can be of the formula:

wherein, q is 1, 2, 3, 4, 5, or 6; and X is pharmaceutically acceptablecounter-ion.

In some embodiments, q is 3.

In some embodiments, aryl is phenyl.

In some embodiments, aryl is phenyl and q is 3.

In some embodiments, X can be hexafluorophosphate.

In some embodiments, the compound can be:

Methods of Synthesis

The compounds described herein can be prepared by the conjugation ofgeldanamycin or the 17-GMB-APA-GA analogue. The use of the either ofthese compounds allows for conjugation with nucleophilic moieties suchas thiols, amines, or alcohols. The elaboration of the cationicmitochondrial-penetrating moiety can be performed to include between oneand 10 of the guanidino moieties containing the monomeric structure:

which can be abbreviated as

A general iterative method of synthesis of such compositions containingoligomeric guanidino structures is shown below. The mesylate G1 can betreated with potassium acetate (KSAc) to provide the thio ester whichupon base treatment followed by exposure to the maleimide derivative(L-GA) of a molecular chaperone inhibitor, such as geldanamycin (GA),can provide the desired first generation compositions G1-GA. TheG1-thioester compound can in turn be treated in sequence such as withmethanesulfonic acid; cesium carbonate in the presence oftributylphosphine; followed by reaction with G1 and finally treatingwith methanesulfonic anhydride provides G2 which is the higher homologueof G1. Such iterative process as can be seen clearly provides access tooligomeric guanidino units. Few compounds are elaborated below in theExamples to demonstrate the process. Although the scheme shown here isdescribed for the linkers with maleimide group for facilitatingconjugation, this method can be extended to linkers with otherfunctionalities for conjugation such as the N-hydroxy succinimide esters(such as 17-NHS-ALA-GA). One of skill in the art will also recognizethat this iterative scheme can be extended to other non-GA based Hsp90inhibitors such as the purine based antagonists or the resorcinolantagonists.

V. Methods of Treatment

The compounds described herein, i.e., mitochondrial-targeted chaperoneinhibitors, are useful in the treatment of disorders associated withuncontrolled cellular proliferation, as occurs, for example, in tumorformation and in cancer. In some embodiments, tumors treated by a methoddescribed herein can be associated with a cancer described herein.

Generally, the methods include administering a therapeutically effectiveamount of a therapeutic compound as described herein, to a subject whois in need of, or who has been determined to be in need of, suchtreatment.

As used in this context, to “treat” means to ameliorate at least onesymptom of the disorder associated with uncontrolled cellularproliferation. Ideally, a treatment can result in the death of theproliferating cells, or in a decrease in the rate of proliferation ofthe cells (i.e., the cancer or tumor cells).

An “effective amount” is an amount sufficient to effect beneficial ordesired results. For example, a therapeutic amount is one that achievesthe desired therapeutic effect. This amount can be the same or differentfrom a prophylactically effective amount, which is an amount necessaryto prevent onset of disease or disease symptoms. An effective amount canbe administered in one or more administrations, applications or dosages.A therapeutically effective amount of a composition depends on thecomposition selected.

The compositions can be administered systemically, locally, or both,using methods known in the art, e.g., parenteral, oral, mucosal, orother routes of administration. As one of skill in the art willappreciate, the route of administration should be selected based onsuitability for the treatment of the specific condition, and theformulation of the composition.

The compositions can be administered from one or more times per day toone or more times per week; including once every other day. The skilledartisan will appreciate that certain factors may influence the dosageand timing required to effectively treat a subject, including but notlimited to the severity of the disease or disorder, previous treatments,the general health and/or age of the subject, and other diseasespresent. Moreover, treatment of a subject with a therapeuticallyeffective amount of the compositions described herein can include asingle treatment or a series of treatments.

The compounds described herein are useful in the treatment of tumors andcancer. The compounds described herein can be administered to a patientdiagnosed with cancer, e.g., any of the types of cancers referred toherein. For example, the mitochondrial-targeted chaperone inhibitordisclosed herein can be used, without limitation, to treat a subjectsuffering from one or more of a cancer or tumor of the lung, breast,epithelium, large bowel, rectum, testicle, gallbladder, bile duct,biliary tract, prostate, colon, stomach, esophagus, pancreas, liver,uterus, ovary, or brain. In certain embodiments, the compounds describedherein are useful in the treatment of chronic myelogenoeous leukemia, Blymphoblastoid leukemia, breast adenocarcinoma, lung adenocarcinoma,prostate adenocarcinoma, glioblastoma, colon adenocarcinoma, andcervical carcinoma. In other examples, the mitochondrial-targetedchaperone inhibitor disclosed herein can be used to treat, withoutlimitation, a subject suffering from haemangioma, Hodgkin's disease,large cell non-Hodgkin's lymphoma, malignant lymphoma, leukemia,polycythemia vera, neuroblastoma, retinoblastoma, myelodysplasticsyndrome with refractory anemia, neuroblastoma, glioma,pheochromocytoma, soft tissue sarcoma, maxillary cancer, lingual cancer,lip cancer, mouth cancer, melanoma, or non-melanoma skin cancer. Ingeneral, cancers that can be treated by the compounds and candidatecompounds described herein include but are not limited to carcinomas,sarcomas, lymphomas, leukemias, or germ cell tumors. In preferredembodiments, the compounds described herein can be administered to apatient diagnosed with cervical cancer, breast cancer, prostate cancer,lung cancer, epithelial carcinoma, colorectal cancer, Burkitt lymphoma,myeloid leukemia, and leukemic monocyte lymphoma.

Administration and Dosing

Toxicity and therapeutic efficacy of such compounds can be determined bystandard pharmaceutical procedures in cell cultures or experimentalanimals, e.g., for determining the LD50 (the dose lethal to 50% of thepopulation) and the ED50 (the dose therapeutically effective in 50% ofthe population). The dose ratio between toxic and therapeutic effects isthe therapeutic index and it can be expressed as the ratio LD50/ED50.Compounds which exhibit high therapeutic indices are preferred. Whilecompounds that exhibit toxic side effects may be used, care should betaken to design a delivery system that targets such compounds to thesite of affected tissue, e.g., bone or cartilage, in order to minimizepotential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from cell culture assays and animal studies can beused in formulating a range of dosage for use in humans. The dosage ofsuch compounds lies preferably within a range of circulatingconcentrations that include the ED50 with little or no toxicity. Thedosage may vary within this range depending upon the dosage formemployed and the route of administration utilized. For any compound usedin the method of the invention, the therapeutically effective dose canbe estimated initially from cell culture assays. A dose may beformulated in animal models to achieve a circulating plasmaconcentration range that includes the IC50 (i.e., the concentration ofthe test compound which achieves a half-maximal inhibition of symptoms)as determined in cell culture. Such information can be used to moreaccurately determine useful doses in humans. Levels in plasma may bemeasured, for example, by high performance liquid chromatography.

The skilled artisan will appreciate that certain factors influence thedosage and timing required to effectively treat a patient, including butnot limited to the type of patient to be treated, the severity of thedisease or disorder, previous treatments, the general health and/or ageof the patient, and other diseases present. Moreover, treatment of apatient with a therapeutically effective amount of a protein,polypeptide, antibody, or other compound can include a single treatmentor, preferably, can include a series of treatments.

If the compound is a small molecule, exemplary doses include milligramor microgram amounts of the small molecule per kilogram of subject orsample weight (e.g., about 1 microgram per kilogram to about 500milligrams per kilogram, about 100 micrograms per kilogram to about 5milligrams per kilogram, or about 1 microgram per kilogram to about 50micrograms per kilogram. It is furthermore understood that appropriatedoses of a small molecule depend upon the potency of the small moleculewith respect to the expression or activity to be modulated. When one ormore of these small molecules is to be administered to an animal (e.g.,a human) to modulate expression or activity of a polypeptide or nucleicacid of the invention, a physician, veterinarian, or researcher may, forexample, prescribe a relatively low dose at first, subsequentlyincreasing the dose until an appropriate response is obtained. Inaddition, it is understood that the specific dose level for anyparticular animal subject will depend upon a variety of factorsincluding the activity of the specific compound employed, the age, bodyweight, general health, gender, and diet of the subject, the time ofadministration, the route of administration, the rate of excretion, anydrug combination, and the degree of expression or activity to bemodulated.

Identifying Subjects for Treatment

In some embodiments, the methods include (i) identifying and selectingan individual suffering from cancer, and optionally (ii) determining ifthe individual's cancer cells express high levels of Hsp90 chaperones inthe mitochondria. If these cells express high levels of Hsp90 chaperonesin the mitochondria, then the individual is a candidate for, i.e., canbe selected for, treatment with a mitochondrial-targeted chaperoneinhibitor, and the method further includes (iii) administering to theindividual a pharmaceutical composition including amitochondrial-targeted chaperone inhibitor.

Individuals with cancer can be identified using methods known in theart, e.g., because they display symptoms or as a result of screening.Additional clinical tests can be performed and include, but are notlimited to, blood tests, X-rays, CT scans, endoscopy, and histologicalexamination of biopsy tissue, to confirm the diagnosis.

Symptoms of cancer in an individual include, but are not limited to,unusual lumps or swelling, hemorrhage, pain and/or ulceration, enlargedlymph nodes, cough and hemoptysis, hepatomegaly (enlarged liver), bonepain, fracture of affected bones and neurological symptoms, weight loss,poor appetite and cachexia (muscle wasting), excessive sweating, andanemia.

Screens for identifying individuals with cancer are known in the art.Screening methods include, but are not limited to, self-examination,mammograms, fetal occult blood testing, cervical cytology (e.g., Papsmear), digital rectal exam, prostate specific antigen (PSA) bloodtesting, sigmoidoscopy, which looks for visual abnormality in the rectumand lower part of the colon, and colonoscopy, which allows visualizationof the rectum and entire colon, and double contrast barium enema (DCBE),which allows radiographic examination of the rectum and colon.

A number of methods are known in the art for detecting high levels ofchaperones in the mitochondria, including immunoassays, e.g., using anantibody to Hsp90. For example, the detection of chaperones inmitochondria can be achieved by obtaining mitochondrial andsubmitochondrial fractions, followed by the use of known detectionmethods, such as Western blotting, immunoelectron microscopy with anantibody to Hsp90, and matrix-assisted laser desorption/ionization(MALDI) proteomics (e.g., mass spectroscopy and time-of-flight analysis)of mitochondrial fractions.

Additional methods of identifying individuals who are candidates fortreatment with a chaperone inhibitor are disclosed herein. In thesemethods, a cancer cell from an individual is (i) exposed to amitochondrial-targeted chaperone inhibitor and (ii) assayed for thepresence of one or more of the following activities: increased celldeath, loss of cell viability, loss of mitochondrial membrane potential,loss of mitochondrial membrane integrity (e.g., Smad or cytochrome crelease), and loss of Hsp90 chaperone activity (e.g., degradation of Aktkinase). Methods for performing such assays are known in the art andinclude flow cytometry, the MTT assay, gel electrophoresis, and westernblotting. Exemplary methods are also described in the Examples herein.

If the cancer cell exhibits one or more of these activities, then theindividual is classified as a candidate for treatment with amitochondrial-targeted chaperone inhibitor. In other new methods, cancercells from the same individual are placed in culture media. Some of thecancer cells are contacted with a mitochondrial-targeted chaperoneinhibitor, and cultured under conditions that allow the cells toproliferate. If the mitochondrial-targeted chaperone inhibitor inhibitsproliferation and/or induces apoptosis of the contacted cancer cells,e.g., relative to cells that are not contacted with an inhibitor, thenthe individual is a candidate for treatment with mitochondrial-targetedchaperone inhibitor.

VI. Pharmaceutical Compositions

The mitochondrial-targeted chaperone inhibitors described herein (all ofwhich can be referred to herein as “active compounds”) can beincorporated into pharmaceutical compositions. Such compositionstypically include the active compound and a pharmaceutically acceptablecarrier. A “pharmaceutically acceptable carrier” can include solvents,dispersion media, coatings, antibacterial and antifungal agents,isotonic and absorption delaying agents, and the like, compatible withpharmaceutical administration. Supplementary active compounds can alsobe incorporated into the compositions. Also included are thepharmaceutical compositions themselves, and pharmaceutically acceptablesalts of the compounds described herein. It is well known in thepharmacological arts that nontoxic addition salts of pharmacologicallyactive amine compounds do not differ in activities from their free base.

Pharmaceutically acceptable salts include both acid and base additionsalts. “Pharmaceutically acceptable salt” refers to those salts whichretain the biological effectiveness and properties of the free bases andwhich are not biologically or otherwise undesirable. Suitablepharmaceutically acceptable acid addition salts can be formed withinorganic acids such as hydrochloric acid, hydrobromic acid, sulfuricacid, nitric acid, phosphoric acid, and the like, and organic acids suchas acetic acid, propionic acid, glycolic acid, pyruvic acid, fumaricacid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelicacid, methanesulfonic acid, and p-toluenesulfonic acid, and the like.Pharmaceutically acceptable base addition salts include those derivedfrom inorganic bases such as sodium, potassium, lithium, ammonium,calcium, magnesium, iron, zinc, copper, manganese, aluminum salts andthe like. Particularly preferred are the ammonium, potassium, sodium,calcium and magnesium salts. Salts derived from pharmaceuticallyacceptable organic non-toxic bases include salts of primary, secondary,and tertiary amines, substituted amines, including naturally occurringsubstituted amines, cyclic amines and basic ion exchange resins, such asisopropylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol,2-dimethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine,caffeine, procain, hydrabamine, choline, betaine, ethylenediamine,glucosamine, methylglucamine, theobromine, purines, piperazines,piperidine, polyamine resins and the like. Particularly preferredorganic non-toxic bases are isopropylamine, diethylamine, ethanol-amineand dicyclohexylamine.

A pharmaceutical composition is generally formulated to be compatiblewith its intended route of administration. Examples of routes ofadministration include parenteral, e.g., intravenous, intradermal,subcutaneous, oral (e.g., inhalation), transdermal (topical),transmucosal, and rectal administration. Solutions or suspensions usedfor parenteral, intradermal, or subcutaneous application can include thefollowing components: a sterile diluent such as water for injection,saline solution, fixed oils, polyethylene glycols, glycerine, propyleneglycol or other synthetic solvents; antibacterial agents such as benzylalcohol or methyl parabens; antioxidants such as ascorbic acid or sodiumbisulfite; chelating agents such as ethylenediaminetetraacetic acid;buffers such as acetates, citrates or phosphates and agents for theadjustment of tonicity such as sodium chloride or dextrose. pH can beadjusted with acids or bases, such as hydrochloric acid or sodiumhydroxide. The parenteral preparation can be enclosed in ampoules,disposable syringes, or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterileaqueous solutions (where water soluble) or dispersions and sterilepowders for the extemporaneous preparation of sterile injectablesolutions or dispersion. For intravenous administration, suitablecarriers include physiological saline, bacteriostatic water, CremophorEL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In allcases, the composition must be sterile and should be fluid to the extentthat easy syringability exists. It should be stable under the conditionsof manufacture and storage and must be preserved against thecontaminating action of microorganisms such as bacteria and fungi. Thecarrier can be a solvent or dispersion medium containing, for example,water, ethanol, polyol (for example, glycerol, propylene glycol, andliquid polyethylene glycol, and the like), and suitable mixturesthereof. The proper fluidity can be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersion and by the use of surfactants.Prevention of the action of microorganisms can be achieved by variousantibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In manycases, it will be preferable to include isotonic agents, for example,sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in thecomposition. Prolonged absorption of the injectable compositions can beachieved by including an agent which delays absorption, e.g., aluminummonostearate or gelatin, in the composition.

Sterile injectable solutions can be prepared by incorporating the activecompound in the required amount in an appropriate solvent with one or acombination of ingredients enumerated above, as required, followed byfiltered sterilization. Generally, dispersions are prepared byincorporating the active compound into a sterile vehicle which containsa basic dispersion medium and the required other ingredients from thoseenumerated above. In the case of sterile powders for the preparation ofsterile injectable solutions, the preferred methods of preparation arevacuum drying and freeze-drying which yields a powder of the activeingredient plus any additional desired ingredient from a previouslysterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an ediblecarrier. For the purpose of oral therapeutic administration, the activecompound can be incorporated with excipients and used in the form oftablets, troches, or capsules, e.g., gelatin capsules. Oral compositionscan also be prepared using a fluid carrier for use as a mouthwash.Pharmaceutically compatible binding agents, and/or adjuvant materialscan be included as part of the composition. The tablets, pills,capsules, troches and the like can contain any of the followingingredients, or compounds of a similar nature: a binder such asmicrocrystalline cellulose, gum tragacanth or gelatin; an excipient suchas starch or lactose, a disintegrating agent such as alginic acid,PRIMOGEL, or corn starch; a lubricant such as magnesium stearate orSTEROTES; a glidant such as colloidal silicon dioxide; a sweeteningagent such as sucrose or saccharin; or a flavoring agent such aspeppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in theform of an aerosol spray from pressured container or dispenser thatcontains a suitable propellant, e.g., a gas such as carbon dioxide, or anebulizer.

Systemic administration can also be by transmucosal or transdermalmeans. For transmucosal or transdermal administration, penetrantsappropriate to the barrier to be permeated are used in the formulation.Such penetrants are generally known in the art, and include, forexample, for transmucosal administration, detergents, bile salts, andfusidic acid derivatives. Transmucosal administration can beaccomplished through the use of nasal sprays or suppositories. Fortransdermal administration, the active compounds are formulated intoointments, salves, gels, or creams as generally known in the art.Although applicants do not wish to be bound by theory, any non-specificcytotoxic effects of a systemically administered mitochondrial-targetedchaperone inhibitor as described herein are expected to be minimal, forat least the following reasons: levels of mitochondrial Hsp90 and TRAP1are low in most normal tissue; as demonstrated herein, mitochondriallocalization of Hsp90 and TRAP-1 is generally tumor cell-specific, sothat the inhibitors will preferentially accumulate in the mitochondriaof tumor cells; in those normal tissues that havemitochondrial-localized Hsp90 and TRAP-1, the activity of Hsp90 andTRAP-1 is decreased relative to the activity in tumor cells; and theblood-brain barrier is expected to protect the brain.

The compounds can also be prepared in the form of suppositories (e.g.,with conventional suppository bases such as cocoa butter and otherglycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers thatwill protect the compound against rapid elimination from the body, suchas a controlled release formulation, including implants andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid.Methods for preparation of such formulations will be apparent to thoseskilled in the art. The materials can also be obtained commercially fromAlza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions(including liposomes targeted to infected cells with monoclonalantibodies to viral antigens) can also be used as pharmaceuticallyacceptable carriers. These can be prepared according to methods known tothose skilled in the art, for example, as described in U.S. Pat. No.4,522,811.

It is advantageous to formulate oral or parenteral compositions indosage unit form for ease of administration and uniformity of dosage.Dosage unit form as used herein refers to physically discrete unitssuited as unitary dosages for the subject to be treated; each unitcontaining a predetermined quantity of active compound calculated toproduce the desired therapeutic effect in association with the requiredpharmaceutical carrier.

Nucleic acid molecules encoding a polypeptide described herein can beinserted into vectors and used as gene therapy vectors. Gene therapyvectors can be delivered to a subject by, for example, intravenousinjection, local administration (see, e.g., U.S. Pat. No. 5,328,470) orby stereotactic injection (see, e.g., Chen et al., Proc. Natl. Acad.Sci. USA, 91:3054-3057, (1994)). The pharmaceutical preparation of thegene therapy vector can include the gene therapy vector in an acceptablediluent, or can comprise a slow release matrix in which the genedelivery vehicle is imbedded. Alternatively, where the complete genedelivery vector can be produced intact from recombinant cells, e.g.,retroviral vectors, the pharmaceutical preparation can include one ormore cells that produce the gene delivery system.

Modifications such as lipidation can be used to stabilize proteins andto enhance uptake and tissue penetration. A method for lipidation isdescribed by Cruikshank et al., J. Acquired Immune Deficiency Syndromesand Human Retrovirology, 14:193, (1997).

The pharmaceutical compositions can be included in a container, pack, ordispenser together with instructions for administration.

VII. Nucleic Acids

Also included within the present disclosure are nucleic acids thatencode peptide-based mitochondrial-targeted chaperone inhibitors asdescribed herein.

Nucleic acids that are part of this invention can encode any of thepeptides identified by the methods disclosed herein that bind to andinhibit mitochondrial Hsp90 chaperones, e.g., Hsp90 and TRAP-1. Thenucleic acids disclosed herein also include nucleic acids encodingmodified versions of peptides that bind to and inhibit mitochondrialHsp90 chaperones, e.g., retro peptides, peptides linked to aheterologous polypeptide sequence, peptides linked to amitochondrial-penetrating sequence, peptides linked to a cellularinternalization sequence, and retro peptides linked to amitochondrial-penetrating sequence.

In some embodiments, the nucleic acids encode mitochondrial-targetedchaperone inhibitors for use in gene therapy.

Nucleic acids disclosed herein include both RNA and DNA, includingrecombinant DNA isolated from a cell and synthetic (e.g., chemicallysynthesized) DNA. Nucleic acids can be double-stranded orsingle-stranded. Nucleic acids can be synthesized using oligonucleotideanalogs or derivatives (e.g., inosine or phosphorothioate nucleotides).Such oligonucleotides can be used, for example, to prepare nucleic acidswith increased resistance to nucleases.

Also included in the invention are genetic constructs (e.g., vectors andplasmids) that include a nucleic acid encoding a mitochondrial-targetedchaperone inhibitor described herein operably linked to a transcriptionand/or translation sequence that enables expression of themitochondrial-targeted chaperone inhibitor, e.g., expression vectors. Aselected nucleic acid, e.g., a DNA molecule encoding a peptide describedherein, is “operably linked” to another nucleic acid molecule, e.g., apromoter, when it is positioned either adjacent to the other molecule orin the same or other location such that the other molecule can directtranscription and/or translation of the selected nucleic acid.

Also included in the invention are various engineered cells, e.g.,transformed host cells, which contain, and optionally express, a nucleicacid disclosed herein. Prokaryotic and eukaryotic cells, e.g., mammaliancells (e.g., tumor cells), yeast, fungi, and bacteria (such asEscherichia coli), and primary and transformed cells, can be host cells.A number of suitable cells are known in the art.

VIII. Methods of Screening

Described herein are methods for identifying candidate compounds, e.g.,small organic or inorganic molecules (e.g., having a M.W. less than1,000 Da), oligopeptides, oligonucleotides, carbohydrates, andantibodies that are useful in the methods of treatment described herein.In some methods, a candidate compound is screened for its ability tobind a chaperone, e.g., Hsp90 or TRAP-1. In some methods, a candidatecompound is screened for its ability to bind Cyclophilin D. In somemethods, candidate compounds are screened in silico by computationalmethods (as described, for example, in Example 12, in order to identifycandidate compounds that are expected to bind to Hsp90, e.g., theapo-open form of Hsp90). Libraries of chemical structures are known inthe art.

These candidate compounds can optionally be linked (via covalent ornon-covalent interactions) to the mitochondrial-penetrating moietiesdescribed herein. In some methods, a candidate compound is screened forits ability to inhibit an interaction between Cyclophilin D and achaperone, e.g., Hsp90 or TRAP-1. In some methods, a candidate compoundis screened for its ability to localize to mitochondria. In somemethods, a candidate compound is screened for its ability to induce celldeath.

Libraries of Test Compounds

In certain embodiments, screens for candidate compounds that can be usedto treat cancer cells use libraries of test compounds. As used herein, a“test compound” can be any chemical compound, for example, amacromolecule (e.g., a polypeptide, a protein complex, glycoprotein, ora nucleic acid) or a small molecule (e.g., an amino acid, a nucleotide,an organic or inorganic compound). A test compound can have a formulaweight of less than about 10,000 grams per mole, less than 5,000 gramsper mole, less than 1,000 grams per mole, or less than about 500 gramsper mole. The test compound can be naturally occurring (e.g., an herb ora natural product), synthetic, or can include both natural and syntheticcomponents. Examples of test compounds include peptides, peptidomimetics(e.g., peptoids), amino acids, amino acid analogs, polynucleotides,polynucleotide analogs, nucleotides, nucleotide analogs, and organic orinorganic compounds, e.g., heteroorganic or organometallic compounds.

Test compounds can be screened individually or in parallel. An exampleof parallel screening is a high throughput drug screen of largelibraries of chemicals. Such libraries of candidate compounds can begenerated or purchased, e.g., from Chembridge Corp., San Diego, Calif.Libraries can be designed to cover a diverse range of compounds. Forexample, a library can include 500, 1000, 10,000, 50,000, or 100,000 ormore unique compounds. In some cases libraries include classes ofcompounds with enhanced potential for having anti-cancer activity.Classes of compounds with enhanced potential include known chaperoneinhibitors and structurally similar compounds. For example libraries caninclude ansamycin antibiotics, geldanamycin analogs, andpyrazolopyrimidines and related analogs. A library can be designed andsynthesized to cover such a class of chemicals.

The synthesis of combinatorial libraries has been reviewed (see, e.g.,Gordon et al., J. Med. Chem., 37:1385, (1994); DeWitt and Czamik, Acc.Chem. Res., 29:114, (1996); Armstrong et al., Acc. Chem. Res.,29:123-131, (1996); Ellman, J. A., Acc. Chem. Res., 29:132, (1996);Gordon et al., Acc. Chem. Res., 29:144, (1996); Lowe, G. Chem. Soc.Rev., 309, (1995), Blondelle et al., Trends Anal. Chem., 14:83, (1995);Chen et al., J. Am. Chem. Soc., 116:2661, (1994); U.S. Pat. Nos.5,359,115, 5,362,899, and 5,288,514; and PCT Publication Nos.WO92/10092, WO93/09668, WO91/07087, WO93/20242, and WO94/08051).

Libraries of compounds can be prepared according to a variety ofmethods, some of which are known in the art. For example, a split-poolstrategy can be implemented in the following way: beads of afunctionalized polymeric support are placed in a plurality of reactionvessels; a variety of polymeric supports suitable for solid-phasepeptide synthesis are known, and some are commercially available (forexamples, see, e.g., Bodansky, Principles of Peptide Synthesis, 2ndedition, Springer-Verlag, Berlin (1993)). To each aliquot of beads isadded a solution of a different activated amino acid, and the reactionsare allowed to proceed to yield a plurality of immobilized amino acids,one in each reaction vessel. The aliquots of derivatized beads are thenwashed, pooled (i.e., recombined), and the pool of beads is againdivided, with each aliquot being placed in a separate reaction vessel.Another activated amino acid is then added to each aliquot of beads. Thecycle of synthesis is repeated until a desired peptide length isobtained. The amino acid residues added at each synthesis cycle can berandomly selected; alternatively, amino acids can be selected to providea biased library, e.g., a library in which certain portions of theinhibitor are selected non-randomly, e.g., to provide an inhibitorhaving known structural similarity or homology to a known peptidecapable of interacting with an antibody, e.g., the an anti-idiotypicantibody antigen binding site. It will be appreciated that a widevariety of peptidic, peptidomimetic, or non-peptidic compounds can bereadily generated in this way.

The split-pool strategy can result in a library of peptides, e.g.,modulators, which can be used to prepare a library of test compounds foruse in the screens described herein. In another illustrative synthesis,a diversomer library is created by the method of DeWitt et al., Proc.Natl. Acad. Sci. U.S.A., 90:6909, (1993). Other synthesis methods,including the “tea-bag” technique, described in Houghten et al., Nature,354:84, (1991), can also be used to synthesize libraries of compoundsaccording to the subject invention.

Libraries of compounds can be screened to determine whether any membersof the library have chaperone, e.g., Hsp90 or TRAP-1, inhibitoryactivity, and, if so, to identify the inhibitor. Methods of screeningcombinatorial libraries have been described. See, e.g., Gordon et al.,J. Med. Chem., supra. Soluble compound libraries can be screened toisolate inhibitors of chaperones, e.g., Hsp90 or TRAP-1, followed byidentification of the isolated ligands by conventional techniques (e.g.,mass spectrometry, NMR, and the like). Screens are described herein.

Screens

Provided herein are methods for identifying candidate compounds for thetreatment of tumors or cancer. Although applicants do not intend to bebound by any particular theory as to the biological mechanism involved,such compounds are thought to inhibit chaperones in mitochondria therebyinhibiting chaperone-mediated antagonism of Cyclophilin D (CypD)function. Cyclophilin D is an immunophilin that induces mitochondrialcell death, and chaperones are thought to antagonize CypD function viaprotein folding/refolding mechanisms. Disabling this pathway using novelHsp90 ATPase antagonists directed to mitochondria causes sudden collapseof mitochondrial function and selective tumor cell death. Thus,chaperones are novel regulators of mitochondrial integrity, and theirorganelle-specific antagonists may provide a novel class of potentanticancer agents.

In certain embodiments, screening for compounds capable of inhibitingchaperones in mitochondria can include identifying from a group of testcompounds those that (i) inhibit and/or bind to a molecular chaperone,(ii) inhibit interaction between a molecular chaperone and CyclophilinD, and/or (iii) decrease levels of chaperones in tumor cellmitochondria. Test compounds that exhibit one or more of activities (i),(ii), or (iii) are referred to herein as “candidate compounds.”Screening assays can optionally include further testing candidatecompounds for their ability to modulate proliferation of cancer cells invitro or in vivo. Screening assays of the present invention may becarried out in whole cell preparations and/or in ex vivo cell-freesystems. In some embodiments, test compounds or candidate compounds arelinked to a mitochondrial-penetrating moiety.

Binding of a test compound to a cell-free sample that includes achaperone protein can be detected, for example, in vitro by reversiblyor irreversibly immobilizing the chaperone protein on a substrate, e.g.,the surface of a well of a plate (e.g., 96-well polystyrene microtitreplate). For example, microtitre plates can be coated with the chaperoneprotein, or a fragment thereof, washed and blocked (e.g., with BSA) toprevent non-specific binding of test compounds to the plates. Thechaperone protein is then cross-linked to the plate. Test compounds areadded to the coated plate under a number of conditions (e.g., at 37° C.for 0.5-12 hours). The plate can then be rinsed and binding of the testcompound to the chaperone protein can be detected by any of a variety ofart-known methods. For example, an antibody that specifically binds tothe chaperone protein can be used in an immunoassay. If desired, theantibody can be labeled (e.g., fluorescently or with a radioisotope) anddetected directly (see, e.g., West and McMahon, J. Cell Biol., 74:264,(1977)). Alternatively, a second antibody can be used for detection(e.g., a labeled antibody that binds to the anti-chaperone proteinantibody). Test compounds that bind to the chaperone protein can bedetected by their ability to inhibit binding of antibody to immobilizedchaperone protein. In an alternative detection method, the test compoundis labeled (e.g., with a radioisotope, fluorophore, chromophore, or thelike), and the binding of a test compound to the chaperone protein isdetected by detecting label that is immobilized on the substrate.

In still another embodiment, test compounds are immobilized on asubstrate, e.g., to a microtitre plate as described above, incubatedwith a cell free sample that includes a chaperone protein (or a fragmentthereof), washed, and the ability of the chaperone protein to bind to animmobilized test compound is detected. For example, Hsp90 (or a fragmentthereof) can be produced as a fusion protein with a protein that can bedetected optically, e.g., green fluorescent protein or a variant thereof(which can be detected under UV light), and the ability of the fusionprotein to bind the test compound is detected. Alternatively, achaperone can be produced as a fusion protein with an enzyme having adetectable enzymatic activity, such as horseradish peroxidase, alkalinephosphatase, β-galactosidase, or glucose oxidase. Genes encoding all ofthese enzymes have been cloned and are available for use by skilledpractitioners. If desired, the fusion protein can include an antigen,which can be detected and measured with a polyclonal or monoclonalantibody using conventional methods. Suitable antigens include enzymes(e.g., horse radish peroxidase, alkaline phosphatase, andβ-galactosidase) and non-enzymatic polypeptides (e.g., serum proteins,such as BSA and globulins, and milk proteins, such as caseins). In thesemethods, the ability of the chaperone fusion protein to bind to a testcompound is detected.

To identify polypeptides that bind to a chaperone protein a two-hybridassays of protein/protein interactions can be used (see, e.g., Chien etal., Proc. Natl. Acad. Sci. USA, 88:9578, (1991); Fields et al., U.S.Pat. No. 5,283,173; Fields and Song, Nature, 340:245, (1989); Le Douarinet al., Nucleic Acids Research, 23:876, (1995); Vidal et al., Proc.Natl. Acad. Sci. USA, 93:10315-10320, (1996); and White, Proc. Natl.Acad. Sci. USA, 93:10001-10003, (1996)). Kits for practicing varioustwo-hybrid methods are commercially available (e.g., from Clontech; PaloAlto, Calif.).

In certain other embodiments, the interaction of a chaperone protein, orfragment thereof, and test compound is detected by fluorescenceresonance energy transfer (FRET) between a donor fluorophore covalentlylinked to either the chaperone protein or the test compound and anacceptor fluorophore covalently linked to either the chaperone proteinor the test compound, wherein the acceptor and donor fluorophore are notboth linked to the chaperone protein or the test compound, and there issuitable overlap of the donor emission spectrum and the acceptorexcitation spectrum to give efficient nonradiative energy transfer whenthe fluorophores are brought into close proximity through the chaperoneprotein-test compound interaction.

In some methods, test compounds that are candidate compounds for thetreatment of tumors or cancer can be identified by contacting a testcompound to a sample that includes one or more chaperone proteins andCypD, and then screening for decreased interaction between a chaperoneand CypD. In one embodiment, a cell-free system is used to determine ifrecombinant TRAP-1 or recombinant Hsp90 co-immunoprecipitate withrecombinant CypD in the presence of a test compound.

In some methods, test compounds that are candidate compounds for thetreatment of tumors or cancer are contacted with one or more tumor cellsand are evaluated for decreased expression of the chaperone. In arelated method, one or more test compound is contacted to a tumor cellthat expresses a recombinant chaperone, and the cells are evaluated fordecreased expression of the recombinant chaperone. Expression of achaperone can be measured, for example, by Northern blot, RT-PCRanalysis, RNAse protection analyses, Western blot, enzyme-linkedimmunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescentactivated cell sorting (FACS). The level of expression in the presenceof the test molecule, compared with the level of expression in itsabsence, will indicate whether or not the test compound inhibits theexpression of the chaperone. In one embodiment, the test compound is asmall interfering RNA (siRNA).

Having identified a test compound as a candidate compound, the candidatecompound can be further tested, e.g., in proliferation assays of tumorcells using in vitro or in vivo model systems. In vitro proliferationassays include contacting a candidate compound to a culture of tumorcells, e.g., Raji cells, and evaluating the ability of the candidatecompound to induce apoptosis in and/or prevent proliferation of thecultured cells. In vivo tumor assays include administering a candidatecompound to an animal model, e.g., a rodent, with a tumor or apredisposition to develop a tumor, and subsequently evaluating thecandidate compound's ability to inhibit tumor development or tumorproliferation in the animal. Exemplary animal models of cancer includeanimals with xenografted cancer cells. Other animal models includerodents with a genetic predisposition to develop tumors, e.g., micebearing mutant forms of (i) adenomatous polyposis coli (APC) gene (e.g.,a multiple intestinal neoplasia (APC^(Min)) mouse (see, e.g., Haigis etal., Proc. Nat'l. Acad. Sci. USA, 101:9769-9773, (2004)), (ii) mut-shomologue-2 (Msh2) gene (see, e.g., Kohonen-Corish et al., CancerResearch, 62:2092-2097, (2002)), and/or (iii) MutL homologue-1 (Mlh1)gene (see, e.g., Cohen et al., Cell, 85:1125-1134, (1996)). TheC57BL/6J-Apc^(Min) mouse is available from Jackson Harbor Labs (BarHarbor, Me.). Alternatively, an animal model can be exposed tocarcinogenic chemicals such as dimethylhydrazine derivatives orheterocyclic amines, such as2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), that have beenreported to induce tumors in animal models.

In some methods, candidate compounds for the treatment of tumors orcancer can be further tested for apoptosis-inducing activity bycontacting the candidate compound to a sample that includes one or moretumor cells, and then screening for decreased cell viability. In oneembodiment, decreased cell viability is measured using an MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reductionassay. The calorimetric MTT assay, developed by Mossman (J. Immunol.Methods 65:55-63 (1983)), is based on the conversion of thewater-soluble MTT to an insoluble purple formazan. The formazan is thensolubilized, and its concentration determined by optical density at 570nm. The methods can be performed, e.g., as described in Plescia et al.(Cancer Cell. 2005 May; 7(5):457-68). Other viability assays can also beused.

In some methods, candidate compounds for the treatment of tumors orcancer can be further tested by contacting a test compound to a samplethat includes one or more tumor cells, and then screening for increasedapoptosis. In one embodiment, increased apoptosis is evident asincreased caspase activity as determined by DEVDase hydrolysis. Methodsfor measuring apoptosis are well known in the art.

In some methods, candidate compounds for the treatment of tumors orcancer can be further tested for their ability to disrupt mitochondrialmembrane integrity. For example, candidate compounds can be furthertested for their ability to induce a change in mitochondrial membranepotential, increase cytochrome c release, or increase Smad release. Inone embodiment, cells are treated with a candidate compound and furthertreated with a mitochondrial membrane potential-sensitive fluorescentdye JC-1, and analyzed for changes in green/red fluorescence ratio byflow cytometry.

In some methods, candidate compounds for the treatment of tumors orcancer can be further tested for their ability to inhibit chaperoneactivity. For example, candidate compounds can be further tested fortheir ability to induce degradation of Akt, an Hsp90 client protein.

Medicinal Chemistry

Once a compound (or agent) of interest has been identified, standardprinciples of medicinal chemistry can be used to produce derivatives ofthe compound. Derivatives can be screened for improved pharmacologicalproperties, for example, efficacy, pharmaco-kinetics, stability,solubility, and clearance. The moieties responsible for a compound'sactivity in the assays described above can be delineated by examinationof structure-activity relationships (SAR) as is commonly practiced inthe art. A person of ordinary skill in pharmaceutical chemistry canmodify moieties on a candidate compound or agent (i.e., a lead compound)and measure the effects of the modification on the efficacy of thecompound or agent to thereby produce derivatives with increased potency.For an example, see Nagarajan et al., J. Antibiot., 41:1430-1438,(1988). Furthermore, if the biochemical target of the compound (oragent) is known or determined, the structure of the target and thecompound can inform the design and optimization of derivatives.Molecular modeling software is commercially available (e.g., fromMolecular Simulations, Inc.) for this purpose.

EXAMPLES

The invention is further described in the following examples, which donot limit the scope of the invention described in the claims.

Example 1 Hsp90 Chaperones in Mitochondria

The experiments described in this example were designed to determinesubcellular localization of the chaperones TRAP-1 and Hsp90.

An antibody to TRAP-1 detected an abundant ˜75 kDa immunoreactive bandin purified mitochondria isolated from various tumor cell types (FIG.1A). This localization was selective because TRAP-1 was found at verylow levels in mitochondria isolated from normal mouse tissues (FIG. 1A),and was absent in the cytosol of tumor or normal cells (FIG. 1A and notshown) (Chen et al., Mol. Cell. Biol., 16:4691-4699, (1996)).Differential TRAP-1 expression in primary tumor specimens and theirrespective normal tissues, in vivo, were examined. Byimmunohistochemistry, TRAP-1 was intensely expressed in the tumor cellsof adenocarcinoma of the pancreas (FIG. 1C), breast (FIG. 1E), colon(FIG. 1G), and lung (FIG. 1I). Conversely, epithelia of normal pancreas(FIG. 1B), breast (FIG. 1D), colon (FIG. 1F), and lung (FIG. 1H)contained very low levels of TRAP-1, and IgG did not stain normal ortumor tissues (not shown).

In addition to its known localization in cytosol, an abundant pool ofHsp90 was detected in mitochondria of various tumor cell types, byWestern blotting (FIG. 1J). Accordingly, an antibody to Hsp90 labeledpurified mitochondria isolated from HeLa cells (26.6±4.1 goldparticles/mitochondria, n=13), by electron microscopy (FIG. 1K), whereasIgG did not significantly stain mitochondria (1.1±0.33 goldparticles/mitochondria, n=13; p<0.0001) (FIG. 1L). Mitochondria werecharacterized as follows. Mitochondrial fractions purified from HeLacells contained TRAP-1 and Hsp90, but not proteins of the endoplasmicreticulum (calnexin), or cytosol (GAPDH), and very low amounts ofLamp-1, a lysosomal marker (FIG. 1M). Hsp90 was actively imported inisolated mitochondria. ³⁵S-labeled in vitro transcribed and translatedHsp90 proteins readily accumulated inside isolated brain mitochondriaafter treatment with proteinase K, and this reaction was completelyinhibited by the uncoupler, valinomycin (FIG. 2A). Similar results wereobtained with ³⁵S-labeled mitochondrial phosphate carrier, PiC, as acontrol for mitochondrial import (FIG. 2A).

To determine if Hsp90 localized to mitochondria in vivo, immunoblotswere performed on mitochondrial extracts obtained from primary testis,lung, spleen, kidney, brain and liver cells. These immunoblots showedthat Hsp90 is expressed at low levels in the mitochondria of primarycells (FIG. 8). Proteinase K degradation of outer membrane proteins,including Bcl-2, did not reduce Hsp90 reactivity in isolatedmitochondria (FIG. 8), suggesting that it was protected fromproteolysis.

Conversely, permeabilization of the outer membrane with digitoninresulted in concentration dependent release of Hsp90 from mitochondrialpellets into the supernatant, whereas matrix associated mt-Hsp70 wasunaffected (FIG. 2B). In the absence of sucrose, mechanical disruptionof the outer membrane completely depleted Smac from the mitochondrialintermembrane space, without affecting matrix-associated Cyclophilin D(CypD) (FIG. 2C). Although reduced by this treatment, substantial Hsp90reactivity remained associated with mitochondria (FIG. 2C), suggestingthat Hsp90 localized to both the matrix and the mitochondrialintermembrane space. A submitochondrial fractionation protocol thatallows analysis of individual organelle compartments, including theouter membrane (OM), intermembrane space (IMS), inner membrane (IM) andthe matrix was used to examine localization of Hsp90. Hsp90 localized toboth the intermembrane space and the mitochondrial matrix (FIG. 2D).

Similar to TRAP-1, the mitochondrial localization of Hsp90 wasselective, and, except for brain and testis, no expression ofmitochondrial Hsp90 was found in other normal mouse tissues surveyed(FIG. 2E). Further, levels of mitochondrial Hsp90 in brain and testiswas significantly lower than mitochondrial Hsp90 levels observed fortumor cell types (FIG. 1J). Conversely, the cytosolic pool of Hsp90 wasubiquitously present in normal and tumor cell types (FIG. 2E). In humancells, both Hsp90 and TRAP-1 were expressed at high levels in varioustumor cell lines, but expressed at low levels in three normal primaryfibroblast cell types (FIG. 2F). This differential localization was notdue to a globally reduced expression of Hsp90 chaperones in normalversus tumor cells. The cytosolic amount of Hsp90 in normal cells wascomparable to that of a representative tumor cell type, whereas itsmitochondrial pool was considerably reduced, and TRAP-1 levels inmitochondria were also decreased (FIG. 2G).

Example 2 Targeting Mitochondrial Hsp90 Chaperones Causes MitochondrialPermeability Transition and Cell Death

In the experiments described in this example, two ATPase pocketantagonists of Hsp90 chaperones were used, the small molecule GAderivative, 17-AAG (Isaacs et al., Cancer Cell, 3:213-217, (2003)), andthe peptidomimetic Shepherdin (Sheph), which is made cell permeable bythe addition of an Antennapedia helix III homeodomain cell-penetratingsequence (“ANT”, Plescia et al., Cancer Cell, 7:457-468, (2005)). Bothmolecules inhibit Hsp90 chaperone activity by competing with ATP bindingand inhibiting Hsp90 ATPase activity (Neckers and Ivy, Curr. Opin.Oncol., 15:419-424, (2003); Plescia et al., Cancer Cell, 7:457-468,(2005)).

Purified mitochondria were isolated from HeLa cells as described below.Fluorescein-conjugated Sheph-ANT accumulated inside the purifiedmitochondria (FIG. 3A), whereas no fluorescence signal was detected forShepherdin lacking the Antennapedia cell-penetrating sequence, Sheph(FIG. 3B), or in the absence of mitochondria (FIG. 3C). Afluorescein-conjugated cell-permeable scrambled peptidomimetic,Scram-ANT, also accumulated inside isolated mitochondria (FIG. 3D), andquantification of fluorescence intensity showed that both Sheph-ANT andScram-ANT sequence were indistinguishable for efficiency ofintramitochondrial penetration (FIG. 3E) in the isolated mitochondria.

The submitochondrial distribution of Shepherdin with (Sheph-ANT) orwithout (Sheph) Antennapedia cell-penetrating peptide was quantified.Cell permeable Sheph-ANT was present in unfractionated mitochondria, aswell as in all submitochondrial compartments, including theintermembrane space, the inner membrane and the matrix (FIG. 3F). Thislocalization was entirely dependent on the Antennapedia peptide (ANT),as Sheph (without ANT) was not found in mitochondria or anysub-mitochondrial compartment (FIG. 3F). To determine whether Shepherdindirectly bound Hsp90 molecules in mitochondria in vivo, we next coupledShepherdin or scrambled peptidomimetic to Sepharose beads. Fractionationof Raji mitochondrial extracts over Shepherdin-Sepharose resulted in thespecific elution of both TRAP-1 and Hsp90, by Western blotting (FIG. 3G,top). In contrast, no association of Hsp90 molecules with immobilizedscrambled peptidomimetic was demonstrated (FIG. 3G, bottom).

Under these experimental conditions, addition of Sheph-ANT to purifiedHeLa cell mitochondria caused sudden loss of mitochondrial membranepotential (FIG. 3H). This response was progressively attenuated atincreasing mitochondria concentrations (FIG. 3H), suggesting arequirement for compound accumulation inside mitochondria. Conversely,Sheph-ANT did not affect mitochondrial membrane potential of normalcells over background levels (see below, FIGS. 4A, C, E, G), and ascrambled peptidomimetic (Scram-ANT) had no significant effect onmitochondrial membrane potential of tumor or normal cells (FIG. 3H andsee below, FIGS. 4A, C, E, G). In addition, Sheph-ANT-inducedconcentration-dependent release of cytochrome c from mitochondriaisolated from Raji lymphoblastoid cells (FIG. 3I), and a primary humansarcoma sample, in vivo (FIG. 3J), whereas Scram-ANT had no significanteffect (FIGS. 3I, J). At variance with these data, the Hsp90 antagonist17-AAG did not induce cytochrome c or Smac release from isolated tumormitochondria (FIG. 3K), and only at high concentrations (20 μM), itcaused a small discharge of mitochondrial cytochrome c, but not Smac, inthe supernatant (FIG. 3L).

Example 3 Differential Regulation of Mitochondrial Homeostasis in TumorVersus Normal Cell Types

Sheph-ANT did not cause loss of membrane potential of mitochondriaisolated from WS-1 normal human fibroblasts (FIG. 4A, left), whereas itreadily depolarized mitochondria purified from B-lymphoblastoid Rajicells (FIG. 4A, right). Scram-ANT did not have significant effect onnormal or tumor mitochondria (FIG. 4A). Hsp90 levels can be modulated bycellular stress. Glucose deprivation of WS-1 fibroblasts increased thelevels of the endoplasmic reticulum Hsp90 homolog, Grp94, used as acontrol (FIG. 4B, left). However, there were minimal changes inendogenous TRAP-1 and Hsp90 expression in WS-1 mitochondria afterglucose deprivation (FIG. 4B, right). Consistent with this, Sheph-ANTdid not significantly affect membrane potential of glucose-deprived WS-1mitochondria, as compared with Scram-ANT (FIG. 4C).

Sheph-ANT-induced cytochrome c release from mitochondria isolated from ap53^(−/−) mouse lymphoma specimen (FIG. 9); this treatment had no effecton cytochrome c or Smac levels of normal mouse liver mitochondria (FIG.4D), and did not affect membrane potential of normal mouse liver (FIG.4E, left), or brain (FIG. 4E, right) mitochondria. A control scrambledpeptidomimetic, Scram-ANT, did not have a significant effect on normalor tumor mitochondria (FIG. 9, FIG. 4D, E).

To examine the basis for the differential recruitment of Hsp90 moleculesto tumor versus normal mitochondria, the effect of oncogene expressionon Hsp90 localization and expression levels were examined. Normal NIH3T3fibroblasts exhibited low levels of mitochondrial Hsp90 (FIG. 4F).However, retroviral transduction of these cells with a mutant Rasoncogene resulted in increased recruitment of Hsp90 to mitochondria,whereas TRAP-1 expression increased less prominently (FIG. 4F).Conversely, cytosolic Hsp90 levels did not change in normal orRas-transformed NIH3T3 cells (FIG. 4F). Sheph-ANT had no effect onmitochondria isolated from normal NIH3T3 cells (FIG. 4G, left), whereasit readily depolarized Ras-transformed NIH3T3 mitochondria (FIG. 4G,right), similarly to established tumor cells.

Example 4 Differential Regulation of Tumor Cell Killing by Inhibition ofMitochondrial Hsp90 Molecules

Sheph-ANT was shown to selectively kill tumor cells.Fluorescein-conjugated Sheph-ANT accumulated in the perinuclear area oftumor cells, and co-localized with the reactivity of a mitochondrialmarker, MitoTracker, by confocal microscopy (FIG. 5A). AlthoughScram-ANT accumulated inside isolated, purified mitochondria (FIG. 3D,E), Scram-ANT did not colocalize with MitoTracker in intact, livingcells (FIG. 5B). These results suggest that while Scram-ANT is competentfor penetrating mitochondria (as indicated by accumulation in isolatedmitochondria), Scram-ANT does not accumulate to levels detectable byconfocal microscopy in mitochondria in situ (in cells). Althoughapplicants do not wish to be bound by theory, the inability to detectaccumulation of Scram-ANT in mitochondria in situ may reflectnon-specific penetration of Scram-ANT in other cytosolic membranouscompartments, e.g., an equilibrium distribution of the Scram-ANTthroughout the compartments of the cell, thereby reducing steady statelevels of mitochondrially-localized Scram-ANT beyond the limit ofdetection of confocal microscopy. Again, not wishing to be bound bytheory, the accumulation of the Sheph-ANT is likely to be due to tightbinding of the Sheph moiety to Hsp90 or TRAP-1 localized inside themitochondria. Consistent with this prediction, quantification offluorescence intensity revealed that Scram-ANT accumulation inmitochondrial extracts of treated cells was reduced, as compared toSheph-ANT (FIG. 5C). Conversely, both sequences comparably accumulatedin total cell extracts and cytosol fractions of treated cells (FIG. 5C).

Within five minutes of addition, Sheph-ANT-induced loss of mitochondrialmembrane potential in tumor cells (FIG. 5D), and discharge ofmitochondrial cytochrome c in the cytosol (not shown). In contrast, acell permeable scrambled peptidomimetic (Scram-ANT) was without effect(FIG. 5D). In parallel experiments, 17-AAG did not affect mitochondrialmembrane potential in HeLa cells (FIG. 5D), and had no effect oncytochrome c release over a wide range of concentrations (FIG. 5E). Whenanalyzed by time-lapse videomicroscopy, tumor cells exposed toSheph-ANT, but not Scram-ANT, exhibited within minutes morphologicalfeatures of apoptosis, including cell shrinkage, membrane blebbing, andfusion/fission of mitochondria around the perinuclear area (FIG. 5F).Accordingly, a 1 hour exposure to Sheph-ANT was sufficient to killdisparate tumor cell types in a concentration-dependent manner, whereasa cell-permeable scrambled peptidomimetic, Scram-ANT, was ineffective(FIG. 5G). Consistent with selectivity of action, comparableconcentrations of Sheph-ANT did not affect the viability of variousnormal human fibroblast cell types (FIG. 5G). In contrast, 17-AAG had noeffect on tumor cell viability within the same kinetics, and only aprolonged exposure to the drug resulted in partial cell killing,detectable 24 hours after treatment (FIG. 5H).

Example 5 An Hsp90-Regulated Chaperone Network in Mitochondria

TRAP-1 immunoprecipitated from isolated Raji mitochondria was found in acomplex with endogenous CypD (FIG. 6A). The CypD inhibitor, cyclosporineA (CsA), prevented the formation of a CypD-TRAP-1 complex, in vivo (FIG.6A). Treatment with GA had no effect (FIG. 6A). Similar to TRAP-1, Hsp90immunoprecipitated from isolated mitochondrial extracts associated withendogenous CypD, in vivo, and this interaction was also prevented by CsA(FIG. 6B). Hsp90 was not found in TRAP-1 immune complexes (not shown),suggesting the existence of independent TRAP-1- and Hsp90-complexescontaining CypD in mitochondria. The interactions between Hsp90chaperones and CypD were confirmed using a cell-free system. In pulldown experiments, recombinant TRAP-1 or Hsp90 bound directly torecombinant CypD, and, vice versa, CypD directly associated withrecombinant Hsp90 molecules, in a reaction also abolished by CsA, butnot GA (FIG. 10). In contrast, GST did not associate with Hsp90 orTRAP-1, in vitro (FIG. 10). Incubation of GST-CypD with Rajimitochondrial extracts resulted in the isolation of both TRAP-1 andHsp90, and these interactions were inhibited by CsA, but not GA (FIG.6C).

Example 6 Molecular Requirements of Hsp90-Directed MitochondrialHomeostasis

Inhibition of CypD activity with CsA completely prevented membranedepolarization of tumor mitochondria by Sheph-ANT (FIG. 6D). Sheph-ANThad no effect on normal liver mitochondria, with or without CsA. CsAsignificantly inhibited Sheph-ANT-induced cell death, preserving a 70%cell viability at concentrations of Sheph-ANT (50 μM) that producecomplete cell killing in cultures that are not treated with CsA (FIG.6E). To confirm that the protective effect of CsA was specific, we nextacutely ablated its target, CypD, by small interfering RNA (siRNA), andquantified tumor cell killing mediated by Shepherdin. siRNA ablation ofCypD also prevented Sheph-ANT-induced tumor cell killing, restoring a60-70% cell viability over a broad range of effective concentrations(50-100 μM) of Sheph-ANT (FIG. 6F). In contrast, a scrambledpeptidomimetic, Scram-ANT, had no effect in the presence or absence ofCsA (FIG. 6E), or after transfection of non-targeted or CypD-directedsiRNA (FIG. 6F).

In order to determine if mitochondrial Hsp90, TRAP-1, or both moleculesantagonize the function of CypD in permeability transition, thefollowing experiments were performed. TRAP-1 expression, which is solelypresent in mitochondria, was ablated by siRNA and the effects on cellviability were determined. TRAP-1 silencing reduced HeLa cell viabilityby approximately 50%, as compared with non-targeted siRNA (FIG. 6G).Preincubation with CsA completely inhibited cell death induced by TRAP-1silencing (FIG. 6G), suggesting that Hsp90 chaperone antagonism of CypDin the mitochondria is required for cancer cell viability. In controlexperiments, siRNA directed to TRAP-1 or CypD reduced the expression ofthese two proteins in HeLa cells, whereas non-targeted siRNA had noeffect (FIG. 6H). To further examine whether mitochondrial Hsp90molecules confer active protection against apoptosis, TRAP-1 wastransfected into normal human fibroblasts, which express very low levelsof this protein (FIG. 2F, G). The transfected human fibroblasts weresubsequently tested for resistance to staurosporine-induced apoptosis.Expression of recombinant TRAP-1 in WS-1 (FIG. 6I) or HFF (FIG. 11)normal human fibroblasts strongly counteracted apoptosis over a broadrange of staurosporine concentrations, as compared with controls.

Example 7 Design and Chemical Synthesis of Mitochondria-Directed GA

Although Sheph-ANT induced permeability transition in isolatedmitochondria and live cells, and triggered selective tumor cell death, awell-characterized Hsp90 antagonist, 17-AAG (Neckers and Ivy, Curr.Opin. Oncol., 15:419-424, (2003)), had no effect on mitochondrialintegrity (FIG. 3K, L), and exhibited modest anticancer activity (FIG.5H). In order to determine if the lack of effect of 17-AAG was due to afailure of 17-AAG to accumulate inside mitochondria, localizationstudies were performed. Fluorescein-conjugated GA failed to accumulateinside isolated tumor cell mitochondria (FIG. 12A). A variant of 17-AAG,17-(3-(4-Maleimidobutyrcarboxanido)propylamino)-demethoxygeldanamycin(17-GMB-APA-GA) (FIG. 12B, C) was covalently coupled by a thioetherlinkage to the Antennapedia cell-penetrating peptide (ANT). Whenconjugated with FITC, this new compound, termed ANT-GA (FIG. 12C),readily accumulated inside isolated tumor mitochondria, whereas nofluorescence signal was detected in the absence of mitochondria (FIG.12A). Pretreatment of ANT-GA with proteinase K abolishedintramitochondrial accumulation, whereas addition of proteinase K afterANT-GA incubation with mitochondria was ineffective (FIG. 12A),indicating that the compound was protected from proteolysis. Overnightincubation of HeLa cells with a suboptimal concentration of ANT-GAresulted in the degradation of Akt, an Hsp90 client protein (FIG. 12D),confirming its ability to inhibit Hsp90 ATPase activity,indistinguishably from the uncoupled mixture of ANT and GA (GA/ANT).

Example 8 Induction of Mitochondrial Permeability Transition andSelective Tumor Cell Death by Mitochondria-Directed GA (ANT-GA)

Incubation of purified HeLa cell mitochondria with ANT-GA resulted insudden loss of mitochondrial membrane potential (FIG. 7A). This responsewas progressively attenuated at increasing mitochondria concentrations,indicating that compound accumulation inside mitochondria was requiredfor activity (FIG. 7A). CsA completely reversed ANT-GA-induced membranedepolarization of tumor mitochondria (FIG. 7B), reinforcing a role ofCypD in this pathway. In addition, ANT-GA was selective for tumor cells,and triggered concentration-dependent release of cytochrome c inisolated tumor mitochondria (FIG. 7C, top), but did not affect themembrane potential of normal brain mitochondria, with or without CsA(FIG. 7B), or the cytochrome c content of normal liver mitochondria(FIG. 7C, bottom). In control experiments, the uncoupled mixture ofGA/ANT, or GA alone, did not significantly affect normal or tumormitochondria membrane potential (FIG. 7B), and had no effect oncytochrome c release (FIG. 7C). When added to tumor cells, ANT-GA, butnot GA alone or the uncoupled ANT/GA mixture, produced rapid (˜2 hours),and concentration-dependent cell killing (FIG. 7D), whereas none of thecompounds affected the viability of various normal human fibroblast celltypes (FIG. 7E). Finally, tumor cell killing induced by ANT-GA had thehallmarks of apoptosis with increased caspase activity, as determined byDEVDase hydrolysis, and was unaffected by the presence or absence of p53(FIG. 7F). In contrast, the uncoupled mixture GA/ANT did not induceapoptosis in p53^(+/+) or p53^(−/−) cells (FIG. 7F).

Example 9 Selective Hsp60 Cytoprotection in Tumors

To determine whether Hsp60 cytoprotection was preferentially exploitedin cancer, its expression and function in normal versus tumor cell typeswas examined. Mitochondrial and cytosolic fractions were extracted fromtumor cells (6-7×107), essentially as described (Dohi et al., J ClinInvest 2004; 114:1117-27). Hsp60 was abundantly present in mitochondrialand extramitochondrial (Soltys and Gupta, Int Rev Cytol 2000;194:133-96), i.e. cytosolic, fractions of Breast adenocarcinoma MCF-7and colon adenocarcinoma HCT116 cells (FIG. 13A, top panel). Incontrast, primary WS-1 and HFF human fibroblasts exhibited considerablyreduced levels of Hsp60 in both subcellular compartments (FIG. 13A,bottom panel). By immunohistochemistry, Hsp60 was undetectable, orexpressed at very low levels in normal epithelium of breast, colon, andlung, in vivo (FIG. 13B). In contrast, Hsp60 was abundantly expressed inthe tumor cell population of adenocarcinoma of breast, colon, and lung(FIG. 13B); the primary tissue specimens of breast, lung and colonadenocarcinoma, and normal matched tissues were obtained anonymouslyfrom the UMass Memorial Cancer Center Tissue Bank. Tissue sections wereprocessed for immunohistochemistry using IgG or an antibody to Hsp60(1:1000), as described (Dohi et al., J Clin Invest 2004; 114:1117-27).In control experiments, IgG did not stain normal or tumor epithelia.

To determine whether Hsp60 cytoprotection was selectively operative intumor cells, Hsp60 expression was targeted in normal and tumor celltypes, and cell viability analyzed. Gene silencing by small interferingRNA (siRNA) was carried out by transfection of non-targeted (VIII) orHsp60-directed double stranded (ds) RNA oligonucleotides usingoligofectamine (3 μl/well), as described (Beltrami et al., J Biol Chem2004; 279:2077-84). Alternatively, cells were transfected with controlor SMART pool siRNA oligonucleotides to Hsp60 (Dharmacon), byoligofectamine. For double transfection experiments, cells were loadedtwice with control or Hsp60-directed siRNA at 48 hour intervals betweeneach transfection.

Transfection of 741INT normal human epithelial cells or WS-1 primaryhuman fibroblasts with Hsp60-directed siRNA resulted in suppression ofHsp60 expression, whereas a non-targeted siRNA was without effect. Atvariance with the results obtained with tumor cell lines, acute siRNAablation of Hsp60 in normal cells did not result in loss of cellviability, or increased caspase activity, as compared with controlcultures transfected with non-targeted siRNA (FIG. 13C).

Thus, Hsp60 (which binds to survivin, data not shown) contributes to abroad anti-apoptotic program that is differentially exploited in tumors,in vivo, and can therefore be targeted for preferentially killing tumorcells while sparing normal cells.

Example 10 Gamitrinibs Efficiently Disrupt Mitochondrial Integrity

Gamitrinibs (GA mitochondrial matrix-inhibitors) are the first class ofsmall molecule antagonists of Hsp90 chaperones compartmentalized inmitochondria. The structure of Gamitrinibs is combinatorial, andcontains a benzoquinone ansamycin backbone derived from the Hsp90inhibitor, 17-allylamino geldanamycin (17-AAG) (Isaacs et al., CancerCell, 3:213-217 (2003)), a linker region on the C17 position, and amitochondrial targeting moiety, either provided by one to four tandemrepeats of cyclic guanidinium (Fernandez-Carneado et al., J Am Chem Soc,127:869-874 (2005)). (Gamitrinib G1-G4), or triphenylphosphonium(Armstrong, Br J Pharmacol, 151:1154-1165 (2007)) (Gamitrinib-TPP) (FIG.15A). The 17-AAG portion of Gamitrinibs is predicted to make contactswith the Hsp90 ATPase pocket, whereas the guanidinium module is excludedfrom the binding interface, pointing outside of the ATPase pockettowards the solvent. In the predicted docking structure, the bindingarrangement of Gamitrinibs to Hsp90 closely follows that of Geldanamycin(GA) (Stebbins et al., Cell, 89:239-250 (1997)), with root mean squaredeviation of heavy atoms of the 17-AAG region being 0.5 Å.

Gamitrinib-G4 effectively competed with GA affinity beads for binding toHsp90 in a tumor cell lysate and inhibited Hsp90 chaperone activity(FIG. 15B) in a purified client protein reconstitution assay (Arlanderet al., J. Biol. Chem., 281:2989-2998 (2006)). Gamitrinib-G4 selectivelyaccumulated in isolated tumor mitochondria, whereas non-targeted 17-AAGdid not penetrate or accumulate in mitochondria (FIG. 15C) (Kang et al.,Cell, 131:257-270 (2007)).

Gamitrinibs disrupted mitochondrial integrity. When added to isolatedtumor mitochondria, Gamitrinibs caused sudden loss of inner membranepotential, all with comparable efficiency (FIG. 16A). In contrast,non-targeted Hsp90 antagonists, GA, 17-AAG or17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (DMAG) did notaffect mitochondrial membrane potential (FIG. 16A). Gamitrinibs (G4 orTPP) promptly depolarized tumor mitochondria, and this reaction wasinhibited by cyclosporine A (CsA), an inhibitor of CypD (FIG. 16B). Incontrast, 17-AAG or GA mixed with the isolated mitochondrial-penetratingmoieties, e.g., TG-OH or TPP-OH, had no effect on mitochondrial membranepotential, with or without CsA (FIG. 16B). All Gamitrinibs also inducedrapid (20 minutes) discharge of mitochondrial cytochrome c, whereas17-AAG was ineffective (FIG. 16C).

Several recently developed purine- and isoxazole resorcinol-based Hsp90antagonists (FIG. 19) were tested for changes in mitochondrialintegrity. Gamitrinib-G4 induced sudden and complete discharge ofcytochrome c from mitochondria (FIG. 16D). In contrast, 17-AAG,hydroquinone derivative of 17-AAG (IPI-504), purine analog (BIIB021), orisoxazole (NVP-AUY922) Hsp90 inhibitors had no effect on cytochrome crelease (FIG. 16D).

Mitochondrial depolarization and release of cytochrome c are hallmarksof mitochondrial permeability transition (Green et al., Science305:626-629 (2004)), which typically results in cell death. Consistentwith this prediction, a 3 hour exposure of lung adenocarcinoma H460cells to Gamitrinib-G3 or -G4 was sufficient to produce aconcentration-dependent (IC₅₀ ˜0.5 μM) and complete loss of cellviability (FIG. 17A, left). Within this time frame, Gamitrinib-G1 or17-AAG had no effect, and Gamitrinib-G2 or Gamitrinib-TPP hadintermediate activity, reflecting different efficiencies ofintracellular accumulation (FIG. 17A, left). By 24 hours, allGamitrinibs had comparably killed the entire tumor cell population,whereas 17-AAG resulted in a partial reduction in cell viability or cellproliferation (FIG. 17A, right).

Current Hsp90 inhibitors predominantly cause cell cycle arrest in mosttumor cell types, followed by a variable degree of apoptosis by 48-72hours. To look for potential mechanistic differences in anticanceractivity of Gamitrinibs compared to non-mitochondrially targeted Hsp90inhibitors, breast adenocarcinoma SKBr3 cells (a model cell type that ishighly sensitive to Hsp90 inhibition) was used. Treatment of SKBr3 cellswith Gamitrinibs (G4 or TPP) or 17-AAG comparably reduced metabolicactivity, by 48 hours and throughout a 96-hours interval (FIG. 17B).However, most SKBr3 cells treated with 17-AAG were still alive after 72hours, whereas Gamitrinibs were cytotoxic, and caused nearly completetumor cell killing by 24 hours (FIG. 17C). This cell death response wascharacterized by loss of mitochondrial inner membrane potential andcaspase activity, indicative of mitochondrial apoptosis (FIG. 17D).Consistent with their cytotoxic properties, Gamitrinibs (G4) suppressedanchorage-independent tumor growth in soft agar (FIG. 17E) and hadcytotoxic effect on a panel of heterogeneous tumor cell types(including, for example, human tumor cell types, chronic myelogenoeousleukemia cells, B lymphoblastoid leukemia cells, breast adenocarcinomacells, lung adenocarcinoma cells, prostate adenocarcinoma cells,glioblastoma cells, colon adenocarcinoma cells, and cervical carcinomacells). The cytotoxic effect of Gamitrinibs was independent of p53status and expression of survival factors, e.g. Bcl-2 (FIG. 17F). Acutesilencing of CypD (Green et al Science, 305:626-629 (2004)) by siRNApartially attenuated tumor cell killing mediated by Gamitrinib (FIG.17G), confirming a role of a permeability transition pore in thispathway.

In order to determine if Gamitrinibs are specific for the mitochondrialpool of Hsp90 chaperones, cervical carcinoma HeLa cells were treatedwith 17-AAG, resulting in destabilization of client proteins, Chk1 andAkt (Isaacs et al., Cancer Cell, 3:213-217 (2003)), and increasedexpression of the chaperone Hsp70 (Beere et al., Nat Cell Biol,2:469-475 (2000)). Decreased levels of Chk1 and Akt and increased levelsof Hsp70 are consistent with inhibition of cytosolic Hsp90 (FIG. 17H).In contrast, Gamitrinibs had undetectable effect on levels of Chk1, Akt,and Hsp70 suggesting that it has minimal effect on cytosolic Hsp90 (FIG.17H).

Example 11 Gamitrinibs are Effective in Xenograft Tumor Models

The effectiveness and toxicity of gamitrinibs was evaluated in xenografttumor models.

To create the models used in this example, HL60 (10×10⁶) or H460 (4×10⁶)cells suspended in sterile PBS (200 μl) were injected subcutaneouslyinto both flanks of 10 week-old CB17 SCID/beige (Taconic Farms)immunocompromised female mice. Alternatively, MDA-MB-231 cells (5×10⁶)suspended in 200 μl of 50% Matrigel (BD Biosciences) were used forsubcutaneous injection in CB17 SCID/beige mice. When superficial tumorsreached volumes of 100-150 mm³, animals were randomized in two groups (2tumors/mouse, 3 animals/group), and treated with vehicle (DMSO) orGamitrinib dissolved in 20% Cremophor EL (Sigma) in PBS byintraperitoneal (i.p.) injection. Gamitrinib-G4 was used as sterile i.p.injections with the following schedules: HL60 xenografts, 2 mg/Kg twicedaily; H460 xenografts, 2 mg/kg twice daily for d 0, 2.5 mg/kg twicedaily for d 1, 3.0 mg/kg twice daily for the duration of treatment;MDA-MB-231 xenografts, 2 mg/Kg twice daily for d 0-2, 2.5 mg/Kg twicedaily for d 3-5, and 3 mg/Kg twice daily throughout the rest of thetreatment. 17-AAG was dissolved in 20% Cremophor EL and used as systemici.p. injections with the same dose-escalating regimen as Gamitrinib-G4in H460 xenograft studies. Gamitrinib-G1 was used with followingschedules: 30 mg/Kg daily (d 0-2), and 50 mg/Kg daily for the rest oftreatment. Gamitrinib-TPP was used as i.p. injections at 10 mg/Kg dailythroughout the duration of the experiment. Tumor measurements were takendaily with a caliper, and tumor volume was calculated with the formula([length in millimeters]×[width in millimeters]²)/2. Mice in the varioustreatment groups were weighed at the beginning and at the end of eachexperiment.

In vivo subcellular fractionation was performed as follows. HL60xenograft tumors from vehicle- or Gamitrinib-treated mice were harvestedwhen they reached a volume of 300-400 mm³, and cytosol fractions wereprepared using a Mitochondria Isolation Kit (SIGMA). Cytochrome creleased in the cytosol was analyzed by Western blotting.

In situ internucleosomal DNA fragmentation (TUNEL) was performed asfollows. At the end of treatment, tumors were harvested from vehicle- orGamitrinib-treated animals, fixed in formalin, embedded in paraffin, andsectioned. TUNEL staining was performed with the ApopTag Plus PeroxidaseIn Situ Apoptosis Detection kit (Chemicon), according to the instructionmanual, as described previously (Dohi et al., Mol Cell, 27:17-28(2007)). Images were captured using an Olympus microscope with anon-line charge-coupled device camera at 400× magnification (necroticregions were excluded from the analysis). For quantification,TUNEL-positive cells were counted in 10 independent areas of a 400×magnification field (10 fields/each group).

Histology was performed as follows. Animals in the vehicle or Gamitrinibgroup were euthanized at the end of the experiment, and organs,including brain, colon, heart, kidney, liver, lung, pancreas, smallintestine, spleen, and stomach were collected, fixed in formalin andembedded in paraffin. Sections (5 μm) were put on high-adhesive slides,stained with hematoxylin eosin and analyzed by light microscopy.

Data were analyzed using the unpaired t-test on a GraphPad softwareprogram (Prism 4.0). All of the statistical tests were two sided. Ap-value of 0.05 was considered to be statistically significant.

Systemic administration of Gamitrinib-G4 to mice inhibited the growth ofestablished human leukemia (FIG. 20A), breast tumors (FIG. 20B), andlung tumors (FIG. 18A) in vivo. Comparable doses of 17-AAG had no effecton human lung cancer growth in mice (FIG. 18A, top). Gamitrinibscarrying different mitochondriotropic moieties (mono-guanidinium (G1) ortriphenylphosphonium (TPP)) also inhibited lung cancer growth in vivo(FIG. 18A, bottom). Lung tumors harvested from Gamitrinib-treatedanimals exhibited extensive apoptosis in situ (FIG. 18B). In addition,lung tumors harvested from Gamitrinib-treated animals exhibitedcytosolic cytochrome c (FIG. 18C), suggesting Gamitrinib inducedmitochondrial dysfunction in vivo. Furthermore, the results suggest thatGamitrinibs could have minimal side effects: at the concentrations used,Gamitrinibs did not cause significant weight loss in animal subjectsover the course of treatment (FIG. 18D), and organs collected fromGamitrinib-treated animals were histologically normal relative totissues from animals not treated with Gamitrinib. In order to determineif Gamitrinibs induction of mitochondrial dysfunction is selective fortumor, but not normal cells, Gamitrinib was used to treat tumor andnormal cells. Effective concentrations of Gamitrinib did not affectmitochondrial membrane potential (in the presence and absence of CsA(FIG. 18E)) of normal human fibroblasts. Neither did Gamitrinib affectthe cytochrome c content (FIG. 18F) of normal human fibroblasts.Concentrations of Gamitrinibs that induce complete tumor cell killingdid not decrease the viability of normal human cell types (FIG. 18G).

These results indicate that Gamitrinibs are selective, effective, andsafe.

Example 12 Computational Methods for Identifying MitochondriotropicChaperone Inhibitors

The crystal structure of Hsp90 used for all docking calculations wastaken from the protein data bank with coordinates corresponding to thepdb code 1YET.pdb (Stebbins et al., Cell, 89:239-250 (1997)). Theoriginal X-ray structure contained the ligand Geldanamycin (GA), whichwas removed from the active site to yield the apo-open form of Hsp90.Gamitrinib was docked into the active site of Hsp90 using differentdocking procedures, different computational approaches programs, andenergy functions to define a consensus structure representative of thefree energy minimum of the Gamitrinib-Hsp90 complex. First, thestructure of Gamitrinib was minimized using the Macromodel program(Mohamadi et al., J. Comp. Chem., 11:440-467 (1990)), the AMBER forcefield (Duan et al., J. Comp. Chem., 24:1999-2012 (2003)) and the GB/SAapproach (Rami Reddy et al., J. Comp. Chem., 19:769-780 (1998)) to takeinto account the effects of the water solvent.

In a first set of docking calculations, the energy minimized structureof Gamitrinib was subjected to blind docking experiments on the putativeN-terminal Hsp90 receptor using the program AutoDock (Morris et al., J.Comp. Chem. 19:1639-1662 (1998)). Mass-centered grid maps were generatedwith 0.35 Å spacing by the program Autogrid around the ATPase pocket ofHsp90. Lennard-Jones parameters 12-10 and 12-6 (default parameters inthe program package) were used for modeling H-bonding and Van der Waalsinteractions, respectively. The distance dependent dielectricpermittivity of Mehler and Solmajer (Mehler and Solmajer, Protein Eng,4:903-910 (1991)) was used for the calculation of the electrostatic gridmaps. The Lamarckian genetic algorithm (LGA) and the pseudo-Solis andWest methods were applied for minimization using default parameters. Thenumber of generations was set to 25 million in all runs, and thestopping criterion was therefore defined by the total number of energyevaluations. Random starting positions on the grid, random orientations,and torsions (flexible ligand only) were used for the ligand. A total of310 runs were performed. At the end of the docking runs, conformationsof the ligand were listed in increasing energy order. Subsequently, theligand conformation with lowest energy was used as a reference, and allconformations with a center of mass to center of mass distance of <1.5 Åfrom the reference were taken to belong to the first cluster. Once aconformation was assigned to a cluster, it was not used again for other(energetically less favorable) clusters. Then the process was repeatedfor all hitherto unclassified conformations until all conformations wereput in a cluster. Most of the docked structures shared commonconformational characteristics which are prototypically represented bythe structure of the global minimum of the complex. The 17-AAG region offree energy minimum structure obtained from the Autodock runs is wellsuperimposable to the benzoquinone ansamicyin backbone of GA with a rootmean square deviation (rmsd) of all heavy atoms of 0.56 Å.

In a second set of docking calculations, the minimized structure ofGamitrinib was docked onto the Hsp90 receptor using the Glide software(Friesner et al., J. Med. Chem., 47:1739-1749 (2004); and Halgren etal., J. Med. Chem., 47:1750-1759 (2004)). A cubic bounding box of 14 Ålength on for each side was build for the ligand around the ATPasebinding pocket. Full flexibility was allowed for the ligand and thedocking poses were scored using the Glide standard-precision (SP) mode.The 17-AAG region of Gamitrinib in best docking pose obtained from thisprocedure is once again superimposable to the benzoquinone ansamicyinbackbone of GA in the X-ray structure (Stebbins et al., Cell, 89:239-250(1997)), and in previous docking calculation (rmsd of 0.51 Å).

Finally, in order to evaluate the possibility that differentconformations of the flexible ligand may determine a different complexgeometry, Gamitrinib was subjected to a preliminary conformationalanalysis in isolation in solution, with an implicit representation ofwater through the GB/SA method. To explore the conformational space ofGamitrinib, a torsion-based conformational search was run using 10000steps of Monte Carlo Multiple Minimum method (Chang et al., J. Am. Chem.Soc., 111:4379-4386 (1989)) and the AMBER force field, as implemented inMacromodel. 4223 unique conformations were identified and saved for theligand. All the conformations obtained from this calculation were thenused as ligands for docking calculations on the Hsp90 receptor using thesame procedures as described in the simple Glide docking approach. Eachthe conformations docked into the receptor with a different score.Importantly, the top-ranked 226 poses are once more fully overlapping intheir 17-AAG region with the to the benzoquinone ansamicyin backbone ofGA, with an average rmsd of 0.6 Å.

Example 13 Synthesis of(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylcarbamate, tetrakis hexafluorophosphate salt (Gamitrinib-G4, 1)

Step 1.((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylmethanesulfonate, tetrakis hexafluorophosphate salt 4

A solution of alcohol 3 (synthesized as described in Fernandez-Carneadoet al., J. Am. Chem. Soc., 127:869-874 (2005), 445 mg, 0.276 mmol) inacetonitrile (5 mL) was treated with N-methylmorpholine (0.30 mL, 2.76mmol) and methanesulfonic anhydride (240 mg, 1.38 mmol) at roomtemperature under N₂. After stirred for 5 hours at room temperature,most of the volatiles were removed in vacuo. The residue was dilutedwith dichloromethane (30 mL) and washed with 0.1 M aq. NH₄PF₆ (20 mL).The aqueous phase was re-extracted with additional dichloromethane (30mL). The combined organic phase was dried over Na₂SO₄, filtered andconcentrated. Purification by column chromatography (2-5% MeOH indichloromethane) afforded 4 as tetrahexafluorophosphate salt (452 mg,97%, pale brown foam). ¹H-NMR (600 MHz, acetone-d₆) δ 7.72-7.67 (m, 4H),7.52-7.48 (m, 2H), 7.48-7.43 (m, 4H), 7.35-7.00 (br, salt protons), 4.46(dd, 1H, J=4.2 Hz, 10.8 Hz), 4.28 (dd, 1H, J=7.2 Hz, 10.2 Hz), 4.00-3.95(m, 1H), 3.85-3.68 (m, 9H), 3.60-3.47 (m, 16H), 3.18 (s, 3H), 3.04-2.95(m, 6H), 2.76-2.68 (m, 6H), 2.28-2.14 (m, 8H), 2.05-1.89 (m, 8H), 1.06(s, 9H).

Step 2.S-((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylethanethiolate, tetrakis hexafluorophosphate salt 5:

A solution of the mesylate 4 (452 mg, 0.267 mmol) and potassiumthioacetate (153 mg, 1.34 mmol) in tetrahydrofuran (THF, 8 mL)/H₂O (3mL) was refluxed for 16 hours. After cooling to room temperature, thereaction mixture was diluted with dichloromethane (30 mL) and washedwith 0.1 M aq. NH₄PF₆ (20 mL). The aqueous phase was re-extracted withadditional dichloromethane (30 mL). The combined organic phase waswashed with 0.1 M aq. NH₄PF₆ (20 mL), dried over Na₂SO₄, filtered andconcentrated. Trituration from diethyl ether-hexanes (1:1) afforded 5 asa tetrahexafluorophosphate salt (420 mg, 94%, pale brown solid). ¹H-NMR(400 MHz, acetone-d₆) δ 7.73-7.66 (m, 4H), 7.53-7.42 (m, 6H), 7.22-6.92(br, salt protons), 3.85-3.65 (m, 10H), 3.62-3.46 (m, 16H), 3.16 (d, 2H,J=6.4 Hz), 3.04-2.86 (m, 6H), 2.77-2.67 (m, 6 H), 2.37 (s, 3H),2.29-2.14 (m, 8H), 2.04-1.88 (m, 8H), 1.06 (s, 9H); MS (EI) m/z 1087(M+1), 1233 (M+HPF₆+1).

Step 3.(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl carbamate, tetrakis hexafluorophosphate salt 1:

A solution of 5 (118 mg, 0.071 mmol) in degassed MeOH (4 mL) under N₂ atroom temperature was treated with potassium tert-butoxide (0.21 mL, 0.21mmol, 1 M in THF). After 30 minutes, the reaction mixture wasneutralized with 1 N aq. HCl (ca. 0.1 mL) and treated with 0.1 Nphosphate buffer (pH 6, 3 mL). To the buffered solution under N₂ at roomtemperature was added a solution of geldanamycin-maleimide 2(synthesized as described in Mandler, et al. Bioconjug. Chem. 13:786-791(2002), 65 mg, 0.085 mmol) in degassed MeOH (2 mL). After 2 hours, thereaction was concentrated to ca. 3 mL. The resulting reaction mixturewas diluted with dichloromethane (20 mL) and washed with 0.1 M aq.NH₄PF₆ (30 mL). The aqueous phase was re-extracted with dichloromethane(20 mL). The combined organic phase was dried over Na₂SO₄, filtered andconcentrated. Separation by prep-HPLC (5-50% acetonitrile in water, 0.1%TFA) followed by concentration afforded 1 as a trifluoroacetate (TFA)salt. The TFA salt was dissolved in dichloromethane (3 mL) and washedsuccessively with 0.1 M aq. NH₄PF₆ (2 mL×5). Concentration followed bytrituration from diethyl ether-hexanes (1:1) afforded 1 astetrahexafluorophosphate salt (88 mg, 52%, purple solid). The purity of1 was more than 99% by HPLC at 254 nm. The measured molecular mass of 1([M+3H]³⁺, m/z 604.9698) measured by HRMS was consistent with thetheoretical mass (m/z 604.9736). ¹H-NMR (400 MHz, CD₃CN) δ 9.25 (s, 1H),7.70-7.60 (m, 4H), 7.53-7.40 (m, 6H), 7.30 (br s, 1H), 7.11 (d, 1H,J=8.4 Hz), 7.06 (s, 2H), 6.80-6.40 (br, salt protons), 6.74 (dt, 1H,J=18.8 Hz, J=6 Hz), 6.63 (t, 1H, J=11.2 Hz), 5.83 (t, 1H, J=10 Hz), 5.68(d, 1H, J=9.6 Hz), 5.24 (br s, 2H), 5.08 (s, 1H), 4.43 (d, 1H, J=9.2Hz), 3.98-3.86 (m, 1H), 3.86-3.78 (m, 1H), 3.75-3.68 (m, 1H), 3.67-3.60(m, 1H), 3.60-3.42 (m, 14H), 3.42-3.23 (m, 21H), 3.22-3.10 (m, 3H), 3.20(s, 3H), 3.03 (dd, 1H, J=14 Hz, 5 Hz), 2.92-2.52 (m, 7H), 2.52-2.40 (m,9H), 2.40-2.30 (m, 1H), 2.25-2.00 (m, 10H), 1.97 (s, 3H), 1.86-1.70 (m,14H), 1.71 (s, 3H), 1.05 (s, 9H), 0.95 (d, 3H, J=6.4 Hz), 0.92 (d, 3H,J=6.8 Hz) MS (EI) m/z 1812.5 (M+1).

Example 14 Synthesis of(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylcarbamate, hexafluorophosphate salt (Gamitrinib-G1, I)

Step 1.S-((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylethanethiolate, hexafluorophosphate salt I-2

A stirred solution of I-1 (synthesized as described inFernandez-Carneado et al., J. Am. Chem. Soc., 127:869-874 (2005), 2.30g, 3.48 mmol) and potassium thioacetate (794 mg, 6.95 mmol) in THF (40mL)/H₂O (16 mL) was refluxed for 16 hours. After cooling to roomtemperature, the reaction mixture was diluted with dichloromethane (100mL) and washed with 0.1 M aq. NH₄PF₆ (50 mL). The aqueous phase wasre-extracted with additional dichloromethane (50 mL). The combinedorganic phase was washed with 0.1 M aq. NH₄PF₆ (30 mL), dried overNa₂SO₄, filtered and concentrated. Purification by column chromatography(25% hexane/ethyl acetate to 100% ethyl acetate) and concentrationafforded I-2 as hexafluorophosphate salt (2.12 g, 95%, pale yellowsolid). ¹H-NMR (400 MHz, acetone-d₆) δ 7.72-7.65 (m, 4H), 7.52-7.41 (m,6H), 6.98 (br, 2H), 3.85-3.73 (m, 3H), 3.73-3.64 (m, 1H), 3.61-3.46 (m,4H), 3.15 (d, 2H, J=6.4 Hz), 2.36 (s, 3H), 2.23-2.10 (m, 2H), 2.08-1.91(m, 2H) 1.06 (s, 9H).

Step 2.(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylCarbamate, Hexafluorophosphate Salt I:

To a solution of I-2 (100 mg, 0.156 mmol) in degassed MeOH (3 mL) underN₂ at room temperature was added potassium tert-butoxide (0.47 mL, 0.47mmol, 1 M in THF). After 30 minutes, the reaction mixture wasneutralized with 1 N aq. HCl (ca. 0.5 mL) and treated with 0.1 Nphosphate buffer (pH=6, 2 mL). To the buffered solution under N₂ at roomtemperature was added a solution of geldanamycin-maleimide 2 (144 mg,0.188 mmol) in degassed MeOH (1 mL). After 2 hours, the reaction wasconcentrated to ca. 2 mL. The resulting reaction mixture was dilutedwith dichloromethane (30 mL) and washed with 0.1 M aq. NH₄PF₆ (30 mL).The aqueous phase was re-extracted with dichloromethane (30 mL). Thecombined organic phase was dried over Na₂SO₄, filtered and concentrated.Purification by prep. HPLC (5-50% acetonitrile in water, 0.1% TFA) andconcentration afforded I as TFA salt. The resulting TFA salt wasdissolved in dichloromethane (3 mL) and washed with 0.1 M aq. NH₄PF₆ (2mL×5). Concentration followed by trituration from diethyl ether affordedI as hexafluorophosphate salt (107 mg, 50%, purple solid). The purity ofI was more than 98% by HPLC at 254 nm. The measured molecular mass of I([M+H]⁺, 1221.6073) measured by HRMS was consistent with the theoreticalmass (m/z 1221.6090). ¹H-NMR (600 MHz, acetone-d₆) δ 9.40 (d, 1H, J=5.4Hz), 7.75-7.60 (m, 4H), 7.53-7.40 (m, 6H), 7.40-7.23 (m, 2H), 7.11 (s,1H), 6.93-6.85 (m, 1H), 6.66 (t, 1H, J=11 Hz), 5.85 (t, 1H, J=10 Hz),5.78 (d, 1H, J=9.6 Hz), 5.12 (s, 1H), 4.55 (d, 1H, J=9.6 Hz), 4.12-4.05(br d, 1H), 4.06-3.98 (m, 1H), 3.98-3.93 (m, 1H), 3.85-3.45 (m, 13H),3.39-3.15 (m, 5H), 3.32 (s, 3H), 3.20 (s, 3H), 3.05-2.95 (m, 1H), 2.87(s, 3H), 2.77-2.68 (m, 1H), 2.64-2.58 (m, 1H), 2.53-2.39 (m, 2H),2.30-2.13 (m, 4H), 2.05-1.91 (m, 2H), 2.01 (s, 3H), 1.88-1.76 (m, 4H),1.75 (s, 3H), 1.75-1.67 (m, 2H), 1.06 (s, 9H), 1.00 (d, 3H), 0.91 (d,3H) MS (EI) m/z 1221.58 (M+1).

Example 15 Synthesis of(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyridin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylcarbamate, bis hexafluorophosphate salt (Gamitrinib-G2, II)

Step 1.S-((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylethanethiolate, bis hexafluorophosphate salt II-2:

A stirred solution of II-1 (synthesized as described inFernandez-Carneado et al., J. Am. Chem. Soc., 127:869-874 (2005), 1.71g, 1.70 mmol) and potassium thioacetate (583 mg, 5.10 mmol) in THF (20mL)/H₂O (8 mL) was refluxed for 16 hours. After cooling to roomtemperature, the reaction mixture was diluted with dichloromethane (100mL) and washed with 0.1 M aq. NH₄PF₆ (50 mL). The aqueous phase wasre-extracted with additional dichloromethane (50 mL). The combinedorganic phase was washed with 0.1 M aq. NH₄PF₆ (50 mL), dried overNa₂SO₄, filtered and concentrated. Purification by column chromatography(100% ethyl acetate→5% MeOH in dichloromethane) and concentrationafforded II-2 as a dihexafluorophosphate salt (1.45 g, 87%, pale brownsolid). ¹H-NMR (400 MHz, acetone-d₆) δ 7.73-7.67 (m, 4H), 7.53-7.42 (m,6H), 7.27 (br d, 2H), 7.11 (br d, 2H), 3.85-3.63 (m, 6H), 3.62-3.48 (m,8H), 3.61-3.46 (m, 4H), 3.14 (d, 2H, J=6 Hz), 2.99 (dd, 2H, J=14, 4.6Hz), 2.73 (ddd, 2H, J=14, 9, 4.6 Hz), 2.36 (s, 3H), 2.28-2.12 (m, 4H),2.05-1.89 (m, 4H) 1.06 (s, 9H).

Step 2.(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylcarbamate, bis hexafluorophosphate salt II:

To a solution of II-2 (110 mg, 0.112 mmol) in degassed MeOH (4 mL) underN₂ at room temperature was added potassium tert-butoxide (0.34 mL, 0.34mmol, 1 M in THF). After 30 minutes, the reaction mixture wasneutralized with 1 N aq. HCl (ca. 0.3 mL) and treated with 0.1 Nphosphate buffer (pH 6, 0.5 mL). To the buffered solution under N₂ atroom temperature was added a solution of geldanamycin-maleimide 2 (94mg, 0.122 mmol) in degassed MeOH (2 mL). After 2 hours, the reaction wasconcentrated to ca. 2 mL. The resulting reaction mixture was dilutedwith dichloromethane (30 mL) and washed with 0.1 M aq. NH₄PF₆ (30 mL).The aqueous phase was re-extracted with dichloromethane (30 mL). Thecombined organic phase was dried over Na₂SO₄, filtered and concentrated.Purification by prep. HPLC (5-50% acetonitrile in water, 0.1% TFA) andconcentration afforded II as TFA salt. The resulting TFA salt wasdissolved in dichloromethane (3 mL) and washed with 0.1 M aq. NH₄PF₆ (2mL×5). Concentration followed by trituration from diethyl ether affordedII as dihexafluorophosphate salt (55 mg, 29%, purple solid). The purityof II was more than 99% by HPLC at 254 nm. The measured molecular massof II ([M+2H]²⁺, m/z 709.8534) measured by HRMS was consistent with thetheoretical mass (m/z 709.8577). ¹H-NMR (600 MHz, CD₃CN) δ 9.26 (s, 1H),7.70-7.65 (m, 4H), 7.52-7.43 (m, 6H), 7.13-7.08 (m, 1H), 7.06 (s, 1H),6.87 (br, 1H), 6.78-6.68 (m, 1H), 6.64-6.55 (m, 2H), 6.46 (br, 1H), 5.83(t, 1H, J=10 Hz), 5.72-5.65 (m, 1H), 5.21 (br, 2H), 5.07 (s, 1H),4.46-4.42 (m, 1H), 3.82-3.78 (m, 1H), 3.73-3.69 (m, 1H), 3.66-3.62 (m,1H), 3.62-3.41 (m, 9H), 3.41-3.25 (m, 11H), 3.29 (s, 3H), 3.22-3.03 (m,3H), 3.20 (s, 3H), 2.93-2.71 (m, 3H), 2.70-2.58 (m, 2H), 2.56-2.39 (m,3H), 2.38-2.32 (m, 1H), 2.25-2.03 (m, 5H), 1.98-1.95 (m, 6H), 1.85-1.70(m, 8H), 1.71 (s, 3H), 1.05 (s, 9H), 0.97-0.93 (m, 3H), 0.92 (d, 3H) MS(EI) m/z 1418.51 (M+1).

Example 16 Synthesis of(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,16,18-pentaen-9-ylcarbamate, tris hexafluorophosphate salt (Gamitrinib-G3, III)

Step 1.((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methanol,tris hexafluorophosphate salt III-1:

A stirred solution of the mesylate I-1 (545 mg, 0.82 mmol) and potassiumthioacetate (188 mg, 1.65 mmol) in THF (10 mL)/H₂O (4 mL) was refluxedfor 16 hours. Methanesulfonic acid (0.27 mL, 4.12 mmol) was added andthe reaction mixture was refluxed for 24 hours. After cooling to roomtemperature, organic and aqueous phases were separated in diethyl ether(50 mL) and water (50 mL). The aqueous phase was re-extracted withadditional water (20 mL). The combined aqueous phases were washed withdiethyl ether. Then the aqueous phases were neutralized with potassiumbicarbonate (495 mg, 4.94 mmol) and the solvent was evaporated todryness. To this resulting solid was added MeOH (100 mL), and theprecipitate was removed by filtration. This procedure was repeated twicewith MeOH/CH₂Cl₂ system (MeOH/CH₂Cl₂=50/50→5/95). Concentration affordedthe crude yellow foam. To a solution of this product in MeOH (10 mL)were added cesium carbonate (322 mg, 0.99 mmol) and tributylphosphine(0.12 mL, 0.49 mmol) at room temperature. After being stirred for 40minutes, a solution of the mesylate II-1 (697 mg, 0.69 mmol) in THF (10mL) was added and the reaction mixture was stirred for 16 hours at roomtemperature. Then most of the volatiles were removed in vacuo. Theresidue was diluted with dichloromethane (50 mL) and washed with 0.1 Maq. NH₄PF₆ (30 mL). The aqueous phase was re-extracted with additionaldichloromethane (30 mL). The combined organic phase was dried overNa₂SO₄, filtered and concentrated. Purification by column chromatography(MeOH/CH₂Cl₂: 2% to 5%) afforded III-1 (560 mg, 64%, white solid) as atrihexafluorophosphate salt. ¹H-NMR (400 MHz, acetone-d₆) δ 7.74-7.70(m, 4H), 7.54-7.44 (m, 6H), 4.28 (t, 1H, J=5.2 Hz), 3.84-3.60 (m, 8H),3.60-3.44 (m, 14 H), 3.07-2.97 (m, 4H), 2.75-2.58 (m, 4H), 2.27-2.14 (m,5H), 2.14-1.74 (m, 7H), 1.06 (s, 9H).

Step 2.((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methanethiol, Tris Hexafluorophosphate Salt III-2:

A solution of alcohol III-1 (433 mg, 0.34 mmol) in THF (5 mL) wastreated with N-methylmorpholine (0.19 mL, 1.70 mmol) and methanesulfonicanhydride (178 mg, 1.02 mmol) at room temperature under N₂. Afterstirred for 2 hours at room temperature, the reaction mixture wasdiluted with dichloromethane (30 mL) and washed with 0.1 M aq. NH₄PF₆(20 mL). The aqueous phase was re-extracted with additionaldichloromethane (30 mL). The combined organic phase was dried overNa₂SO₄, filtered and concentrated. Purification by column chromatography(MeOH/CH₂Cl₂: 2% to 5%) afforded III-2 as trihexafluorophosphate salt(359 mg, 78%, pale brown foam). ¹H-NMR (400 MHz, acetone-d₆) δ 7.80-7.65(m, 4H), 7.55-7.40 (m, 6H), 4.41 (dd, 1H, J=10.4 Hz, 4.4 Hz), 4.25 (dd,1H, J=10.4 Hz, 7.6 Hz), 3.95-3.87 (m, 1H), 3.84-3.58 (m, 7H), 3.58-3.40(m, 12H), 3.20 (s, 3H), 3.07-2.94 (m, 4H), 2.76-2.57 (m, 4H), 2.28-2.10(m, 6H), 2.05-1.86 (m, 6H), 1.06 (s, 9H).

Step 3.S-((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylethanethiolate, tris hexafluorophosphate salt III-3:

A stirred solution of the mesylate III-2 (359 mg, 0.27 mmol) andpotassium thioacetate (97 mg, 0.85 mmol) in THF (8 mL)/H₂O (3 mL) wasrefluxed for 16 hours. After cooling to room temperature, the reactionmixture was diluted with dichloromethane (50 mL) and washed with 0.1 Maq. NH₄PF₆ (30 mL). The aqueous phase was re-extracted with additionaldichloromethane (30 mL). The combined organic phase was washed with 0.1M aq. NH₄PF₆ (20 mL), dried over Na₂SO₄, filtered and concentrated.Trituration from diethyl ether-hexanes (1:1) afforded III-3 astrihexafluorophosphate salt (294 mg, 83%, pale yellow solid). ¹H-NMR(600 MHz, acetone-d₆) δ 8.20-7.74 (br, salt protons), 7.74-7.68 (m, 4H),7.53-7.44 (m, 6H), 3.86-3.75 (m, 3H), 3.73-3.56 (m, 5H), 3.56-3.44 (m,12H), 3.21 (dd, 1H, J=13.8, 6 Hz), 3.08-2.95 (m, 5H), 2.80-2.61 (m, 4H),2.37 (s, 3H), 2.24-2.10 (m, 6H), 2.00-1.82 (m, 6H) 1.06 (s, 9H).

Step 4.(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(3-(4-(3-(((2R,8R)-8-((((2R,8R)-8-((((2R,8R)-8-((tert-butyldiphenylsilyloxy)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)methyl)-2,3,4,6,7,8-hexahydro-1H-pyrimido[1,2-a]pyrimidin-2-yl)methylthio)-2,5-dioxopyrrolidin-1-yl)butanamido)propylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylcarbamate, tris hexafluorophosphate salt III:

To a solution of III-1 (209 mg, 0.157 mmol) in degassed MeOH (4 mL)under N₂ at room temperature was added potassium tert-butoxide (0.47 mL,0.47 mmol, 1 M in THF). After 30 minutes, the reaction mixture wasneutralized with 1 N aq. HCl (ca. 0.1 mL) and treated with 0.1 Nphosphate buffer (pH 6, 3 mL). To the buffered solution under N₂ at roomtemperature was added a solution of geldanamycin-maleimide 2 (133 mg,0.173 mmol) in degassed MeOH (2 mL). After 2 hours, the reaction wasconcentrated to ca. 3 mL. The resulting reaction mixture was dilutedwith dichloromethane (20 mL) and washed with 0.1 M aq. NH₄PF₆ (30 mL).The aqueous phase was re-extracted with dichloromethane (20 mL). Thecombined organic phase was dried over Na₂SO₄, filtered and concentrated.Purification by prep. HPLC (5-50% acetonitrile in water, 0.1% TFA) andconcentration afforded III as TFA salt. The resulting TFA salt wasdissolved in dichloromethane (3 mL) and washed with 0.1 M aq. NH₄PF₆ (2mL×5). Concentration followed by trituration from diethyl ether-hexanes(1:1) afforded III as trihexafluorophosphate salt (110 mg, 34%, purplesolid). The purity of III was more than 96% by HPLC at 254 nm. Themeasured molecular mass of III ([M+3H]³⁺, m/z 539.2695) measured by HRMSwas consistent with the theoretical mass (m/z 539.2740). ¹H-NMR (400MHz, CD₃CN) δ 9.26 (s, 1H), 7.70-7.63 (m, 4H), 7.52-7.40 (m, 6H),7.15-7.08 (br, 1H), 7.06 (s, 1H), 6.81-6.68 (m, 2H), 6.65-6.57 (m, 2H),6.45-6.15 (br, 6H), 5.83 (t, 1H, J=10.2 Hz), 5.69 (d, 1H, J=7.2 Hz),5.21 (br s, 2H), 5.08 (s, 1H), 4.44 (dd, 1H, J=9.6, 4.8 Hz), 3.83-3.78(m, 1H), 3.73-3.70 (m, 1H), 3.66-3.61 (m, 1H), 3.61-3.42 (m, 10H),3.42-3.25 (m, 18H), 3.22-3.14 (m, 3H), 3.20 (s, 3H), 2.85-2.71 (m, 7H),2.71-2.41 (m, 7H), 2.38-2.32 (m, 1H), 2.25-2.18 (m, 1H), 2.18-2.04 (m,8H), 1.97 (s, 3H), 1.85-1.70 (m, 10H), 1.72 (s, 3H), 1.06 (s, 9H), 1.01(d, 3H), 0.95 (dd, 3H) MS (EI) m/z 1615.51 (M+1).

Example 17 Synthesis of(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(6-(triphenylphosphonio)hexylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylcarbamate hexafluorophosphate (Gamitrinib-TPP, 9)

Step 1. tert-butyl 6-(triphenylphosphonium)hexylcarbamate, Bromide Salt7

To a solution of 6 (synthesized as described in Egbertson, et al. J.Med. Chem., 37:2537-2551 (1994), 1.60 g, 5.71 mmol) in acetonitrile (10mL) was added triphenylphosphine (1.57 g, 5.99 mmol) and the reactionwas refluxed for 16 hours. After the reaction was cooled to roomtemperature, excess triphenylphosphine was removed by extraction withn-hexane (100 mL×3). Concentration and drying under vacuum gave thephosphonium salt 7 (3.09 g, 99%, white solid). ¹H-NMR (600 MHz, DMSO-d₆)δ 7.89-7.84 (m, 3H), 7.80-7.71 (m, 12H), 6.72 (br t, 1H), 3.57-3.50 (m,2H), 2.85-2.79 (m, 2H), 1.50-1.38 (m, 4H), 1.30-1.16 (m, 4H).

Step 2. 6-(triphenylphosphonium)hexan-1-amine Chloride Hydrochloride 8:

A solution of the phosphonium salt 7 (1.5 g, 0.765 mmol) indichloromethane (100 mL) was treated with HCl solution (4 N in1,4-dioxane, 171 mL) at room temperature. After being stirred for 3hours, the reaction was concentrated. Drying under vacuum afforded theamine 8 (1.31 g, 99%, white solid). The amine 8 was used without furtherpurification. ¹H-NMR (600 MHz, DMSO-d₆) δ 8.12 (br s, 3H), 7.94-7.88 (m,3H), 7.86-7.75 (m, 12H), 3.70-3.60 (m, 2H), 2.75-2.68 (m, 2H), 1.58-1.44(m, 6H), 1.38-1.30 (m, 2H).

Step 3.(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-19-(6-(triphenylphosphonio)hexylamino)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-ylcarbamate hexafluorophosphate 9:

To a solution of geldanamycin (GA, 150 mg, 0.27 mmol) in chloroform (25mL) under N₂ at room temperature was added amine 8 (390 mg, 0.81 mmol)and N,N-diisopropylethylamine (0.47 mL, 2.70 mmol). After being stirredfor 3 hours, additional amine 8 (390 mg, 0.81 mmol) was added. After 10hours, the reaction was concentrated and purified by columnchromatography (2-10% methanol in dichloromethane). The resulting saltwas dissolved in dichloromethane (3 mL) and washed with 0.1 M aq. NH₄PF₆(2 mL×5). Concentration followed by trituration from diethyl etherafforded 9 as a hexafluorophosphate salt (173 mg, 62%, purple solid).The purity of 9 was more than 98% by HPLC at 254 nm. The measuredmolecular mass of 9 (M+, m/z 890.4559) measured by HRMS was consistentwith the theoretical mass (m/z 890.4509). ¹H-NMR (600 MHz, acetone-d₆) δ9.39 (s, 1H), 8.00-7.87 (m, 9H), 7.87-7.75 (m, 6H), 7.30 (d, 1H, J=11.4Hz), 7.10 (s, 1H), 6.66 (t, 1H, J=11 Hz), 6.58 (br, 1H), 5.85 (t, 1H,J=10 Hz), 5.78 (d, 1H, J=9.6 Hz), 5.11 (s, 1H), 4.55 (d, 1H, J=9.6 Hz),4.06 (d, 1H, J=6 Hz), 3.66-3.55 (m, 4H), 3.54-3.47 (m, 1H), 3.37-3.33(m, 1H), 3.31 (s, 3H), 3.21 (s, 3H), 2.78-2.68 (m, 1H), 2.59 (dd, 1H,J=13.8, 4.2 Hz), 2.40 (dd, 1H, J=13.8, 9.6 Hz), 2.01 (s, 3H), 1.90-1.77(m, 3H), 1.74 (s, 3H), 1.74-1.62 (m, 6H), 1.54-1.45 (m, 3H), 0.97 (d,3H, J=7.2 Hz), 0.91 (d, 3H, J=7.2 Hz) MS (EI) m/z 890.08 (M+).

Example 18 Design and Chemical Synthesis of Mitochondria-Permeable GA

A maleimido GA derivative, 17-(3-(4-Maleimidobutyrcarboxamido)propylamino)-demethoxygeldanamycin (17-GMB-APA-GA) was purchased fromInvitrogen. The cell permeable helix III Antennapedia peptide (ANT) wassynthesized with or without an amino-terminal FITC group, and an amide(CONH2)-capped Cys residue at the COOH-terminus with the amino acidsequence, RQIKIWFQNRRMKWKKC (SEQ ID NO:40). The sulfhydryl group of theCOOH-terminal Cys in ANT was reacted with the maleimido group of17-GMB-APA-GA to generate thioether linkages. For the conjugationreaction, ANT and 17-GMB-APA-GA were dissolved in 50 mM Hepes, pH 7.0,and DMSO, respectively, at a final concentration of 10 mM, and mixed ina 1:1 ANT:17-GMB-APAGA ratio for 1 hours at 22° C. with gentle mixing.The resulting ANT-17-GMB-APA-GA conjugate was analyzed by massspectrometry, and used for analysis of mitochondrial permeabilitytransition and cell viability.

General Methods

Chemical characterization. ¹H-NMR spectra were obtained on either VarianInova 400NB (400 MHz) or Varian Inova 600 (600 MHz) spectrometers. Massspectra were recorded on a HP 1100 series LC/MS spectrometer. Theprogress of reaction was checked on TLC plates (Macherey-Nagel 0.25 mmsilica gel 60 with fluorescent indicator UV₂₅₄), and the spots werevisualized under UV light (254 nm) and/or charring after dipping the TLCplate into ninhydrin or Ce—Mo staining solution. Column chromatographywas performed on silica gel (Merck 9385 silica gel 60). The finalproducts were analyzed by HPLC (Waters alliance) equipped with YMC-PackPro C₁₈RS column (YMC) and detected at 254 nm. Chemical identity ofsynthesized compounds was confirmed by high resolution mass spectrometry(HRMS) using Waters Q-TOF Premier mass spectrometer with the [M+2H]²⁺ion or singly charged product ions from [Glu1]-fibrinopeptide B (CAS103213-49-6) as the lock mass reference. Theoretical molecular masseswere calculated using MassLynx™ software (Waters Corp.) and comparedwith the measured mass. All measured masses were within measurementerror (5 amu) of the theoretical values and are consistent with theexpected elemental compositions. All reagents and solvents(acetonitrile, methanol, diethyl ether and hexanes) were purchased asreagent grade, and used without further purifications. Tetrahydrofuranand dichloromethane were distilled from Na-benzophenone and CaH₂,respectively.

Cell lines and antibodies. Cervical carcinoma HeLa, colorectaladenocarcinoma HCT116, breast adenocarcinoma MCF-7 and MDA-MB-231, lungadenocarcinoma H460 and H1975, prostate adenocarcinoma PC3 and DU145,epidermoid squamous cell carcinoma A431, and B-lymphoblastoid Raji,HL-60 and U937 cells were obtained from the American Tissue CultureCollection (ATCC, Manassas, Va.), and maintained in culture according tothe supplier's specifications. Human chronic myelogenous leukemia inblast crisis K562, monocytic leukemia THP-1, glioblastoma U87MG,cervical carcinoma HeLa, colorectal adenocarcinoma HCT116, breastadenocarcinoma MCF-7 (ER-positive) and MDA-MB-231 (Estrogenreceptor-negative), lung adenocarcinoma H460 and H1975, prostateadenocarcinoma PC3 and DU145, epidermoid squamous cell carcinoma A431,and B-lymphoblastoid Raji, myeloblastic leukemia HL-60 and U937 cellswere obtained from the American Tissue Culture Collection (ATCC,Manassas, Va.), and maintained in culture according to the supplier'sspecifications. The normal human cell types, HGF, foreskin fibroblastHFF, epithelial fibroblast WS-1, and intestinal epithelial INT were alsoobtained from ATCC. Bovine aortic endothelial cells and human umbilicalvein endothelial cells were isolated, and maintained in cultureaccording to published protocols 16 (Mesri et al., “Suppression ofvascular endothelial growth factor-mediated endothelial cell protectionby Survivin targeting,” Am. J. Pathol., 158:1757-1765 (2001)). Bax^(−/−)and p53^(−/−) HCT116 cells were kindly provided by Dr. Bert Vogelstein(Johns Hopkins University). The following antibodies were used:cytochrome c (Clontech), Cox-IV (Clontech), Hsp90 (BD Biosciences),TRAP-1 (BD Biosciences), cyclophilin D (CypD, peptidylprolyl isomeraseF, ppif, Calbiochem), Bcl-2 (BD Biosciences), Smac (ProSci), mt-Hsp70(ABR), and β-actin (Sigma-Aldrich).

Peptides, plasmids and recombinant protein expression. HPLC-purifiedcell permeable retro-inverso Shepherdin peptidomimetic (survivinsequence Lys79-Leu87) and its scrambled cell-permeable variant weresynthesized as described (Plescia et al., Cancer Cell, 7:457-468,(2005)), and used in analysis of cell viability, cytochrome c releaseand mitochondrial membrane potential. FITC conjugated native Sheph, andcell-permeable Sheph-ANT, Scram, Scram-ANT were also synthesized asdescribed (Plescia et al., 2005, supra). A Mammalian Gene Collection(MGC) full-length clone of CypD (GenBank Acc. No. BC030707) waspurchased from Invitrogen, and amplified by PCR using primers 5′AAAAAGAATTCCTGGCGCTGCGCTGCGGCTC 3′ (SEQ ID NO:31) and 5′AAAAACTCGAGCAGATTAGCTCAACTGGCCACAGTC 3′ (SEQ ID NO:32) or,alternatively, 5′ AAAAAGAATTCGGCGGCATGTGCAGCAAGGGCTCCGGCG 3′ (SEQ IDNO:33) and 5′ AAAAACTCGAGCAGATTAGCTCAACTGGCCACAGTC 3′ (SEQ ID NO:34).

An MGC full length clone of TRAP-1 (GenBank ACC. No. NM_(—)004257(protein is NP004248)) was purchased from Invitrogen and the full lengthclone used for transfection experiments and the transcript correspondingto the mature form of the protein starting at Ser60 were amplified usingforward primers 5′ AAAAAGGATCCGTACGACATGGCGCGCGA 3′ (SEQ ID NO:35) and5′AAAAAGGATCCAGCACGCAGACCGCCGAGG 3′ (SEQ ID NO:36), respectively, and a3′ reverse primer: 5′ AAAAACTCGAGCTAGTGTCGCTCCAGGGCCTT 3′ (SEQ IDNO:37). The PCR products were digested with EcoRI/XhoI (CypD) orBamHI/XhoI (TRAP-1), and ligated in pGEX-4T (Pharmacia) or pcDNA3.0(Invitrogen) for prokaryotic or eukaryotic/in vitro translationexpression, respectively. pGEX-CypD, pGEX-TRAP-1, or pGEX-Hsp90 cDNA wastransformed into BL21-CodonPlus-RIL E. coli strain (Stratagene).

A full length clone of mouse PiC (Solute carrier family 25(mitochondrial carrier, phosphate carrier), member 3 (GenBank Acc. No.AL360268 (protein is CA113838)) was purchased from Invitrogen. A PiCcDNA was amplified using primers 5′ AAAAAGGATCCAGGAGGATGTTCTCGTCCGTAGC3′ (SEQ ID NO:38) and 5′ AAAAACTCGAGCTACTCAGTTAACCCAAGCTTCTTCTTC 3′ (SEQID NO:39) and PCR products were digested with BamHI/XhoI, and subclonedinto pcDNA3 to generate pcDNA-PiC. Recombinant proteins were inducedwith 0.2 mM IPTG at 30° C. for 5 hours, and purified from bacterialextracts, as described (Fortugno et al., Proc. Natl. Acad. Sci. U.S.A.100(24):13791-6, (2003)).

Protein concentration was determined with a Protein Assay reagent(Bio-Rad) using Bovine Serum Albumin (BSA) as standard.

Submitochondrial fractionation. Submitochondrial fractionation wasperformed by phosphate swelling-shrinking as described before with minormodifications (Bijur and Jope, J. Neurochem., 87:1427-1435, (2003);Hovius et al., Biochim. Biophys. Acta, 1021:217-226, (1990)). Briefly,highly purified mitochondrial pellets isolated by sucrose step gradientas described above were suspended in swelling buffer (10 mM KH2PO4, pH7.4 and protease inhibitor) and incubated for 20 minutes at 0° C. withgentle mixing. Swelled mitochondria were mixed with equal volume ofshrinking buffer (10 mM KH2PO4, pH 7.4, 32% sucrose, 30% glycerol, 10 mMMgCl2 and protease inhibitor) and incubated for additional 20 minutes at0° C. After centrifugation at 10,000×g for 10 minutes, the supernatantwas collected as containing outer membrane and inner membranemitochondrial fractions (OM & IMS). The pellets were washed with 1:1mixture of swelling/shrinking buffer three times, suspended in swellingbuffer, and sonicated to disrupt the inner membrane, which was collectedas containing inner membrane and matrix mitochondrial fractions (IM &MA). OM & IMS and IM & MA were further fractionated by centrifugation at150,000×g for 1 hour at 4° C. The pellets were collected as OM and IMfractions, respectively. Supernatants were further concentrated usingCentricon 10K and Microcon 10K centrifugal filter devices (Millipore)and collected as IMS and MA fractions, respectively.

In other experiments, mitochondria isolated from HeLa cells or mousebrain (2 μg/μl, 15 μl) were suspended in SHE buffer (250 mM sucrose inHE buffer), diluted in 135 μl of SHE buffer or HE buffer (10 mM Hepes, 1mM EDTA, pH 7.2), and incubated for 15 minutes at 0° C. with mechanicaldisruption of the mitochondrial outer membrane by repeated pipetting.Samples were incubated with 50 μg/ml proteinase K (Roche), for 10minutes at 0° C., mixed with 1 mM PMSF, centrifuged at 10,000×g for 10minutes, and analyzed by Western blotting. Alternatively, samples weretreated with increasing concentrations of digitonin (0-0.4%) topermeabilize the mitochondrial membrane and repartition of mitochondrialproteins from pellets to supernatants was analyzed by Western blotting,as described (Dohi et al., J. Clin. Invest. 114(8):1117-27, (2004)).

Isolation of mitochondria and ‘mitochondriotropic’ property of drugs.Mitochondria were isolated from HeLa cells, as described previously(Kang et al., Cell, 131:257-270 (2007)). Briefly, HeLa cells wereharvested and washed with TD buffer (135 mM NaCl, 5 mM KCl, 25 mM Tris,pH 7.6). The cell pellet was suspended in CaRSB buffer (10 mM NaCl, 1.5mM CaCl₂, 10 mM Tris, pH 7.5, protease inhibitor), and incubated for 5minutes at 0° C. Swelled cells were homogenized in a Dounce grinder, andimmediately mixed with 1.5 volume of MS buffer (210 mM mannitol, 70 mMsucrose, 5 mM Tris, pH 7.6, 5 mM EDTA). Nuclei and other cellular debriswere removed by centrifugation at 600×g for 15 minutes. Samples werefurther incubated with 200 μM Gamitrinib or 17-AAG per 2600 μgmitochondria for 5 minutes at 0° C., and treated mitochondria werere-isolated by centrifugation at 6,000×g for 10 minutes. Themitochondrial pellet was suspended in MS buffer, and applied onto a 1M/1.5 M sucrose step gradient in 10 mM Tris, 5 mM EDTA, pH 7.6, 2 mMDTT, plus protease inhibitors for 1.5 hours at 110,000×g. Themitochondrial bands were isolated, washed in MS buffer, and lysed inbuffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 0.5% IGEPAL CA-630, 1mM EDTA, plus protease inhibitors. Protein concentrations weredetermined using a Bio-Rad protein assay reagent with BSA as a standard.Absorbance on comparable protein concentrations was determined at 338 nmusing a DU530 spectrophotometer (Beckman Coulter). Due to maximumabsorption and comparable signals to 17AAG and Gamitrinibs, absorbanceat 338 nm was used for drug detection.

Fluorescence analysis of isolated mitochondria. Individual mitochondrialsubfractions (20 μg) incubated with FITC-conjugated Shepherdin wereincubated in 3 ml of 20 mM Tris buffer, and fluorescence intensity (U,arbitrary units) was measured at 497 nm of excitation wavelength and 525nm of emission wavelength using a CARY ECLIPSE FluorescenceSpectrophotometer (Varian Inc. CA, USA). In some experiments, MCF-7cells were treated with 20 μM of FITC-Shepherdin or FITC-scrambledpeptide for 30 minutes. Cells were harvested and mitochondria werefractionated using a Mitochondria Isolation kit from PIERCE. Proteinconcentration was determined using a Protein assay reagent (Bio-Rad),with BSA as a standard. Fifty μg of protein samples were mixed with 3 mlof 20 mM Tris buffer, pH 7.4, and fluorescence intensity was measured at497/525 nm excitation/emission wavelength on a spectrophotometer (VarianInc. CA, USA).

In vitro mitochondrial import assay. Import of recombinant proteins inisolated mitochondrial fractions was carried out as described (Young etal., Cell, 112:41-50, (2003)) with minor modifications. Briefly,isolated mouse brain mitochondria were washed in MC buffer containing250 mM sucrose, 80 mM potassium acetate, 20 mM HEPES-KOH, pH 7.5, 5 mMmagnesium acetate, as described. In vitro transcribed and translated35S-labeled proteins were diluted with one vol of MCS buffer (500 mMsucrose, 80 mM potassium acetate, 20 mM HEPES-KOH (pH 7.5), 5 mMmagnesium acetate), and mixed in a total volume of 50 μl with purifiedmitochondria (30 μg) for 1 hour at 30° C. in the presence or absence of1 μM valinomycin. Samples were cooled on ice and treated with 50 μg/mlproteinase K for 10 minutes at 0° C. The proteolytic digestion wasstopped by addition of 1 mM PMSF, and mitochondria were re-isolated bycentrifugation at 6,000×g for 10 minutes. Differential protein importinto mitochondria was determined by autoradiography.

Immunoprecipitation, pull down assays and affinity chromatography.Isolated Raji mitochondria were lysed in buffer containing 150 mM NaCl,10 mM Tris, pH 7.4, 1% Triton X-100, 0.5% IGEPAL CA-630 plus proteaseinhibitors (Roche) for 1 hour at 4° C. under constant agitation. Aftercentrifugation at 13,000×g for 10 minutes at 4° C., the supernatant wasprecleared with Protein G-agarose beads (Calbiochem) for 3 hours at 4°C., and 200 μg of precleared protein extracts were incubated with anantibody to Hsp90 or TRAP-1 for 16 hours at 4° C. in the presence orabsence of CsA (5 μM) or GA (10 μM). The precipitated immune complexeswere washed in lysis buffer and bound proteins were separated by SDS gelelectrophoresis, and analyzed by Western blotting. For pull downexperiments, GSH-bead-bound GST-CypD, GST-TRAP-1, or GST-Hsp90 wereblocked with H-buffer containing 20 mM Hepes, pH 7.7, 75 mM KCl, 0.1 mMEDTA, 2.5 mM MgCl2, 0.05% NP40, 1 mM DTT plus 1 mg/ml BSA. Blocked beadswere incubated with purified recombinant proteins or 35S-labeledproteins in H-buffer for 16 hours at 4° C. in the presence of CsA or GA.At the end of the incubation, pelleted beads were washed in Hbuffer andbound proteins were separated by SDS gel electrophoresis, and analyzedby Western blotting or autoradiography. For in vivo capture assays, GSTor GST-CypD was mixed with isolated Raji mitochondria in H-buffer for 16hours at 4° C. in the presence of CsA (5 μM) or (10 μM) GA. Boundproteins were washed, and analyzed by Western blotting. In someexperiments, Shepherdin or scrambled peptidomimetic (5 mg/ml) werecoupled to Sepharose beads, and used to fractionate purified Rajimitochondria. After washes, bound material was eluted with 0.1 Mglycine, pH 2.5, immediately neutralized, and analyzed by Westernblotting.

Cytochrome c release. Tumor cell types were treated with controls or thevarious Hsp90 antagonists, and cytosolic extracts were harvested atincreasing time intervals between 5-30 minutes and analyzed by Westernblotting. For experiments in a cell-free system, purified mitochondria(20 μg) were suspended in 500 μl of SB buffer (0.2 M sucrose, 10 mMTris-MOPS, pH 7.4, 5 mM succinate, 1 mM sodium phosphate, 10 μMEGTA-Tris, and 2 μM rotenone). Samples were treated with controls or thevarious Hsp90 antagonists for 20 minutes at 22° C. At the end of eachincubation reaction, mitochondria and supernatants were separated bycentrifugation at 6,000×g for 10 minutes, and analyzed by Westernblotting.

Mitochondrial membrane potential. Raji cells were treated withShepherdin or control scrambled peptidomimetic (100 μM) or 17-AAG (5μM), loaded with the mitochondrial membrane potential-sensitivefluorescent dye JC-1, and analyzed for changes in green/red fluorescenceratio by flow cytometry. For experiments in a cell-free system, purifiedmitochondria isolated from primary normal cells, various tumor cellstypes, or normal mouse organs were suspended in SB buffer. Samples (100μg) were incubated with 0.1 μM tetramethylrhodamine methyl ester (TMRM)in SB buffer, treated with Shepherdin or control scrambledpeptidomimetic (0.5-1.5 μM), 17-AAG (1.5 μM), or ANT-GA (1-1.5 μM) inthe presence or absence of CsA (5 μM), and analyzed continuously at 549nm excitation and 575 nm emission (Photon Technology International,Inc). For these experiments, TMRM-loaded mitochondria in SB buffer wereallowed to reach stable fluorescence, which was set as fully polarizedstate (maximum membrane potential). The fluorescence intensity aftertreatment with 2 mM CaCl₂ was set as minimum membrane potential (fullydepolarized state). Changes in fluorescence intensity after eachtreatment were plotted as a ratio between maximum and minimum membranepotential. In some experiments, increasing concentrations (10-100 μg) ofTMRM-loaded mitochondria isolated from HeLa or MCF-7 cells were dilutedin 3 ml of SB buffer, normalized to a total protein concentration of 500μg with BSA, and analyzed for changes in membrane potential in responseto control or the various Hsp90 antagonists.

Mitochondrial function. Normal or tumor mitochondria (100 μg) wereloaded with 0.1 mM tetramethylrhodamine methyl ester (TMRM), incubatedwith Gamitrinibs or 17-AAG, with or without CsA, and analyzedcontinuously for changes in inner membrane potential at 549 nmexcitation and 575 nm emission (Photon Technology International, Inc.).The fluorescence intensity after treatment with 2 mM CaCl₂ correspondedto a fully depolarized state. Alternatively, H460 cells were labeledwith the fluorescent dye JC-1 (Molecular Probes), and analyzed forchanges in red/green (Fl-2/Fl-1) fluorescence ratio after treatment withthe various agents, by multiparametric flow cytometry. Cytochrome ccontent in pellets or supernatants of drug-treated isolated mitochondriawas determined by Western blotting.

Analysis of cell death. Modulation of cell viability was determined byMTT (Kang et al., “Regulation of tumor cell mitochondrial homeostasis byan organelle-specific Hsp90 chaperone network,” Cell, 131:257-270(2007)). For determination of apoptosis, cells were analyzed for caspaseactivity (DEVDase activity) and plasma membrane integrity (propidiumiodide) using CaspaTag (Intergen, Burlington, Mass.), by multiparametricflow cytometry (Kang et al., “Regulation of tumor cell mitochondrialhomeostasis by an organelle-specific Hsp90 chaperone network,” Cell,131:257-270 (2007)).

Analysis of Hsp90 function. For GA-bead competition experiments, SkBr3breast cancer cells were lysed in TNESV lysis buffer (50 mM Tris-HCl, pH7.4, 1% Nonidet P-40, 2 mM EDTA, 100 mM NaCl, 1 mM sodium orthovanadate,1 mM phenylmethylsulfonyl fluoride, 20 μg of aprotinin and leupeptin perml). After centrifugation to clarify the supernatant, lysates wereincubated with 0, 0.5, 1, or 10 μM Gamitrinib, or 0, 0.05, 0.1, or 0.5μM GA, on ice for 30 minutes. Lysates (equal protein) were thensubjected to affinity purification of Hsp90 using GA-bead precipitationand blotted for Hsp90 as previously described (Marcu et al., “Novobiocinand related coumarins and depletion of heat shock protein 90-dependentsignaling proteins,” J Natl Cancer Inst, 92:242-248 (2000)). The levelsof Hsp90 remaining in the lysates are determined by densitometricquantifications by scanning and image analysis of Hsp90 bands visualizedby Western blotting. Data were representative of two independentexperiments with identical results and indicated that Gamitrinib is aseffective as GA in competing with GA-beads for Hsp90 binding.

In other experiments, chaperone-dependent GST-Chk1 reconstitution wasdetermined as described previously (Arlander et al., “Chaperoningcheckpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones,”J Biol Chem, 281:2989-2998 (2006)). Briefly, each sample contained 0.7μg of resin-bound GST-Chk1 (residues 1-265), 1 μg of purified humanHsp90α, and the following amounts of other purified chaperone proteins:10 μg Hsp70, 2 μg Hdj1, 2 μg p50^(cdc37), 0.06 units CK2, 2.5 μgp60^(Hop). Optical densities due to Chk1-dependent phosphorylation ofCdc25 in the presence and absence of Gamitrinib or 17-AAG weredetermined and plotted as fold activation above the sample lacking addedchaperone proteins. In some experiments, HeLa cells were treated withGamitrinibs (G1-G4) or 17-AAG (5 μM) for 24 hours, and isolated extractswere analyzed for modulation of Akt or Hsp70 expression, by Westernblotting

Cellular imaging. For fluorescence labeling studies, HeLa cells wereincubated with FITC-conjugated Shepherdin or cell permeable scrambledpeptidomimetic in the presence of the mitochondrial marker, MitoTracker.Images were taken on an inverted microscope (Zeiss Axiovert 200) using aPerkin-Elmer CSU-10 spinning-disc confocal scanner. Z-sections weretaken every 0.3 μm for the entire cell using a Hamamatsu ORCA camera,and presented as a projection using Metamorph 6.3r5 (Universal ImagingCorp.). For time lapse videomicroscopy, HeLa cells were maintained in 35mm glass-bottom tissue-culture dishes (Mat-tek). Prior to imaging, cellswere incubated with 400 nM CM-H2XRos (M7513, Molecular Probes) undergrowth conditions for 15 minutes. After washes, fresh culture medium wasadded, and cells were imaged in an environmental chamber (PDMI-2;Harvard Apparatus) in complete medium with CO2 exchange (0.5liters/minute) at 37° C. Cells were imaged every 1 minute using a 100×phase contrast lens with a green interference filter on an invertedmicroscope (Olympus IX-70). Images were captured on a CoolSnap HQ CCDcamera (Roper Scientific) and concatenated using Metamorph software(Universal Imaging Corp.). Cells were imaged in the absence of anyreagent for the first 10 minutes of the time lapse, at which pointShepherdin or cell permeable scrambled peptidomimetic was added dropwisein between acquisitions. Phase-contrast images of mitochondria wereverified by the presence of CM-H2XRos labeling. In some experiments,isolated mitochondria were equilibrated with ANT-GA, treated with 50μg/ml proteinase K, and analyzed by fluorescence microscopy.

Electron microscopy. Isolated HeLa cell mitochondria were fixed in 3%formaldehyde and 0.1% glutaraldehyde (EM grade) for 10 minutes at 37°C., incubated in 50 mM NH4Cl in PBS, pH 7.4, for 60 minutes at 22° C. toaminidate free aldehydes, dehydrated through a gradual series of ethanolto 100%, and transferred into a mixture of 50:50 (v/v) resin (LowicrylK4M):100% ethanol overnight at 22° C. Samples were transferred toaliquots of fresh resin (×3) and applied to filling embedding capsulesfor 24 hours at 60° C. Thin sections were cut using an ultramicrotome(Reichert-Jung Ultracut E), placed on gold support rids, blocked (Zymed)for 30 minutes at 22° C., and incubated with an antibody to the N-domainof Hsp90 or control non-binding IgG. After addition of gold-conjugatedsecondary antibodies (1:20, Jackson ImmunoResearch Laboratories),samples were washed, exposed to OsO4 vapor for 1 hour at 22° C.,post-stained with uranyl acetate and lead citrate, and analyzed on aPhilips EM10 electron microscope at 80 kV, as described (Dohi et al., J.Clin. Invest. 114(8):1117-27, (2004)).

Analysis of cell viability and apoptosis. Normal or tumor cell typeswere treated with increasing concentrations of Hsp90 antagonists ortheir respective controls (Shepherdin, 0-150 μM; 17-AAG, 0-100 μM;ANT-GA, 0-100 μM) for 1-2.5 hours at 37° C., and analyzed for loss ofcell viability by an MTT assay (Plescia et al., Cancer Cell, 7:457-468,(2005)). Alternatively, HeLa cells were treated with the CypD inhibitor,CsA (1 μM), or transfected with control non-targeted siRNA or SmartPoolsiRNA (Dharmacon) to CypD, incubated with Shepherdin or controlscrambled peptidomimetic after 48 hours, and analyzed for cell viabilityby MTT. In other experiments, HeLa cells were transfected with controlnon-targeted siRNA or TRAP-1-directed siRNA (Dharmacon), incubated inthe presence or absence of CsA (1 μM), and analyzed for cell viabilityby MTT after 48 hours. Changes in protein expression in the variousexperiments of siRNA targeting were assessed by Western blotting. Foranalysis of TRAP-1-directed cytoprotection, primary nontransformed humanfibroblasts HFF and WS-1 were transfected with control pcDNA3 or TRAP-1cDNA by lipofectamine for 24 hours, exposed to increasing concentrations(0-1 μM) of the cell death stimulus staurosporine (STS), and analyzedfor cell viability after additional 24 hours incubation by MTT. Foranalysis of apoptosis, p53+/+ or p53−/− HCT116 cells were treated withcontrol or ANT-GA (100 μM), and analyzed for DEVDase activity (CaspaTag)and propidium iodide staining by simultaneous multiparametric flowcytometry, as described (Dohi et al., J. Clin. Invest. 114(8):1117-27,(2004); Plescia et al., Cancer Cell, 7:457-468, (2005)).

Tissue procurement and immunohistochemistry. Anonymous primary surgicalspecimens of human breast adenocarcinoma, pancreas adenocarcinoma, lungadenocarcinoma, colon adenocarcinoma, and their respective normaltissues were obtained without identifiers from the UMass Memorial CancerCenter Tissue Bank. Tissue specimens were fixed in buffered formalin,and embedded in paraffin. For tissue staining, sections weredeparaffinized, rehydrated in water, and quenched for endogenousperoxidase. Epitope heat retrieval was carried out by steaming theslides in 10% sodium citrate for 60 minutes. Processed slides wererinsed in PBS, and stained with an antibody to TRAP-1 or control IgGusing standard avidin-biotin-peroxidase technique (Histostain-plus,Zymed Laboratories). Slides were incubated with DAB as a chromogen andcounterstained with haematoxylin. Two independent cases per eachhistopathologic diagnosis, and respective normal tissues were analyzedwith identical results.

Statistical analysis. Data were analyzed using the two-sided unpaired ttest on a GraphPad software package for Windows (Prism 4.0). A p valueof 0.05 was considered as statistically significant.

Other Embodiments

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

What is claimed is:
 1. A composition comprising a compound consisting ofa geldanamycin analogue covalently bonded to a linking moiety that iscovalently bonded to (aryl)₃P, wherein the linking moiety consists of analkylene with six carbon atoms and the geldanamycin analogue is selectedfrom the group of: 17-allylamino-demethoxygeldanamycin,17-dimethylaminogeldanamycin, 17-(3-(4-maleimidobutyrcarboxamido)propylamino)-demethoxygeldanamycin,17-(dimethylaminoethylamino)-17-demethoxygeldanamycin,17-[2-(pyrrolidin-1-yl)ethyl]amino-17-demethmoxygeldanamycin,17-dimethylaminopropylamino)-17-demethoxygeldanamycin,and

wherein R² is H, alkyl, aryl, or arylalkyl; R³ is H or alkyl; and R⁴ isH, alkyl, aryl, arylalkyl, or OR^(d) , wherein R^(d) is H, alkyl, orarylalkyl; or a pharmaceutically acceptable salt of the compound.
 2. Thecomposition of claim 1, wherein the geldanamycin analogue is17-allylamino-demethoxygeldamycin (17-AAG).
 3. The composition of claim1, wherein the geldanamycin analogue is 17-dimethylaminogeldanamycin. 4.The composition of claim 1, wherein the geldanamycin analogue is

wherein: R² is H, alkyl, aryl, or arylalkyl; R³ is H or alkyl; and R⁴ isH, alkyl, alkenyl, aryl, arylalkyl, or OR^(d), wherein R^(d) is H,alkyl, or arylalkyl.
 5. The composition of claim 4, wherein R² is H oralkyl; R³ is H or alkyl; and R⁴ is H or OR^(d), wherein R^(d) is H oralkyl.
 6. The composition of claim 4, wherein R² is H; R³ is methyl; andR⁴ is H.
 7. The composition of claim 1, wherein the compound is in theform of a pharmaceutically acceptable salt.
 8. The composition of claim1, wherein the (aryl)₃P is (phenyl)₃P.
 9. The composition of claim 1,wherein the compound consists of:


10. A method for treating a subject having lung cancer, breast cancer,or prostate cancer, the method comprising administering to a subjecthaving lung cancer, breast cancer, or prostate cancer a therapeuticallyeffective amount of the composition of claim
 1. 11. A method fortreating a subject having lung cancer, breast cancer, or prostatecancer, the method comprising: identifying a subject having lung cancer,breast cancer, or prostate cancer; and administering to the subject atherapeutically effective amount of the composition of claim
 1. 12. Themethod of claim 10, wherein the subject has lung cancer.
 13. The methodof claim 10, wherein the subject has breast cancer.
 14. The method ofclaim 10, wherein the subject has prostate cancer.
 15. The method ofclaim 11, wherein the subject is identified as having lung cancer. 16.The method of claim 11, wherein the subject is identified as havingbreast cancer.
 17. The method of claim 11, wherein the subject isidentified as having prostate cancer.
 18. A method for treating asubject having lung cancer, breast cancer, or prostate cancer, themethod comprising administering to a subject having lung cancer, breastcancer, or prostate cancer a therapeutically effective amount of acomposition comprising a compound consisting of:

or a pharmaceutically acceptable salt of the compound.
 19. The method ofclaim 18, wherein the subject has lung cancer.
 20. The method of claim18, wherein the subject has breast cancer.
 21. The method of claim 18,wherein the subject has prostate cancer.
 22. The method of claim 11,wherein the compound consists of:


23. The method of claim 22, wherein the subject is identified as havinglung cancer.
 24. The method of claim 22, wherein the subject isidentified as having breast cancer.
 25. The method of claim 22, whereinthe subject is identified as having prostate cancer.